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Background: Epilepsy is a common neurological condition resulting in recurrent seizures. Research
evidence in long-term conditions suggests that patients benefit from self-management education and that
this may improve quality of life (QoL). Epilepsy self-management education has yet to be tested in a
UK setting.
Objectives: To determine the effectiveness and cost-effectiveness of Self-Management education for
people with poorly controlled epILEpsy [SMILE (UK)].
Design: A parallel pragmatic randomised controlled trial.
Setting: Participants were recruited from eight hospitals in London and south-east England.
Participants: Adults aged ≥ 16 years with epilepsy and two or more epileptic seizures in the past year,
who were currently being prescribed antiepileptic drugs.
Intervention: A 2-day group self-management course alongside treatment as usual (TAU). The control
group received TAU.
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Main outcome measures: The primary outcome is QoL in people with epilepsy at 12-month follow-up
using the Quality Of Life In Epilepsy 31-P (QOLIE-31-P) scale. Other outcomes were seizure control, impact
of epilepsy, medication adverse effects, psychological distress, perceived stigma, self-mastery and
medication adherence. Cost-effectiveness analyses and a process evaluation were undertaken.
Randomisation: A 1 : 1 ratio between trial arms using fixed block sizes of two.
Blinding: Participants were not blinded to their group allocation because of the nature of the study.
Researchers involved in data collection and analysis remained blinded throughout.
Results: The trial completed successfully. A total of 404 participants were enrolled in the study [SMILE
(UK), n = 205; TAU, n = 199] with 331 completing the final follow-up at 12 months [SMILE (UK), n = 163;
TAU, n = 168]. In the intervention group, 61.5% completed all sessions of the course. No adverse events
were found to be related to the intervention. At baseline, participants had a mean age of 41.7 years
[standard deviation (SD) 14.1 years], and had epilepsy for a median of 18 years. The mean QOLIE-31-P
score for the whole group at baseline was 66.0 out of 100.0 (SD 14.2). Clinically relevant levels of anxiety
symptoms were reported in 53.6% of the group and depression symptoms in 28.0%. The results following
an intention-to-treat analysis showed no change in any measures at the 12-month follow-up [QOLIE-31-P:
SMILE (UK) mean: 67.4, SD 13.5; TAU mean: 69.5, SD 14.8]. The cost-effectiveness study showed that
SMILE (UK) was possibly cost-effective but was also associated with lower QoL. The process evaluation
with 20 participants revealed that a group course increased confidence by sharing with others and
improved self-management behaviours.
Conclusions: For people with epilepsy and persistent seizures, a 2-day self-management education course
is cost-saving, but does not improve QoL after 12-months or reduce anxiety or depression symptoms.
A psychological intervention may help with anxiety and depression. Interviewed participants reported
attending a group course increased their confidence and helped them improve their self-management.
Future work: More research is needed on self-management courses, with psychological components and
integration with routine monitoring.
Trial registration: Current Controlled Trials ISRCTN57937389.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 21.
See the NIHR Journals Library website for further project information.
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Glossary
Absence A generalised seizure in which the patient loses consciousness but does not fall or
have convulsions.
Acute A condition that only lasts for a short amount of time or that recurs only at sporadic intervals
over time.
Adherence The degree to which a treatment or protocol is followed. This can be used in the context of a
patient taking medication as prescribed. In addition, in this report it is used as a measure to assess whether
or not facilitators delivered the SMILE (UK) components as specified by the teaching manual.
Adverse event Any untoward incident experienced by a participant that does not necessarily have a
causal relationship with the intervention.
Aetiology The cause or set of causes attributed to a condition.
Antiepileptic drug Medicine taken for the treatment of seizures.
Arthritis A condition causing painful joint inflammation.
Attrition Rate at which participants are lost throughout a trial.
Aura A sensation that comes before the onset of a seizure. It is classified as a simple focal seizure, which
can become a generalised seizure.
Autonomous The ability and assertiveness to act independently.
Blinding The act of ensuring that the participant group allocation is concealed from one or more
individuals involved in a research study.
Chronic Any condition that lasts over a long period of time.
Clonic seizure The rapid contraction and relaxation of the muscles (i.e. jerking).
Cochrane review A systematic review of health-care research internationally accepted as the gold
standard in evidence-based health-care research.
Cognition The cerebral action or process of attaining knowledge and understanding through thought,
experience and the senses.
Comorbidity Any condition that occurs alongside the primary diagnosis.
Complex intervention An intervention that contains several interacting components.
Complex partial seizure A seizure that causes a high level of impairment and loss of consciousness or
memory. Other names include complex focal seizure.
Compliance See Adherence.
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Computer tomography Scans are carried out by using 360-degree radiography and the computerised
images used in assessment.
Congenital Present from birth.
Contamination Group contamination can occur when participants from one trial arm behave as if they
are in the other arm. In the SMILE (UK) trial, this happened when participants in the treatment-as-usual
group attended the course in error.
Control(s)/group Participants who have not received the intervention. In the SMILE (UK) study, they
received treatment as usual.
Diabetes mellitus A disease in which the body’s ability to produce or respond to the hormone insulin
is impaired.
Diagnosis Identification of a disease or disorder.
Didactic A method of teaching that provides students with the required theoretical knowledge. It mainly
involves the teacher or facilitator speaking rather than having interaction or discussion between students.
Electroencephalogram Form of testing used to detect abnormal electrical activity in the brain.
Epidemiology The incidence and distribution of medical conditions in a population.
Epileptic activity Neurological electrical activity associated with epilepsy.
Epileptology The study of epilepsy.
Facilitators The health-care professionals who provided the intervention to participants.
Febrile seizure A type of seizure that occurs in infants or young children, which starts with a fever.
Fidelity The measure of adherent and competent delivery of the intervention.
Focal seizure A partial seizure that causes alterations in attention, movement or behaviour.
Further education Any education beyond secondary education (e.g. Advanced levels, Bachelor of
Technology).
Generalised seizure A seizure that affects both hemispheres in the brain. Seizures are accompanied by a
loss of consciousness and are categorised by the following categories: generalised tonic–clonic, myoclonic,
absence and atonic.
Generalised tonic–clonic seizure A type of seizure that combines the symptoms of both a tonic seizure
and a clonic seizure. It affects both hemispheres of the brain.
Health economics The study of the cost-effectiveness, value and benefits in the use of an intervention.
Higher education Any education beyond further education (e.g. degree, Doctor of Philosophy).
Idiopathic Of unknown origin.
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Index of Multiple Deprivation A measure of relative deprivation for small areas of each county in
England constructed from a number of different types, or domains, of deprivation (e.g. income,
education, crime).
Intention-to-treat analysis All patients who were enrolled and randomly allocated to either treatment or
control are analysed in the groups to which they were randomised.
Inverse association A contrary relationship between two variables such that they move in
opposite directions.
Magnetic resonance imaging A diagnostic method that uses magnetic fields and radio waves to
produce a detailed image of the body’s soft tissue and bones.
Nerve cell A specialised cell transmitting nerve impulses.
Nested process A research design in which levels of one factor are hierarchically included under levels of
another factor.
Neurophysiologist A health-care professional who specialises in the physiology of the brain.
NHS perspective A health economics term used to describe cost-effectiveness for the NHS.
Pilot study A study carried out on a small scale before the intended study in order to test the robustness
and integrity of the intended study.
Poorly controlled epilepsy An individual who experiences more than two seizures a year (National
Institute for Health Research definition).
Positron emission tomography An imaging test that helps to reveal how tissues and organs are
functioning using a radioactive drug (tracer) to show this activity.
Pragmatic A deconstructive paradigm that encourages the use of mixed methods in research eliminating
a position between two opposing theoretical views.
Prevalence The rate of the presence of a specific condition in the population.
Primary care Health care provided in the community for people making an initial approach to a general
practitioner or clinic for advice or treatment.
Process evaluation A qualitative exploration of participants’ experience of the intervention.
Prognosis Outlook for individuals diagnosed with a condition.
Proxy A variable that is not directly relevant to the analysis, but serves in place of an unobservable or
immeasurable variable.
Psychogenic A symptom that presents as a medical condition but in fact has an underlying
psychological cause.
Psychosocial A combination of factors that originate from both psychological and social influences.
Qualitative research Research that explores the underlying reasons, opinions and motivations of
participants, providing rich insight into the experiences of participants in a study.
DOI: 10.3310/hta22210 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 21
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ridsdale et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii
Quality-adjusted life-year A generic measure of the burden of a condition, including both the quality
and the quantity of life lived. It is used in economic evaluation to assess the cost-effectiveness of
the intervention.
Quantitative research A formal, objective process that uses numerical data to acquire information about
the intervention by defining variables, investigating relationships between variables and establishing
cause-and-effect interactions between variables.
Retention The rate at which participants remain in the study at specified intervals throughout the process
(i.e. 6 months and 12 months).
Secondary care Care that is provided by a specialist on referral by a primary care physician and that
requires more advanced investigation or treatment than a general practitioner can provide.
Seizures Any abnormal electrical activity in the brain that can be caused by numerous factors, including
those not related to epilepsy.
Self-efficacy/mastery An individual’s confidence in his or her ability to accomplish behaviours essential
for specific management of their condition.
Self-management Any method of treatment for a condition that is initiated by the patient.
Serious adverse event Any adverse event resulting in an inpatient hospital admission or prolongation of
hospital stay, is life-threatening, or causes persistent disability or death.
Societal perspective A health economics term for cost-effectiveness for the society.
Status epilepticus An incident in which a seizure lasts > 5 minutes or when two seizures occur within
10 minutes of each other with no period of recovery in between.
Symptomatic Any indication that a symptom is the result of a specific medical condition. It can also mean
displaying symptoms that are characteristic of a specific medical condition.
Taxonomy The process of classification according to a predetermined system, with the result providing a
conceptual outline for discussion or analysis.
Tonic seizure A seizure that involves the experience of muscles becoming rigid and stiff.
Treatment as usual A study condition in which patients continue to receive the treatment they were
receiving prior to being recruited into the study.
Triggers Any factor that an individual attributes as causing an acute seizure.
Visual analogue scale A psychometric response scale in the form of an image used in questionnaires to
determine subjective characteristics or attitudes that cannot be directly measured.
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List of abbreviations
AE adverse event
AED antiepileptic drug
CACE complier average causal effect
CEAC cost-effectiveness acceptability
curve
CEP cost-effectiveness plane
CI confidence interval
CSRI Client Service Receipt Inventory
DAFNE Dose Adjustment For Normal
Eating
DESMOND Diabetes Education for
Self-Management for Ongoing
and Newly Diagnosed
DMEC Data Monitoring and Ethics
Committee
EARN Epilepsy Action Research Network
eCRF electronic case report form
ED emergency department
EEG electroencephalogram
ENS epilepsy nurse specialist
EQ-5D EuroQol-5 Dimensions
EQ-5D-5L EuroQol-5 Dimensions, five-level
version
GP general practitioner
HADS Hospital Anxiety and Depression
Scale
HADS-A Hospital Anxiety and Depression
Scale Anxiety
HADS-D Hospital Anxiety and Depression
Scale Depression
HCP health-care professional
HRQoL health-related quality of life
ICER incremental cost-effectiveness ratio
IMD Index of Multiple Deprivation
IoPPN Institute of Psychiatry, Psychology
and Neuroscience
IQR interquartile range
ITT intention to treat
KCH King’s College Hospital
KCL King’s College London
LTC long-term condition
MICE multivariate imputation by chained
equations
MOSES Modular Service Package for
Epilepsy
MRC Medical Research Council
NHNN National Hospital for Neurology
and Neurosurgery
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
PI principal investigator
PWE people with epilepsy
QALY quality-adjusted life-year
QoL quality of life
QOLIE-31 Quality Of Life In Epilepsy 31
QOLIE-31-P Quality Of Life In Epilepsy 31-P
RCT randomised controlled trial
SAE serious adverse event
SD standard deviation
SEE Sepulveda Epilepsy Education
SMILE (UK) Self-Management education for
adults with poorly controlled
epILEpsy
TAU treatment as usual
TSC Trial Steering Committee
VAS visual analogue scale
WTP willingness to pay
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Plain English summary
Epilepsy affects up to 1% of people in the UK and some would like to know more about living withepilepsy and managing their seizures.
To help people who have epilepsy and a lot of seizures, we tested a group course called Self-Management
education for adults with poorly controlled epILEpsy or SMILE (UK).
The study had 404 people with epilepsy. People were asked questions about their general well-being
(‘quality of life’), health, whether or not they felt worried or depressed, and how epilepsy had an impact
on their lives. The study also aimed to find out what people thought about the course and whether or not
it could lower the costs of epilepsy care.
The results showed that people who were less happy with their general well-being may also feel depressed
and worried, feel that others treat them differently and feel less able to control their epilepsy. They may
not take their medicine as they should and they may have other health problems or a lot of seizures. At
the end of the study, general well-being was the same between the people who took the course and
those who did not. The course was not found to save costs for epilepsy treatment, but people said that
learning in a group helped them feel less alone and let them open up to discuss feelings. They were also
more confident, which improved their outlook and coping with epilepsy. However, some said that they
had trouble recalling parts of the course because of memory problems.
The study testing SMILE (UK) for people with epilepsy in groups did not find any difference in general
well-being in people 1 year after attending the course. But the course gave people the chance to learn
from experts and, by talking with others, they felt less alone and more confident.
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Scientific summary
Background
Epilepsy is a common chronic neurological disorder affecting approximately 1% of the UK population.
With medication, about 60–70% of people with epilepsy (PWE) can live without seizures. For the rest,
recurring seizures can have an impact on their social and work life and can lead to injuries, frequent visits
to emergency departments (EDs), psychological conditions and an increased risk of death. For this group of
PWE, self-management is potentially important to manage epilepsy and the consequences of recurring
seizures. Different methods can be used to increase self-management for chronic conditions. For diabetes
mellitus, self-management courses are routinely offered free to users in the UK. There is also a course
offered for PWE in German-speaking Europe called Modular Service Package for Epilepsy (MOSES). In the
context of a trial, those attending that self-management education course had demonstrated increased
knowledge of epilepsy and coping with epilepsy, improved seizure control, better antiepileptic drug (AED)
tolerance and fewer side effects.
Objectives
We tested a group Self-Management course for adults with poorly controlled epILEpsy in the UK [SMILE (UK)].
Specific objectives were as follows.
l adapt MOSES for the UK population
l assess the feasibility of this adapted version of MOSES in the UK in an external pilot qualitative study
l assess the effectiveness of SMILE (UK) in a randomised controlled trial (RCT) with quality of life (QoL)
after 12 months as the primary outcome measure
l evaluate the delivery of the intervention by assessing implementation fidelity in the main trial
l evaluate the cost-effectiveness of SMILE (UK)
l conduct a process evaluation of SMILE (UK) exploring participant views.
Methods
The study was a RCT comparing the effects of SMILE (UK) plus treatment as usual (TAU) with TAU alone.
At the end of the trial, SMILE (UK) was offered to the TAU group.
The SMILE (UK) consists of a 2-day group learning course, which aims to support people becoming experts in
managing their epilepsy. Courses were provided for groups of 8–12 people. Initial piloting of SMILE (UK) was
completed with volunteer members from the user group Epilepsy Action, UK. This pilot study also evaluated
the views of the volunteers on the course, benefits of the intervention and how it might be improved.
Participants
Trial participants were recruited from epilepsy clinics from eight hospitals in London and south-east England.
Inclusion criteria were adults aged ≥ 16 years with epilepsy who were prescribed AEDs, with two or more
seizures in the previous 12 months and able to provide informed consent, participate in the course and
complete questionnaires in English. Exclusion criteria included acute symptomatic seizures as a result of
acute neurological illness or substance misuse, psychogenic or non-epileptic seizures only, or severe current
psychiatric or medical illness.
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The recruitment process involved two stages when patients could opt out from further contact, with
3 weeks per opt-out to return the slips. In the first stage, patients received a letter from their neurologist
about the study, advising they could opt out from the next stage. For the patients not opting out of the
second stage, medical notes were screened by clinic staff to check eligibility. Potentially eligible patients
received a letter about the study from their neurologist, advising that a research worker would contact
them with more information if they did not opt out by returning a form within 3 weeks. A research worker
then contacted patients to explain the study and verify eligibility. If a patient chose to enrol, the research
worker met with them face to face to ensure the patient understood the study and then took written
informed consent. Only at this stage was the patient considered enrolled in the RCT and then a baseline
assessment was done.
Outcome measures
Outcomes and cost-effectiveness were measured by validated self-report questionnaires at pre-randomisation
and at 6 months and 12 months post randomisation. The primary outcome was measured using the
Quality Of Life In Epilepsy 31-P (QOLIE-31-P) scale. Secondary outcome measures included the Hospital
Anxiety and Depression Scale (HADS), seizure frequency, Impact of Epilepsy scale, Medication Adherence
scale from the Epilepsy Self-Management Scale, Stigma of Epilepsy scale, Self-Mastery of Epilepsy scale, and
medication adverse effects. We measured quality-adjusted life-years (QALYs) [using EuroQol-5 Dimensions,
five-level version (EQ-5D-5L)] and health service use using the Client Service Receipt Inventory. Qualitative
research conducted during the pilot and main trial evaluated users’ views on barriers to participation,
benefits and how the intervention might be improved.
Sample size
Pharmacological interventions for those with poorly controlled epilepsy using the QOLIE-31-P to measure
outcome found an effect size of 0.4 to be clinically significant. A total sample size of 320 (randomised 1 : 1)
would provide 91% power to detect an effect size of d = 0.4 using a two-sided analysis of covariance test with
significance set at p< 0.05. This effect size is considered to be 6–7 points on the QOLIE-31-P scale. This would
allow for standard error inflation as a result of group effects [SMILE (UK) is a group treatment]. Assuming an
average group size of 10 patients and an intragroup correlation between QOLIE-31-P scores of intraclass
coefficient of 0.025, we would need 160 patients in the TAU arm and 16 groups of 10 patients in the SMILE
(UK) arm. Inflating the sample size to allow for an estimated 25% attrition required an initial sample of 428.
Primary analysis
The primary clinical effectiveness analysis was by the intention-to-treat (ITT) principle to evaluate the
effectiveness of SMILE (UK). The intervention under study [SMILE (UK) + TAU] was compared with TAU
on the primary outcome (QOLIE-31-P at 12 months) and the secondary outcomes. An analysis was first
undertaken to determine whether or not receiving the full intervention was predictive of missing primary
outcome data. As this was found to be the case, multivariate imputation by chained equations (MICE) was
used to produce inferences that are valid under such a missing at random data-generating process. The
analysis model was a linear mixed-effects model. The random effects were added to account for potential
clustering as a result of participants attending the same educational group in the SMILE (UK) arm.
There were seven secondary outcomes that were measured as continuous variables: HADS-anxiety,
HADS-depression, self-mastery and control, impact of epilepsy, medication adherence, medication adverse
events (AEs), and stigma of epilepsy. All of these were analysed in the same way as QOLIE-31-P (i.e. using
MICE followed by a linear mixed-effects model for the respective secondary outcome variable).
Seizure frequency was collected on two different scales: Baker (Baker GA, Jacoby A, Buck D, Stalgis C,
Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 1997;38:353–62) and
Thapar [Thapar A, Kerr M, Harold G. Stress, anxiety, depression, and epilepsy: investigating the relationship
between psychological factors and seizures. Epilepsy Behav 2009;14(Suppl. 1):134–40]. The seizure
frequency variable as measured by the Baker scale was analysed as a binary outcome: less than one seizure
per month versus one or more seizure per month. A similar analysis approach was used as above, except
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MICE imputed missing outcome values by assuming a logistic regression and a logistic mixed-effects model
was used as the analysis model. Similarly, seizure frequency as measured by the Thapar scale was analysed
as an ordered categorical outcome: 0–3 seizures, 4–6 seizures, 7–9 seizures or ≥ 10 seizures. The MICE
and mixed-effects models used ordinal logistic regression.
Additional analyses
An analysis of baseline data was carried out to better describe the group recruited. In addition, we
assessed which clinical, psychosocial and secondary outcome measures were associated with the primary
outcome, QOLIE-31-P. This was done using using univariate regressions. When comparing categorical
values, predicted means of QOLIE-31-P were calculated within each factor to enable comparisons. One
category within each factor was used as a reference (‘ref’).
An assessment of implementation fidelity was also done. A novel instrument was developed to measure
adherence and competence of SMILE (UK) facilitators.
Cost-effectiveness analyses
The primary perspective of the economic evaluation was the NHS/Personal Social Services perspective.
Other resources relevant to a wider societal perspective such as informal care and productivity loss (because
of time off work) were included in the secondary analyses (societal perspective). Data were assessed two
ways: complete cases (i.e. only including participants completing service use and QoL data) and on an
ITT basis (i.e. according to the group to which they were randomised regardless of intervention receipt).
Costs and outcomes were compared between the two arms at baseline and the 12-month follow-up.
Cost-effectiveness was assessed by combining the costs with data on the primary outcome measure
(QOLIE-31-P) at 12 months. Cost–utility was explored by combining total costs with QALYs, derived
from EQ-5D-5L data.
Process evaluation
Within 6 months of attending the course, participants were interviewed about their experience of attending
SMILE (UK). Face-to-face semistructured interviews were held on topics about the participant’s experience
with epilepsy, negative and positive aspects of the course and whether or not they had changed anything in
their self-management behaviours. Interviews were audio-recorded and transcribed verbatim. A line-by-line
coding approach was undertaken with codes later grouped into broader emerging themes.
Results
Outcome measures
The study included 404 participants, with a mean age of 41.7 years [standard deviation (SD) 14.1 years];
54.2% were female and 75.2% were white. The group had been diagnosed with epilepsy for a median of
18 years and 45.8% had another medical condition. The mean QOLIE-31-P score for the whole group at
baseline was 66.0 (SD 14.2), with 69.3% having ≥ 10 seizures in the previous year. Clinically relevant
levels of anxiety symptoms were reported in 53.6% of the group and depression symptoms in 28.0%.
Assessment of self-stigma revealed 63.1% of the group felt mild to high levels of stigma because of
their epilepsy.
Characteristics associated with lower QoL were being female, having lower qualifications, not being in
employment, having a more recent diagnosis of epilepsy and comorbidity, especially a diagnosed psychiatric
condition. Secondary outcome measures associated with QOLIE-31-P were HADS-depression, HADS-anxiety,
self-stigma, seizure frequency, self-mastery and medication adherence.
In the intervention group, 74% attended at least one session of SMILE (UK) (i.e. one session was defined
as one half-day) and 62% attended the 2 full days. Retention rates in the study were high with 331 out of
404 (82%) completing the 12-month follow-up. AEs were reported from 41 participants and none was
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found to be related to the intervention. At the 12-month follow-up, there were no significant differences
between the SMILE (UK) and TAU group in any of the outcomes measured.
The implementation fidelity analysis revealed that SMILE (UK) was delivered with a high adherence to the
prescribed topics with a high level of facilitator competence.
Cost-effectiveness evaluation
Service use was similar between the two groups. At baseline, general practitioners were the most
frequently reported contact, with two or three visits in the previous year. At enrolment, about 40% of the
group reported attending EDs in the previous year. At the 12-month follow-up, the proportion of patients
reporting use of hospital services had reduced for both groups. The percentage of participants who
reported informal care was low, but those who did received substantial help from family and friends.
Findings from the complete-case analysis show that SMILE (UK) is cost-saving, but produces fewer QALYs
than TAU. Therefore, the intervention could save costs compared with current treatments available but is
associated with lower QoL. The associated incremental cost-effectiveness ratio from a NHS and social care
perspective is £5548 and this is how much extra it costs for TAU to produce one extra QALY. The probability
of SMILE (UK) being cost-effective (compared with TAU) at the £20,000 willingness-to-pay threshold from
the NHS perspective is slightly above 40% (for both the complete case and the ITT analyses). However, this
probability is somewhat higher (60%) from the societal perspective, at the same threshold.
Process evaluation
The process evaluation with 20 participant interviews revealed that participants felt that they benefited
from the course by being in a group with people similar to them. Some met other PWE for the first time.
They reported that learning from others and sharing their own experiences helped them to gain
confidence to become experts in their condition. However, nearly half reported memory or language
problems that they felt may have either reduced their learning or impaired their ability to self-manage in
practice. Many said that the knowledge and confidence led them to interact with health-care professionals
more efficiently. Over half (60%) of those interviewed said that they were managing their epilepsy
differently. Nineteen out of 20 participants would recommend SMILE (UK) to others.
Conclusion
The SMILE (UK) programme is designed to increase knowledge for PWE. It contains topics addressing
medical issues, the science behind epilepsy and the social aspects of living with epilepsy. Delivering this in
a group setting allows people to share their own experiences and gain confidence. Participants wished
they had attended such a course when first diagnosed, which could have improved their self-management.
However, some participants who were approached for interviews reported language or memory problems,
which limited the impact of a stand-alone group course and its ability to help them manage behaviour
changes in practice.
At the final follow-up, there were no significant differences between the SMILE (UK) group and the TAU
group in QOLIE-31-P or any secondary outcome measures. The cost-effectiveness analysis showed that
offering SMILE (UK) to epilepsy patients is cost-saving, but does not result in more QALYs than TAU.
A limitation of the SMILE (UK) evaluation is using self-reported data to measure outcomes. This can be
problematic in a patient group who report memory problems when follow-up is > 12 months. However,
for some outcomes, such as seizure frequency, there is no reliable alternative. The courses were held on
weekdays, which may have limited the attendance of people who have work and family commitments.
Our group had epilepsy for a median of 18 years and a 2-day course may be too little too late to change
behaviour. In addition, about half of the group displayed some symptoms of anxiety and around 30%
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had depression symptoms. Disturbed mood can also be associated with self-reported memory impairment.
A psychological component in addition to a self-management course may be necessary for behaviour change.
A strength of the trial was the study design with its large sample size, generalisable to other populations.
In addition, the study included a cost-effectiveness and process evaluation, and an assessment of
implementation fidelity of a self-management course in epilepsy, which, to our knowledge, are the first of
their kind.
Recommendations for research
A group course can help PWE overcome a sense of isolation and loss of self-esteem, probably when newly
diagnosed. This research shows that psychological distress is strongly associated with impaired QoL. Based
on this, psychological interventions could be tested for PWE with psychological comorbidity. A combination
of educational, psychological and peer-group work interventions could be tested also within an integrated
primary–secondary care context. This study highlighted the need for research on appropriate outcome
measures in this population.
Trial registration
This trial is registered as ISRCTN57937389.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The original funding application referred to the study intervention as SMILE. Over time, we have foundthat SMILE is a common acronym for other interventions (including other interventions for epilepsy).
For this reason, we used SMILE (UK) in our publications. To remain consistent, we will use SMILE (UK) in
our report.
Background
In 2010, the National Institute for Health Research (NIHR) issued a call for a randomised controlled trial (RCT)
on a self-management education programme for people with epilepsy (PWE) (see Appendix 1). The call
specified that the trial was to include people with poorly controlled epilepsy who were aged ≥ 16 years.
It was specified that effectiveness should be evaluated based on quality of life (QoL) measures and that
participants should be followed up 1 year post intervention. Two existing studies were cited, one based in
Germany1 and one in North America.2 Both featured 2-day self-management education programmes. The
investigators of this study responded to the NIHR call by offering to adapt the intervention developed in
German-speaking countries for the UK. Funding was agreed for the current RCT.
The trial was named Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)].3
This study was a pragmatic, parallel design, multicentre RCT in the UK.4 The broad objective of the
research was to evaluate the clinical effectiveness and cost-effectiveness of a group self-management
programme for people aged ≥ 16 years who were experiencing ‘poorly controlled’ epilepsy. This was
defined as epilepsy resulting in two or more seizures per year.
Epilepsy in the UK: causes, challenges and consequences
Epilepsy is a common neurological condition defined as the occurrence of two or more seizures more than
a day apart.5 Prevalence rates range from 4.2 to 9 per 1000 people6 and currently up to 1% of the UK
population live with the condition.7
The aetiology of epilepsy is variable. It can arise as a result of cerebrovascular disease (i.e. stroke), head
trauma, congenital abnormalities and neurodegenerative disease (i.e. Alzheimer’s disease) or it can be
idiopathic.8 Mortality risk varies for PWE and is higher than in the general population.9
The NHS recommends that epilepsy care should consist of a combination of regular general practitioner
(GP) consultations, adherent medication use, patients’ knowledge of seizure triggers and adequate
self-management.10 Pharmacological intervention is currently the mainstay of treatment. Most PWE are
able to eliminate seizure occurrence through use of antiepileptic drugs (AEDs). However, up to 40% are
considered to have drug-resistant epilepsy.11 The present research focuses on patients who experience
epilepsy with two or more seizures per year, despite medical intervention, which, following the wording of
NIHR guidelines, is defined as ‘poorly controlled epilepsy’.
Epilepsy is costly to UK health-care services. Recurrent seizures are a significant cost for the NHS,4 particularly
when services are used on an emergency basis.12 From 2014 to 2015, almost 130,000 people were admitted
to UK hospitals for epilepsy and around 83,000 used emergency services.13 Indirect costs of epilepsy are
also likely to be high as a result of missed days of employment14 and early retirement because of illness.15
Given the direct and indirect financial consequences of epilepsy (i.e. emergency service use, time off work),
better ambulatory care management strategies offer a potential for secondary prevention and could be
cost-effective for health-care service providers.16
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Epilepsy diagnosis is associated with significant psychological and social costs. Being labelled negatively as
‘epileptic’ can be accompanied by discrimination.17,18 This further undermines well-being and QoL.19,20
Educators and health-care service providers are mindful of the complex psychosocial nature of epilepsy,21
particularly as poor QoL and psychosocial well-being has a bidirectional relationship with seizure frequency
and severity.22 Structured education programmes that target psychosocial and biological aspects of seizure
management may result in better outcomes for people with poorly controlled epilepsy and could improve QoL.
Improving quality of life of people with epilepsy
In the planning stages of an intervention designed to improve the lives of PWE, and using QoL as a
primary outcome measure, the factors that could affect QoL were considered. The factors that were
identified will be presented in the following sections.
Seizures
Seizure frequency and QoL are linked. PWE are likely to have similar QoL to the general population when
seizures are controlled.23 QoL is inversely associated with the amount of time since last seizure (i.e. ‘seizure
recency’).24 Given this association, even a minor improvement in seizure frequency may have a beneficial
effect on health-related quality of life (HRQoL)25 and vice versa.
Seizures are associated with physical consequences that can negatively affect QoL. For instance, sustaining
a serious injury during a seizure can be associated with long-lasting repercussions. Thus, minimising seizure
frequency is also likely to reduce the ongoing consequences of seizure-related injury.
Antiepileptic drugs
The primary means of treating epilepsy is with AEDs; however, patients may also experience debilitating
side effects from their medication. Adverse effects of medication significantly reduce QoL.26 Apart from
seizure frequency, adverse side effects from AEDs may be the biggest predictor of poor QoL in PWE.24
Failure to comply with treatment regimens (i.e. ‘non-adherence’) also has serious implications for PWE.
Non-adherence may result in increased seizure frequency, decreased QoL and missed employment.27
Results of one AED adherence study showed that depression is associated with medication non-adherence.28
This suggests a complex association between medication use, QoL and psychosocial well-being. These
factors could be targeted by self-management intervention.
Psychological comorbidity
Psychosocial consequences may be as important as the physical consequences of epilepsy. Although
treatment success is often reliant on biomedical factors, there are also important psychosocial issues to
consider when managing the condition.21 There is an elevated risk of poor mental health following
epilepsy diagnosis.29 PWE are more likely to experience higher rates of depression,30 anxiety31 and suicidal
ideation.32 Depressive symptoms can diminish QoL33,34 and influence seizure frequency.35,36 Moreover,
some forms of psychological conditions frequently co-occur,36 such as anxiety and depression, having a
further impact on seizure frequency. Given the complex relationship between seizure frequency and
psychological well-being, interventions that address both treatment targets seem worthwhile.
Stigma and resilience
Stigma is a major factor that influences QoL in PWE.37,38 Although public perceptions about epilepsy have
changed,38 negative beliefs and lack of knowledge continue to perpetuate stigma and discrimination.39 In a
survey of attitudes of the UK general public, participants felt epilepsy was embarrassing, frightening and meant
being unable to drive or participate in employment.40 Participants attributed seizures to stress, intoxication and
mental health problems. These findings illustrate some of the prevalent, general attitudes and misconceptions
about epilepsy. Despite epilepsy being a neurological condition, psychological and social factors are often
attributed to its development,41 which may exacerbate feelings of ‘differentness’ and isolation in PWE.
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Scambler and Hopkins42 divided stigma into felt versus enacted. Enacted stigma is discrimination against
PWE based on a belief that the attributes of PWE are undesirable or unacceptable. Low employment rates
among PWE may partly be a manifestation of enacted stigma.38 Felt stigma is linked with the fear and
shame tied to being ‘epileptic’.42 Felt stigma is associated with low self-esteem, anxiety and depression.38
Dilorio et al.43 suggest that people with frequent seizures may internalise felt stigma and have unhelpful
perceptions about their treatment. On the other hand, resilience can help to combat the diminished QoL
associated with epilepsy diagnosis.24 Those involved with epilepsy care can help PWE to combat stigma by
giving them information and support strategies for overcoming stigma and discrimination.38
Mastery and control
The term mastery is used to describe a state of confidence in which a person feels able to independently
overcome the challenges with which they are faced.44 Mastery is used in combination with self-efficacy to
reduce stress and develop positive new behaviours.45 In the literature, the term ‘self-mastery’ has been
used interchangeably with self-efficacy. Evidence suggests when a person feels more confident in their
ability to cope and manage their illness effectively, they are more likely to put self-management behaviours
into practice.46 Therefore, a sense of mastery and control is important for PWE as they have the potential
to have an impact on seizure control and QoL.47
Age and socioeconomic factors
The effect of epilepsy-related challenges on QoL can be related to the person’s life stage.48 In a focus
group study of UK adolescents, epilepsy diagnosis had an effect on QoL and identity formation.49 In a
study from the USA, seizure frequency was less concerning for older adults and their QoL than maintaining
‘normalcy’ in social and emotional function.50 Other lifestyle variables such as socioeconomic status are
also important for QoL in PWE. For instance, low socioeconomic status is related to an elevated risk of
developing epilepsy,51,52 frequent hospital visits53 and attrition from epilepsy care,54 all of which can be
associated with QoL. In interpreting the results of an intervention aiming to improve QoL and reduce
seizure frequency, consideration of these factors will be important.
Summary of quality of life research
Living with epilepsy can influence QoL in PWE. In the present study, we aim to test the effect of an
intervention designed to improve psychological, physical and social consequences of epilepsy. In considering
the complexity of the above factors in managing this condition, the benefits of ‘self-management’ have
been proposed in the literature. This addition to epilepsy treatment will be discussed in the remainder of
this chapter.
Self-management education
What is self-management?
There is no widely accepted description of what self-management means, but the Department of Health
has used the 2002 definition from Barlow et al.:55
Self-management refers to the individual’s ability to manage the symptoms, treatment, physical and
psychosocial consequences and lifestyle changes inherent in living with a chronic condition.
Barlow et al.55
The notion that self-management encompasses all of the aspects of living with a chronic condition is
summarised in the following:
Self-management is defined as the tasks that individuals must undertake to live with one or more
chronic conditions. These tasks include having the confidence to deal with medical management, role
management and emotional management of their conditions.
Adams and Corrigan. p. 5756
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Corbin and Strauss identified these tasks (i.e. medical, role and emotional management) as the key aspects
of disease self-management.57 It is axiomatic that those living with a long-term condition (LTC) must be
self-managing their condition. Thus, interventions that focus on self-management are really directed at
supporting people to manage their LTC optimally (i.e. supported self-management interventions).
To facilitate the core tasks of self-management described above, Lorig and Holman58 proposed the
acquisition of five core self-management skills including ‘problem-solving, decision-making, appropriate
resource utilisation, forming a partnership with a health care provider, and taking necessary actions’. For a
schematic representation of how this might be incorporated into an intervention, refer to Appendix 2.
Extensive qualitative research has identified a number of common themes relating to self-management
support among individuals living with a wide range of LTCs. These common themes include:
l the need for collaborative relationships with health-care professionals (HCPs)
l the need for support from HCPs regarding information and education
l medication adherence issues
l the need for emotional and peer support
l the need for carers to balance support and independence
l the individuality of each person’s experience of illness
l the importance of psychological support to help with adjustment for some people with LTCs.59
The first two items on this list are reported in most studies looking at the experience of people living with
any LTC.57
What are self-management interventions?
Self-management interventions teach behaviours that seek to alleviate the consequences of a chronic
illness.60 The objectives are to facilitate patients taking an active role in their own health care by
encouraging autonomy and providing accurate information on symptom management.61
Recent work has attempted to identify the different activities that could be involved in supporting
self-management (Box 1).62 This taxonomy, derived from an expert advisory workshop and a systematic
BOX 1 The Practical Reviews in Self-Management Support (PRISMS) taxonomy of potential self-management
components
1. Information about the LTC and/or its management.
2. Information about available resources.
3. Establishing specific clinical safety plans and/or rescue medication.
4. Regular assessment and evaluation.
5. Offering the patient feedback and monitoring.
6. Practical support regarding treatment.
7. Provision of equipment.
8. Providing opportunities to practise practical self-management.
9. Providing opportunities to practise everyday activities.
10. Providing opportunities to communicate with a HCP.
11. Providing training on psychological approaches.
12. Provision of easy access to advice or support when needed.
13. Peer support.
14. Lifestyle advice and support.
Note that not all of these components are appropriate for self-management support of all LTCs and the
effectiveness of the individual components in self-management support for different LTCs is often unknown.
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overview of the literature, describes only the potential components of self-management interventions as
described in the literature.59 Efficacy of these components in different LTCs has not been established.
How, for example, does self-management support work?
Self-management courses have been successfully implemented in the UK for other LTCs such as diabetes
mellitus and arthritis [e.g. Dose Adjustment For Normal Eating (DAFNE),63 Diabetes Education for
Self-Management for Ongoing and Newly Diagnosed (DESMOND),64 X-PERT65].55 DESMOND, for instance,
is a group education programme based on psychosocial theories of learning and self-mastery as a basis for
behaviour change.66 The diabetes mellitus course is generally 1 or 2 days long and consists of non-didactic
teaching methods.66 Increased self-confidence and empowerment have been reported following these
targeted self-management education courses.64,65,67 Thus, previous research suggests that short-term
self-management programmes can be of benefit in UK health-care settings and diabetes mellitus courses
are now offered to all people with diabetes mellitus in the UK free of charge.
Why self-management for people with epilepsy?
The National Institute for Health and Care Excellence (NICE) recommends that PWE are given adequate,
structured information, and empowered to be successful in managing their condition.68 Past studies
indicate that PWE want to know more about how to effectively manage their condition.69,70
Although PWE might wish to speak with someone other than their doctors about managing their epilepsy;70
many do not know who to ask or lack the confidence to do so.21 The level of information needed to
enhance seizure control and facilitate patient empowerment may require more detail than can be delivered
through traditional outpatient consultation.71 Interventions that aim to improve knowledge, confidence and
empowerment may encourage PWE to seek support from a wider range of services to help manage their
condition. At present, there are no standardised group education programmes available for PWE in the UK.
A Cochrane review of epilepsy interventions found that there is a potential benefit of self-management
groups, although it is essential that further empirical evidence is generated.72 The review was later
updated, indicating that evidence exists to support the benefit of self-management and epilepsy nurse
specialist (ENS) involvement in interventions.73 However, the review stressed the limitations of findings to
particular settings and called for improved service models for widespread intervention delivery. In order
to test the usefulness of self-management interventions in helping improve QoL for PWE across the UK,
further research is needed.74,75
What evidence exists on self-management for people with epilepsy?
Epilepsy is a condition that requires targeted behaviour and management (such as medication adherence
and avoidance of seizure triggers) to alleviate epilepsy-related consequences. For PWE, self-management
strategies are defined as the behaviours that minimise frequency and severity of seizures76 and improve
overall QoL.77 Good self-management strategies may also help PWE to potentially feel more confident
about health-care decisions and overcome psychosocial consequences of living with epilepsy.76
At the time of developing the research protocol for this project, there was little evidence on the efficacy
of group self-management programmes for PWE. Two key studies on group-based interventions were
highlighted during trial design. The interventions that informed development of the SMILE (UK) trial are
described below.
Sepulveda Epilepsy Education
The Sepulveda Epilepsy Education (SEE) programme was developed with an aim of meeting the complex
psychosocial and educational needs for a wide range of PWE in the USA.2 Helgeson et al.2 evaluated the
effect of the 2-day SEE intervention on psychological and physical outcome measures (i.e. self-efficacy, AED
adherence). With a sample size of n = 38 (18 treatment, 20 waiting list control), limited statistically significant
differences were found between groups at follow-up (Table 1). Nevertheless, compared with controls, the
treatment group showed a significant decrease in seizure-related fear, hazardous self-management behaviour
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and misconceptions about epilepsy. The study also showed a statistically significant decrease in self-rated
depression in the treatment group (p < 0.0007) immediately after participating in the course; however, this
did not persist at their 4-month follow-up. No other statistically significant differences were observed
between groups at the last follow-up, 4 months after enrolment (i.e. seizure frequency, self-efficacy).
Modular Service Package for Epilepsy
The Modular Service Package for Epilepsy (MOSES) intervention was originally developed in Germany.78
After programme development, MOSES was tested in three German-speaking countries in a RCT.1
The programme was adapted for both in- and out-patient contexts, and the course content was covered
over 2 consecutive days. Participants were recruited from 22 specialist outpatient clinics and allocated to
either the treatment or the waiting list control group receiving treatment as usual (TAU). Their sample
contained 242 adults with epilepsy aged > 16 years with no other major comorbidity (see Table 1).
The final follow-up was carried out at 6 months. At this time point, course attendance had a positive effect
on epilepsy-related knowledge, overall coping ability, seizure frequency and medication use. Thus, the
authors concluded that MOSES is effective and reduces seizure frequency. They did not find, however,
any effect of the intervention on a generic measure of QoL, self-esteem and other aspects of coping with
epilepsy (i.e. information seeking).1 They used the Short Form questionnaire-36 items during the trial,
which may not have adequately detected the effect of the education programme. An epilepsy-specific
measure of QoL [e.g. Quality Of Life In Epilepsy 89 (QOLIE-89) or Quality Of Life In Epilepsy 31 (QOLIE-31)]
may be more sensitive in future research.1
Overall, the effect of the MOSES programme on seizure frequency was encouraging and MOSES has now
been routinely offered across Germany for approximately 15 years. Its success in practice led us to hope
that it may be appropriate in UK health settings. Thus, MOSES was selected to trial for use in the UK.
TABLE 1 Two options of group self-management interventions for PWE for UK evaluation
Study Setting Sample Design Key findings
Helgeson et al.2 Medical care clinic,
CA, USA
PWE n= 38 Pre-/post-test
controlled outcome
study; 4-month
follow-up period
Statistically significant increase in
understanding of epilepsy at 4-month
follow-up. Statistically significant
decrease in seizure-related fear,
hazardous self-management behaviour
and misconceptions about epilepsy.
Statistically significant increase in AED
compliance in treatment group at
follow-up
Limitations: small sample size. Short
follow-up period
May and
Pfäfflin1
Epilepsy centres in
Austria, Germany
and Switzerland
PWE n= 242;
16–80 years
Pre-/post-test
randomised study;
6-month follow-up
period
Statistically significant improvement at
follow-up in epilepsy-related knowledge
and coping
In treatment group, seizure outcomes
improved and participants reported
feeling more satisfied with AED therapy
Limitations: per-protocol analysis may
bias the results. No long-term follow-up
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These two seminal studies offered important conclusions about the benefits of self-management education
in group settings. However, these studies lacked:
l a sample size adequate to detect significant differences in QoL with enough statistical power while
minimising type 1 errors (false positives)
l a long-term follow-up period (e.g. at least 1 year)
l a process evaluation of self-management courses using qualitative methods to gain the
patient’s perspective
l a health economics evaluation of the cost-effectiveness of self-management courses
l an assessment of implementation fidelity to determine whether or not the intervention was delivered
according to protocol.
The SMILE (UK) programme was designed to address these topics.
Summary and methodological rationale
Epilepsy is a highly stigmatised condition, associated with multiple potential psychosocial consequences.
Past research indicates that many PWE want to know more about their condition,69,70 but may not know
where to find information. This suggests that offering guidance and information may be valuable for PWE
in the UK.
Self-management education offers an opportunity to address a gap in outpatient or community service
provision. Self-management programmes are different to traditional educational offerings as they are
designed to educate and empower those living with chronic health-care conditions.79 No such programme
has been evaluated for UK-based health-care services for epilepsy.
Research objectives
The main aim of this research, as required by the NIHR call, was to evaluate the effect of an intervention
[the SMILE (UK) course] on patient QoL compared with TAU. The primary outcome was assessed using
total QOLIE-31-P (Quality Of Life In Epilepsy 31-P)80 score at 12-month follow-up. Secondary outcomes
included seizure frequency and recency, impact of epilepsy, adverse effects of medication, depression,
anxiety, stigma and self-efficacy (measured via mastery and control). We also collected health economics
data to determine the cost-effectiveness of the intervention.
Objectives of this research were to:
1. refine the content and delivery of the SMILE (UK) course after receiving feedback from Epilepsy Action
Information Reviewers, who assessed the content of research materials for PWE
2. recruit and provide training for SMILE (UK) course facilitators
3. conduct a pilot study with volunteers to determine the suitability of outcome measures in terms of
ease of completion
4. obtain qualitative feedback on the SMILE (UK) course by conducting an external pilot study with
Epilepsy Action volunteers
5. describe the experiences of those who attended the SMILE (UK) course, as well as perceptions of
barriers to attendance and benefits of the programme
6. assess the delivery of SMILE (UK) courses by conducting a fidelity analysis
7. test the hypothesis that participants with poorly controlled epilepsy would report improved QoL
12 months after being offered the SMILE (UK) course with TAU compared with those who received
TAU alone
8. evaluate changes in secondary outcome measures at 6- and 12-months after randomisation
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9. assess the cost-effectiveness of the SMILE (UK) course
10. highlight training requirements for implementing SMILE (UK) in the UK
11. disseminate findings to researchers, service users and commissioners of policy development.
Taking into account Medical Research Council (MRC)81 guidelines, the SMILE (UK) trial was undertaken in a
series of stages.
l The SMILE (UK) intervention was adapted for a UK context based on existing evidence from a similar
intervention developed in Germany1 and an early English translation.
l A complex intervention protocol was developed and published.3
l The SMILE (UK) intervention was piloted externally.82
l A statistical analysis plan was published.4
l A process evaluation of participants’ views of the courses was undertaken.83
l A baseline description of SMILE (UK) participants was combined with an analysis of which outcome
measures are related to QoL (measured by QOLIE-31-P).84
l A fidelity analysis was undertaken on complex intervention delivery.85
l Clinical effectiveness and cost-effectiveness follow-up data were collected for both trial arms
and analysed.
l Results would be disseminated when the study was complete.
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Chapter 2 Intervention development
Introduction
The SMILE (UK) intervention was adapted from MOSES, an educational treatment programme designed in
Germany for PWE. It is a group course designed with input from specialists, non-medical professionals and
patient groups. The intervention was originally developed by Ried et al.78 for German-speaking adults aged
> 16 years with any severity of epilepsy. The course is also suitable for patients with both epilepsy and mild
learning difficulties. This chapter will outline the process by which the intervention was developed for use
by PWE in the UK. A schematic of this process can be found in Appendix 3.
Overview of the MOSES intervention
The MOSES programme was designed to promote coping with epilepsy, increase participation in everyday
activities and improve general self-esteem. Content is focused on supporting patients to become experts in
managing their epilepsy, which is also consistent with NICE guidelines.68
The MOSES developers did not adopt a specific behavioural change model.78 Instead, they designed the
intervention pragmatically, incorporating three levels of information processing to achieve change:78
1. the cognitive level (providing information)
2. the emotional level (identifying and discussing emotions)
3. the behavioural level (discussing actual activities).
Cognitive, emotional and behavioural aims are included in all nine MOSES modules, which were
subsequently adapted for the SMILE (UK) intervention. Ried et al.78 specified educational aims for PWE
taking part in the course, as well as for those teaching the courses.78 Although not conceptualised as
such,78 key evidence-based behavioural change elements include:86
l education about self-monitoring (of seizures)
l obtaining support
l increasing confidence (through identifying previous strengths and successes)
l exposure to role models, both within the formal teaching material and to others within the group
teaching format
l provision of encouragement from others
l discussion within the sessions of realistic outcome expectations.
The MOSES programme is intended to improve participants’ self-mastery (i.e. their confidence in being able
to perform behaviours)87 to manage their condition. It focuses on a number of lifestyle changes, including
obtaining sufficient sleep, avoiding alcohol, reducing stress, obtaining social support, understanding and
coping with adverse effects of medication, following their prescribed medication schedule and planning
ahead for collecting medicines.88 Self-mastery may also be increased by exposure to the experiences of
other PWE and facilitators during the course. By improving the self-mastery of PWE and their expectations
regarding the outcomes of treatment and seizures,89 it was anticipated that MOSES and, therefore, SMILE
(UK) would lead to better outcomes for PWE.
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The MOSES programme has a flexible timetable arrangement. It can be run over a short period of time
(i.e. a weekend) or longer (i.e. weekly sessions for up to 8 weeks) if preferred.78 Topics covered during the
programme include the following.78
1. Living with epilepsy: identifying and expressing how it feels having epilepsy and how it felt being
first diagnosed.
2. Epidemiology: teaching how common epilepsy is and learning about famous people with the condition.
3. Basic knowledge: causes of epilepsy and different types of seizures.
4. Diagnostics: tools and techniques used for epilepsy diagnosis.
5. Therapy: treatments for epilepsy, such as AEDs.
6. Self-control: recognising what can cause seizures and using countermeasures to interrupt auras.
7. Prognosis: discussing seizure control and the possibility of seizure freedom.
8. Psychosocial aspects: discussing the impact that epilepsy has on daily life, relationships, employment
and day-to-day functioning.
9. Network epilepsy: talking about help that is available from self-help groups and other institutions.
The content is delivered in a workshop-style environment in which patients are encouraged to share their
experiences with group members and engage with structured teaching activities.
The programme’s aims address understanding and coping with epilepsy, how it is diagnosed and treated,
how to be more involved with the treatment plan, how it can impact life socially and at work, how to
become independent and lead a normal life, and especially how to become expert representatives for
one’s own condition.78
At the conclusion of the course, it was hoped that participants would gain a deeper understanding of
epilepsy, have generated ideas within the group about effective coping strategies and learn how to
manage their condition autonomously.
Mechanisms whereby MOSES modules may lead to improvement in QoL in PWE are outlined in Table 2.
Numbers in the table refer to the specific MOSES modules 1–9, as listed above.
In order to teach the MOSES programme, course facilitators are required to have experience of facilitating
groups and to have completed a MOSES-specific training seminar.78 Facilitators are nurses, psychologists,
clinicians or social workers. Resources for facilitators during programme delivery consist of a ‘trainer
manual’ and a workbook for group participants. Various techniques were developed to teach the course
material in an interactive way and these were also used for SMILE (UK).
The course modules can be delivered on separate days over a period of weeks. For the MOSES trial,
researchers offered the nine course modules over 2 consecutive days. The ideal group size was thought to
be between 7 and 10 participants, with a maximum of 12;78 however, the group size in the RCT was
not specified.1
Presently, MOSES is offered to all PWE aged ≥ 16 years, regardless of seizure frequency, who can follow
90-minute teaching sessions.90 It has been offered for approximately 15 years with great success, with over
20 courses scheduled in the current year.90
Developing the SMILE (UK) intervention
There were a number of components involved with adapting the intervention for use in the UK. We
adapted the patient workbook and teaching manual, liaised with patient user groups and trained
UK-based facilitators to deliver the course. The following sections will outline how this was undertaken
prior to intervention delivery. A schematic representation of the timeline is presented in Appendix 3.
INTERVENTION DEVELOPMENT
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TABLE 2 Potential relationship between MOSES modules and factors influencing QoL
Factors influencing
QoL in PWE
Relevant MOSES
modules Specific content
Seizures (frequency
and recency)
4. Diagnostics
5. Therapy
6. Self-control
7. Prognosis
Knowing difference between seizure types; accurate recording of seizures and
their semiology to assist better medical management
Understanding importance of tests (e.g. blood tests) to monitor treatment;
use of aids (e.g. dosette boxes) to assist adherence; encourage use of seizure
diary to monitor progress/help medical management achieve better seizure
control; being able to explain treatment to others and why one may have to
take drugs at certain times; planning medication for holidays etc.; what to do
if a dose is omitted; understanding other non-pharmacological treatments
(e.g. surgery, vagus nerve stimulation)
Learning to identify, record and respond to seizure triggers; learning to
identify and respond to seizure auras (using countermeasures)
Learning about factors likely to improve prognosis (i.e. to increase chances of
becoming seizure free)
Seizures (injury) 5. Therapy
6. Self-control
8. Psychosocial
aspects
Being able to tell others about one’s seizures, what they look like; how others
should respond to prevent injury
Learning to identify, record and respond to seizure triggers; learning to
identify and respond to seizure auras (using countermeasures)
Learning how to minimise risks at home/work
AEDs 5. Therapy Reducing/improving acceptance of AED adverse effects
Psychological
comorbidity
1. Living with
epilepsy
4. Diagnostics
5. Therapy
6. Self-control
8. Psychosocial
aspects
Dealing with anger/anxiety about having epilepsy
Understanding the purpose of/reducing anxiety about different investigations
Reducing psychiatric comorbidities associated with adverse effects of some
AEDs
Improving seizure control
Improving self-esteem, using problem-solving approaches and seeking
psychological support; seeking neuropsychological assessment to identify
cognitive difficulties and address these; identifying own positive attributes and
weaknesses
Stigma 2. Epidemiology
5. Therapy
7. Prognosis
8. Psychosocial
aspects
9. Network
epilepsy
Learning that epilepsy is common and can affect everybody; learning about
achievement potential of PWE
Provision of advice on family planning; learning that taking medication can be
part of everyday life
Learning what can still be achieved if PWE do not achieve seizure freedom
Learning to reduce unnecessary restrictions on activities; maintaining social
contacts; engaging in physical exercise; understanding relevant disability
legislation and entitlements
Identifying/contacting/joining relevant organisations/support groups
Resilience 1. Living with
epilepsy
Helping with reactions to diagnosis and planning future coping strategies
Age 7. Prognosis
9. Network
epilepsy
Learning about what can be achieved at different ages even if PWE do not
achieve seizure freedom
Identifying age-appropriate sources of support/services
DOI: 10.3310/hta22210 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 21
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ridsdale et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
Adapting the participant workbook and teaching manual for the United Kingdom
The SMILE (UK) research team obtained course material from the MOSES group. Most content had been
translated from German except for personal testimonies from PWE. Personal testimonies were translated
into English within the research department. Each SMILE (UK) collaborator edited and revised one module
of the patient workbook. Some module titles were modified for ease of understanding.
Changes were made to several sections. For example, the section on ‘Famous PWE’ was modified to
include celebrities and public figures that would be recognisable to people living in the UK. The section on
‘Networks’ was also changed to reflect local support network information. Epilepsy Action contributed as
subeditors during this part of the intervention adaptation. They reviewed the use of English throughout
the patient workbook to reduce the required reading age and improve accessibility for a wide range of
audiences. Current information on antiepileptic medication was adapted from information available from
the Epilepsy Society. Local regulations (e.g. regarding insurance and driving) were changed to reflect
UK legislation.
Overview of the SMILE (UK) intervention
The SMILE (UK) course is a group-based, interactive education programme based on MOSES, developed to
provide strategies for individuals living with poorly controlled epilepsy in the UK.3 SMILE (UK) was designed
to be delivered in 16 hours over 2 days.
The number of people per group was intended to range from 6 to 12 participants (including carers or
family). All participants assigned to the treatment group were given the option to have a carer or
significant other accompany them to the course if they wished. This was encouraged to make the
participant feel supported, but also to add another perspective to group conversations (i.e. family or carer
perspective). The group number was selected based on the original MOSES research78 and because it
might have helped allay anxiety about speaking in front of a large audience and would thus be small
enough to share personal experiences comfortably.
Two trained HCPs acted as group facilitators during the course, wherein attendees progressed through
set modules and participated in group discussions. A workbook was used throughout the course so
participants could become familiar enough with it to be able to use it at home. The programme covered
the same nine modules offered by MOSES (i.e. living with epilepsy, epidemiology, basic knowledge,
diagnostics, therapy, self-control, prognosis, psychosocial aspects, and network epilepsy)78 renamed for
SMILE (UK) (see Table 3).
SMILE (UK) teaching materials
The SMILE (UK) course is taught using a number of items, including two sets of workbooks (teaching
manual and participant workbook), a flip chart for teaching demonstration, stickers for group exercises
(used with flip chart), and Microsoft PowerPoint® (Microsoft Corporation, Redmond, WA, USA) slides.
Each of these teaching resources will be discussed in the following sections.
Teaching manual
A teaching manual was developed based on the MOSES ‘trainer workbook’.78 For copyright reasons,
specific content will not be provided here (please see Acknowledgements for more information). Content
can be requested from the MOSES group. The aim of this resource is to guide facilitator teaching of the
SMILE (UK) course. In the preface section of the book, it is suggested that course content may be
negotiated between participants and facilitators in the future. The teaching manual is divided into
two sections.
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Section 1
This contains six introductory modules: (1) a preface, (2) SMILE (UK) teaching aims, (3) structure and
implementation of SMILE (UK), (4) requirements for teaching SMILE (UK), (5) key terms, and (6) sources for
further information. The guide stresses the need to provide participants with accurate information and the
importance of adopting an interactive teaching style. Facilitators are encouraged to adapt their teaching
methods and speed according to the needs of the group. Overall teaching goals include (1) promotion of
active learning, (2) support sympathetic and friendly communication between course participants and
(3) fostering a stimulating and varied learning environment.
Section 2
This contains a summary of each module from the participant workbook. Each module contains
information on the duration of each session, teaching methods and materials. Teaching advice is given
as a guideline that can be used flexibly or supplemented during the course. Throughout each module,
suggestions are made to facilitators to indicate where certain teaching materials (i.e. flip chart, stickers)
can be used. Throughout the course, facilitators are encouraged to allow time for social interaction and
discussion rather than focusing solely on teaching.
Participant workbook
Participants were provided with a workbook at the beginning of the SMILE (UK) course and encouraged to
use it as a home reference after the course had finished. Each of the nine modules (Table 3) begins with a
summary page (about the topic, aims and contents), and includes note-taking space, interactive questions
(e.g. what does my doctor need to know about my seizures?) and a final summary of key points (see
Acknowledgements for more information about copyright).
Not all workbook material is covered during the 2-day programme, so facilitators suggest that participants
refer to the book in their own time and share content with family and friends. At the end of each module,
there is a series of questions that encourage further consideration of issues raised and further teaching
session. Ample time is provided for sharing problems and solutions.
TABLE 3 Participant workbook modules
Module Topic Objective Page
Introduction 5
One Living with
epilepsy
How to recognise and express different emotions that you may experience
because of epilepsy. How to develop better ways to cope with epilepsy
25
Two PWE How common is epilepsy in the UK? When are you most likely to develop
epilepsy? Famous PWE and what they have achieved
47
Three Basic
knowledge
The causes of epileptic seizures, how seizures develop and how to identify the
different seizure types
57
Four Diagnosis How to observe and describe seizures accurately. How to document seizures, the
results of investigations and understand the different diagnostic methods
67
Five Treatment An overview of the most common AEDs and different treatment options. How to
actively participate in your treatment
81
Six Self-control How to avoid seizure triggers and become aware of auras/warnings. Working out
what might be relevant to developing abilities of self-control
113
Seven Prognosis The chances of achieving seizure freedom and the chances of staying seizure-free
after stopping AEDs. Options if seizure freedom is not achieved
131
Eight Personal and
social life
How to improve self-esteem and social contacts. Support for independent living,
sports and professional life, driving regulations and how to explain epilepsy to others
136
Nine Network Addresses and other information related to treatment, psychosocial support and
specific information for your epilepsy
193
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Course slides
Facilitators are provided with a Microsoft PowerPoint file to show slides during the course. In the original
MOSES study, course facilitators were encouraged to use overhead transparencies. We opted for
PowerPoint slides based on these transparencies adapted for a UK audience. Slides correspond to
participant workbook content and provide supplementary information.
Flip chart
A freestanding flip chart with large paper sheets was set up in full view of course participants. Throughout
each day, discussion statements were written on the flip chart and participants were asked to respond
during a group discussion. For example, participants were given ‘dot’ stickers on the first morning and
these were used throughout the course as a method to compare participants’ views on certain topics.
Questions were asked about how participants felt regarding certain statements and they were asked to
place a sticker on a scale of responses (Figure 1). The array in the placement of stickers along the scale was
then used as a way to initiate discussion on the topic.
SMILE (UK) course delivery
To balance out emotional and teaching topics, the modules were delivered to participants in a different
order than in the workbook. Each day of the course followed set schedules (see Appendix 4) corresponding
to the workbook modules described in Table 3. The timing of course activities followed an organised but
not prescriptive structure. The SMILE (UK) course was divided into four sessions: day 1 morning session,
day 1 afternoon session, day 2 morning session and day 2 afternoon session. Each session lasted 3 hours
and contained a tea/coffee break. Lunch was provided between the morning and afternoon sessions.
There were always two facilitators present at the course so that should a seizure occur, one facilitator
could continue the course while the other attended to the participant. One facilitator led each module
while the other assisted. Who would lead each module was discussed between the two facilitators prior
to the start of the course. The course began with individual introductions of course facilitators and
participants. One facilitator explained housekeeping rules and building facilities. The first module on ‘living
with epilepsy’ had a heavy emotional component and was divided into two parts. The first part focused on
discussing experiences and naming emotions experienced following diagnosis. Course participants were
reminded that there are no ‘right or wrong feelings’ in response to living with epilepsy. The point of this
module was that thoughts and feelings about epilepsy can be shared with others. The second part
consisted of a discussion on how group members had coped with their condition in the past. Depending
on the size of the groups, there was likely to have been a range of experiences and feelings described
regarding diagnosis length, seizure severity and seizure management.
The ‘people with epilepsy’ module contained discussions about famous PWE and risk factors/causes of the
condition. Facilitators compared the prevalence of epilepsy with other chronic health conditions to show
how common epilepsy is. Module three on ‘basic knowledge’ covered causes of epilepsy, epileptic activity
in the nerve cell and where seizures originate from in the brain. Participants were asked if they knew what
type of seizures they had and were given a chance to share their experiences with the group.
When I was told that I had epilepsy . . .
I was scared I wasn’t scared
FIGURE 1 Example of reflective exercise using stickers on a flip chart. Participants were asked to place a sticker
(represented by a green circle) on the scale according to how they felt.
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Module six covered ‘self-control’. During this section, participants were asked to place a sticker on the
flip chart with other course participants, to show how preventable they believed seizures were. Course
facilitators then shared instances where this may or may not be possible, discussed triggers and how to
keep records of seizures. Module nine addressed personal support networks for PWE. Participants were
asked to share their own sources of support they used to cope with epilepsy. Local support networks were
also discussed and the day closed with an overall summary of the course.
Day 2 began with a brief outline of what would be covered for the day, as well as ‘checking in’ with
how participants felt about day 1 (see Appendix 4). Emotional responses to the first day were discussed
together as a group. The first module of the day was a discussion on ‘treatment’. The facilitators outlined
different treatment options available in the UK. Ideas and strategies were shared on how participants
could actively be involved with their treatment plans. Participants were asked to write down personal drug
therapy goals in their workbook.
The next module on ‘diagnosis’ listed diagnostic methods during this session and, with time permitting,
described means of assessing seizure activity, such as electroencephalogram (EEG) information collected
during routine assessment. Module seven focused on ‘prognosis’. Participants were asked when or if they
expected to become seizure free. This topic was discussed as a group and the facilitator explained their
answers from a medical viewpoint. Factors affecting prognosis were also discussed.
The final topic of day 2 was on ‘personal and social life’, which covered ways of helping people cope and
overcome challenges associated with epilepsy in daily life. At the end of the course, participants were
thanked for their participation. Those who wished to remain in contact with other attendees were able to
give their permission for contact details to be circulated by e-mail at a later date (if not shared by individual
group members during the course already).
SMILE (UK) course facilitators
The teaching model for SMILE (UK) required there to always be two course facilitators present during
teaching. In international provisions of group education courses for PWE, various clinicians have acted as
group facilitators. These have included psychologists,46 researchers,91 social workers and neurologists.71
The literature is unclear on ‘who is best’ to deliver self-management education programmes. Past research
suggests that lay persons might be well placed to deliver self-management groups; however, limited long-term
benefits have been demonstrated.79 Based on national literature92 and staff availability,93 we chose to recruit
ENSs and EEG technicians to run the course.
In the UK, ENSs are likely to be part of outpatient epilepsy care. The role of an ENS is to provide specialist
outpatient care for PWE and to support primary and secondary care teams.94 They incorporate social
support and counselling in their role, but also focus on consultation and advice for PWE. ENS services may
be provided in person or over the telephone on topics ranging from AED side effects, pregnancy queries
and overall support.94
Past UK-based research found that ENSs were important support for PWE, especially those with a recent
epilepsy diagnosis and with long term epilepsy.95 ENSs are well-placed to take group courses with PWE
because they possess specialist knowledge of managing epilepsy and experience of managing
interpersonal dynamics and psychological issues (such as those that occur in group settings).
The chief investigator who was responsible for recruiting facilitators found that ENSs in London and the
South Thames were enthusiastic about the course. Nevertheless, many felt overstretched by their NHS roles
and did not have the capacity to volunteer additional time delivering the course. ENSs on the whole choose
Monday to Friday work hours and it seemed unlikely that they would undertake courses at the weekends.
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The decision to have EEG technicians as facilitators was primarily because of their specialist experience of
epilepsy diagnosis and training in medical aspects of epilepsy. EEG technicians collect diagnostic information
and have specific experience in assessing PWE. These clinicians were available at King’s College Hospital
(KCH) and were willing to be involved with the trial. Many have higher education training (e.g. Master
of Science-level education) and an interest in teaching others about epilepsy. Furthermore, the lead
neurophysiologist at KCH (Dr F Brunnhuber) had previously trained to deliver MOSES and was able to
assist with recruiting of EEG staff at the hospital and also mentored the facilitators during their SMILE (UK)
training and delivery of the programme. Although EEG technicians do work out of hours, the reimbursement
allowed for locum substitutions is for weekdays only.
Facilitator training
The chief investigator and co-investigators of the study underwent several stages in recruiting and training
of SMILE (UK) facilitators. LR was responsible for recruitment of facilitators and staff.
The first step involved the engagement of London- and Kent-based ENSs. Requests to hospitals were
generally received well, although were dependent on resource availability. Several centres had staff who
expressed enthusiasm to teach, but had workloads that prevented their involvement with the study.
After an initial group of prospective facilitators had applied, the trial chief (LR) and a co-investigator (AJN)
held interviews to assess each candidate’s suitability for SMILE (UK) facilitator training. A final group of
facilitators was selected (see Appendix 5). In total, there were eight female and three male facilitators;
seven were EEG technicians and four were ENSs. Four facilitators had a Bachelor of Science-level degree
and seven had a Master of Science in epilepsy or epileptology. The average length of experience in
epilepsy care for the group was 20 years (range 5–40 years).
SMILE (UK) facilitator training course
Three clinicians/researchers from the MOSES group came to London to conduct a 2-day facilitator training
course held on 10 and 11 June 2013 (for topics covered during training, see Appendix 6). The study chief
investigator (LR) and a co-investigator (LHG) attended the training course as well.
The MOSES trainers went through the SMILE (UK) course material, showed a facilitator training digital
versatile disc (DVD), and went through group-based exercises with trainee facilitators. Attendees were
provided with a ‘teaching manual’, which is organised similarly to the patient’s workbooks, with indications
on the techniques to use such as mind maps and writing out participant answers on a flip chart or slides.
Attendees were able to ask questions on why activities were undertaken in a certain way and learn from the
experiences of the MOSES facilitators who were undertaking the course with patients in Germany. Strategies
were shared for enhancing participant engagement and understanding, such as focusing on topics in
the workbook relevant or of interest to course participants (e.g. if participants already use a seizure diary,
move on to another topic), or asking someone to clarify what they mean (e.g. ‘Can you please elaborate on
that?’ or ‘Could you give an example?’). When teaching SMILE (UK), facilitators were encouraged not to
follow all workbook content sentence by sentence. All sessions during the 2-day facilitator training were
video-recorded so that facilitators could review them. On conclusion of the SMILE (UK) training course, all
facilitators received a certificate of completion. Throughout the SMILE (UK) study period, there was attrition
of facilitators owing to work commitments in their clinics. New facilitators received training by watching the
video of the 2-day training session and sitting in on an active SMILE (UK) course.
Patient and public involvement during SMILE (UK)
Patient and epilepsy care groups were consulted throughout intervention development in order to assure
acceptability of the treatment technology. The Epilepsy Action Research Network (EARN) is the largest
national user group that supports academic research for PWE and so became user partners in the SMILE (UK)
trial. Members of EARN are PWE, carers and members of the public who are familiar with health research.
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To verify the content and reading levels were appropriate for PWE in the UK, documents intended for
patients such as the patient information sheet and the participant workbook were sent to Epilepsy Action
Information Reviewers. Comments received were on the reading difficulty and on the volume and level of
information given in the participant workbook. It was decided to give workbooks out at the beginning of
the course, in order to go through it selectively during the sessions. With this arrangement, participants
could ask questions on content covered in the workbook and choose for themselves if they wanted to
read further once they had completed the course, but not be put off by its length and complexity before
the course began.
Service user feedback from EARN was sought during the design of the study protocol (see Appendix 1).
Information was provided about the study, then PWE were asked, via Epilepsy Action’s website and online
forum, if group-based education was something that they would find helpful.
In order to ensure that findings from SMILE (UK) would be communicated to the public on study completion,
a dissemination plan was drafted. We actively sought feedback from Epilepsy Action about this plan by
discussing it during collaborators’ meetings. Following the completion of the trial, a website would be
created with study results and researchers or facilitators would attend meetings to present final results.
Two key individuals represented service user groups and remained in regular contact throughout the trial.
We involved Mary-Jane Atkins from the patient/service user group at KCH in the early phases of the
research (pre-pilot). Mary-Jane assisted by participating in the external pilot study82 and completing the
battery of assessment questionnaires used during the baseline and follow-up assessments. She provided
feedback on her experience of completing the questionnaires in order to ensure that they could be
answered comfortably (i.e. easy to fill in, ≤ 60 minutes to complete). As the trial was being undertaken,
the epilepsy services manager from Epilepsy Action (Angela Pullen) attended and participated in
collaborator meetings throughout the study.
External pilot of SMILE (UK)
The external pilot was conducted prior to starting the main RCT. The aims were to identify whether or not
any changes would be required to content or delivery and to explore the beliefs and understandings of
those attending the SMILE (UK) course. The results from the pilot study were published82 and this section
serves as a summary of the study.
Methods
Recruitment
We aimed to test the SMILE (UK) course with two groups of 10 PWE. Volunteers were sought by placing
an advertisement in Epilepsy Today96 and via Epilepsy Action’s website.97 From March to May 2013,
22 participants were recruited. Eleven did not participate as a result of illness, work obligations, being
uncontactable or fatigue (and other effects of a recent seizure). A further one participant declined to take
part in the research interviews after attending the SMILE (UK) course. In the end, 10 volunteers participated
in the external pilot study
SMILE (UK) course delivery
Two pilot courses were given from 9:30 until 17:00, each over 2 days. Two sets of course facilitators gave
the course, and this also served as a practice after their training. Each course had an ENS and an EEG
technician facilitating. The courses were held at an education facility part of King’s College London (KCL),
located next to KCH. The course days followed the schedule described in Appendix 4. All volunteers
received the participant workbook. Courses were generally delivered by an ENS and an EEG technician
working in tandem. This pairing enabled their knowledge and skills to combine optimally.
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Data collection
The groups were then asked to provide feedback on their experience. Data were collected in two ways:
three participants completed a focus-group interview and seven completed one-on-one semistructured
interviews (two over the telephone, four in person and one by e-mail). Both took place less than 1 month
after participants took part in the pilot SMILE (UK) course. The focus group lasted 60 minutes and the
semistructured interviews lasted between 20 and 30 minutes.
Interview procedure
Discussion topics were established with input from Epilepsy Action.82 The resulting topic guide was flexible
and served as a prompt during discussions (see Appendix 7). Topics focused on (1) reasons for interest in
the SMILE (UK) pilot study, (2) views on content covered during the course, (3) appraisal of group learning
processes, (4) appraisal of teaching methods and (5) overall utility of the SMILE (UK) course. To minimise
chances of bias, the study interviewer was not involved with facilitating or co-ordinating the SMILE (UK)
programme. The topic guide was flexible in that prompts could be revised on the spot and returned to
throughout the interview sessions.
Data analysis
Interviews and focus group discussions were audio-recorded and transcribed verbatim. The transcripts were
checked by the interviewer and two co-investigators (MM and LR). Analysis began by manual marking of
topics in margins. This process took on an iterative format of going back and forth between notes and
emerging themes. Software (NVivo 9, QSR International, Warrington, UK) was used to formally code
themes from transcripts and grouping into broader themes.
Results and discussion
Many themes emerging from the pilot study were similar to those from the process evaluation presented
in Chapter 9. For these common themes, data will be presented together. In the section that follows, we
will present the results relevant to the intervention that helped us to shape the SMILE (UK) course for the
RCT. Full characteristics of volunteers from the pilot are also presented in Chapter 9. Briefly, six females
and four males participated, aged from 21 to 60 years, having had epilepsy for 8 to 52 years.
Reasons for participating
Most volunteers said they chose to participate in the pilot study for general interest, especially as it offered
a chance to meet other PWE. Two saw it as a way to be involved in developing a new intervention and
one saw it as a way to help in taking control of her life. These reasons give insight into why PWE may wish
to participate in the SMILE (UK) RCT.
SMILE (UK) content
Out of the nine modules, four were found to be especially useful. These were module 3, basic knowledge;
module 4, diagnosis; module 6, self-control; and module 8, personal and social life. This was useful to
know when we considered how to evaluate implementation fidelity of SMILE (UK) (described in Chapter 7).
Importantly, the volunteers did not find any parts of the course to be redundant.
SMILE (UK) duration
The volunteers considered the duration of the course days to be too long and would have preferred to
spread the course over 3 days. This was considered by the research team. As the target group was PWE
with active seizures, there would be a higher risk of non-completion of the course as a result of seizures if
it was spread out over more days. PWE may also not want to participate because of the longer time
commitment if the course was longer. As a result of this, the investigators decided to keep the course
length to 2 days.
SMILE (UK) materials
All volunteers considered the participant workbook to be a valuable source of information that could
be used as a reference for the future. It was also a source of information for their family and friends.
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One common criticism was not incorporating the participant workbook into the course. Volunteers said they
would have like to have time to take notes during sessions and to fill in some of the relevant exercises.
Following this, the facilitators were instructed to include the workbook more often by indicating on which
page participants could find the relevant information and invite them to complete relevant exercises
(e.g. describing what happens to them during a seizure). To ensure course facilitators implemented this,
workbook use throughout the course was measured in the implementation fidelity assessment (see Chapter 7).
Two participants had seizures during the course, reinforcing the value of holding SMILE (UK) near hospital
emergency department (ED) services. It also confirmed the need to have two facilitators at every course so
that one could assist with the seizure while the other continued with the group.
Other topics emerged, such as the positive value of a group setting, using new information to empower
their discussions with HCPs and improving their personal lives. Full results from this external pilot will be
presented in Chapter 9.
Summary
By incorporating local information on epilepsy care and approaching local epilepsy care networks,
we adapted a German-based intervention called MOSES78 for use in the UK. Training was provided to
11 facilitators (ENSs and EEG technicians) in order to be able to deliver the SMILE (UK) intervention.
A teaching manual and participant workbook were adapted from the MOSES course materials. Workbooks
and course content were largely unchanged from MOSES, with the exception of topics such as local
support networks, UK regulations and famous PWE. The SMILE (UK) course contained a mix of teaching
modules, largely containing factual topics and others touching on emotional aspects of life with epilepsy.
This balance offers a unique opportunity for PWE to gain knowledge about their condition but also to
share with people like themselves. The pilot study of two SMILE (UK) courses resulted in positive feedback.
The volunteers concluded that there were no major barriers perceived with running this kind of
intervention in the UK.
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Chapter 3 Methods
Study design
The trial was designed as a multicentre, pragmatic, parallel arm RCT of a complex intervention. Participants
were randomised in a 1 : 1 intervention-to-control ratio. The intervention group received TAU and was
offered the SMILE (UK) course, while the waiting list control group received TAU until the 12-month
follow-up assessment. The intervention was offered to the TAU group once they had completed the final
trial assessment. In addition, the study contained two qualitative elements: an external pilot and a nested
process evaluation. Prior to the RCT, an external pilot was conducted of SMILE (UK) (see Chapter 2). For
the nested process evaluation, 20 participants were recruited after having attended the SMILE (UK) course
(see Chapter 9).
Study settings
The chief investigator (LR) visited and arranged for local principal investigators (PIs) to recruit participants
from epilepsy clinics in eight hospitals in south London and south-east England: KCH (Lambeth, London);
University Hospital Lewisham (Lewisham, London); the National Hospital for Neurology and Neurosurgery
(NHNN) (Camden, London); St George’s Hospital (Wandsworth, London); Croydon University Hospital
(Croydon, Surrey); Princess Royal University Hospital (Bromley, Kent), Darent Valley Hospital (Dartford,
Kent); and Guy’s and St Thomas’ Hospital (Southwark and Lambeth, London).
The trial was run from a central location at KCL. Throughout the study, face-to-face meetings between
participants and research workers were held at a location convenient to the participant – at KCH (Denmark
Hill campus in Southwark, London), a public place or their own homes.
Trial approval and monitoring
The study was approved by the National Research Ethics Service Committee London – Fulham (Research
Ethics Committee reference 12/LO/1962; see Appendix 8). The study was approved by the local research
and development departments at each recruitment site. The study was monitored regularly by the Trial
Steering Committee (TSC) and the Data Monitoring and Ethics Committee (DMEC). Meetings with both
groups were held at least once a year with interim reports sent when needed.
Screening and recruitment
Participants were recruited from eight sites in London and south-east England. Local PIs identified patients
from having attended neurology clinics within the previous 12 months.
Stage 1
Individuals having attended a neurology clinic were sent a letter from the local clinical PI along with
information about the study in a patient information sheet (see Appendix 9). At this stage, patients had
the chance to opt out from the next stage of the study. They had a 3-week period to return their opt-out
slip in a pre-paid envelope. As this stage did not involve screening medical notes, patients contacted may
not have necessarily met the eligibility requirements. The only requirement at this stage was that they had
attended the neurology clinic within the past year.
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Stage 2
At the second stage of recruitment, medical notes were screened by clinicians at the local hospital and a
second invitation was sent to eligible participants along with the patient information sheet. Once again,
patients had the opportunity to opt out from further contact from the research team. Again, at this stage,
patients had 3 weeks to return their opt-out slip. Patients who did not opt out of either stage were
contacted by the research team to invite them to enrol in the study.
Stage 3
At this point of contact, the research team telephoned eligible participants who had not opted out to
invite them to join the study. Research workers confirmed eligibility criteria of interested individuals and
arranged a face-to-face meeting to explain the study in more detail, obtain informed consent and conduct
a baseline assessment. Participants gave written consent themselves. All meetings were arranged at
participants’ homes or public locations convenient for them.
Eligibility criteria
Inclusion criteria:
l confirmed epilepsy diagnosis (all epilepsy-related conditions and seizure types included)
l current AED prescription
l aged ≥ 16 years
l ability to give informed consent, contribute during groups and complete questionnaires in English
l have experienced two or more seizures in past 12 months (self-reported).
Exclusion criteria:
l only having seizures that are psychogenic or non-epileptic in origin
l only experiencing seizure related to acute neurological illness or substance misuse
l diagnosis of a serious psychiatric disorder or terminal illness
l participation in other epilepsy-related research.
Informed consent
Written informed consent was obtained during a face-to-face meeting between the participant and a
research worker, arranged either at their home or somewhere convenient for them. The study was
explained in detail and participants were given the opportunity to ask questions. Once the consent form
was signed (see Appendix 10), baseline data were collected.
Randomisation
Two to three weeks following enrolment, participants were randomised in batches of 12–24 participants
per recruitment site to obtain a sufficient group size for the intervention. For each batch, participants were
randomised in a 1 : 1 ratio between the SMILE (UK) group and the TAU group using fixed block sizes of
two, to ensure equal number of participants in each group. Thus, the randomisation was stratified by the
location of recruitment sites (KCH, University Hospital Lewisham, the NHNN, St George’s Hospital, Croydon
University Hospital, Princess Royal University Hospital, Darent Valley Hospital, Guy’s and St Thomas’ Hospital).
To reduce bias, randomisation was carried out by the King’s Clinical Trials Unit at the Institute of Psychiatry,
Psychology and Neuroscience (IoPPN). The trial manager had the only access to the online randomisation
request system. For each batch, participant information was entered into the system by the trial manager
who then sent the request for randomisation to the Clinical Trials Unit. This ensured that randomisation was
performed independently of the research or statistical teams. An e-mail was generated to the trial manager
reporting the assigned group for each participant, thus the trial manager remained unblinded. A letter was
posted to each participant to advise them of the group to which they had been allocated.
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Blinding and protection from bias
Treatment allocation could not be kept from participants. In addition, the trial manager and administrator
were unblinded as they were involved in contacting participants to attend the course. Research workers
collecting data, the trial statistician and health economist, along with investigators, remained blinded.
Participants were asked to not disclose their allocated group during assessments. To ensure that the
blinding process worked, research workers completed a ‘Research Worker Treatment Guess’ form after
the 12-month follow-up assessment or at point of withdrawal of participants leaving the study early. They
stated to which group they thought the participant had been randomised and then whether this was a
guess or whether they already knew. If unblinding had occurred during the course of the study, they noted
how this happened. Any reporting to oversight boards was also done in a blinded manner, excepting in
closed DMEC reports in which data were reported in a semi-blinded manner (i.e. groups were labelled A
and B without specifying the treatment allocation).
Intervention delivery
The SMILE (UK) course was held at several locations during the trial. Locations were chosen based on being
easily accessible, familiar to the patient and having access to emergency care services, if required. Originally,
it was hoped that all courses would be offered at the hospital nearest the patient; however, this was not
possible because of challenges with off-site room bookings and staff availability. Therefore, participants
were mostly invited to attend a course at KCH. The data for course attendance are given in Chapter 5.
All participants were sent a venue map and room location by post in advance. When possible, and to
facilitate group interaction, chairs were arranged in a semicircle. A flip chart was set up for writing notes
and discussion points. Workbooks, pens, name badges and stickers were ready for participants on arrival
and a sign-in sheet was positioned beside the workbooks.
Completion of follow-ups
Every effort was made to minimise dropouts at follow-ups, including researcher phone calls to ask
whether or not the questionnaire was received and whether or not any help was needed at 6-month
follow-ups, and mailing questionnaires by post and e-mail for 12-month follow-ups. On completion of the final
questionnaire, participants were given a £20 store voucher. We also opted for additional procedures to improve
response rates when posting questionnaires,98 such as using colour printing for the participant questionnaires.
Adverse event reporting
Information about adverse events (AEs) was collected at the 6- and 12-month follow-ups by a research
worker. An AE was defined as a health-related event that was experienced by a trial participant. The AEs
were self-reported by participants and any change in health was recorded. Seizures and any event related to
a seizure (including hospitalisations) were not recorded, as these are expected events related to the nature
of poorly controlled epilepsy. Any AEs requiring hospitalisation (unrelated to seizures) or prolongation of
hospital stay, that were life-threatening, or that resulted in death or in persistent disability were recorded as
serious adverse events (SAEs). Status epilepticus was considered as a SAE. SAEs were reported to the site PI
and reviewed by the chief investigator. A list of AEs and SAEs was included in the reports to the trial
oversight committees and to the ethics committee.
DOI: 10.3310/hta22210 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 21
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ridsdale et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
Summary of changes to project protocol
During the 6-month follow-up period, some participants were slow in returning their posted questionnaire.
Similarly, during the 12-month follow-up stage, it became apparent that some participants could not
commit to a meeting to complete questionnaires in person. The protocol was amended to include sending
questionnaires by post or e-mail or completing them over the telephone for both follow-up time points,
depending on the preference of the participant.
The nested process evaluation was to be conducted after the 12-month follow-up. During the first few
interviews, it became apparent that some participants could not remember details of the course so long
after they attended. Thus, the protocol was amended to have interviews within 6 months of attending
the course. To ensure that there was no impact on the design of the study (i.e. the only contact with
researchers was a postal contact at 6 months and face-to-face contact at 12 months), it was decided to
invite only participants from the TAU group to interviews, as they would have already completed their
12-month assessment. As the interviews for the process evaluation were done by two researchers,
independent from the main trial assessments, no unblinding occurred.
Outcome measures
Primary outcome measure
The primary outcome measure used in the SMILE (UK) study is the QOLIE-31-P score at 12 months post
randomisation. It is a short, easy-to-use measure based on the original QOLIE-31.80 The QOLIE-31-P varies
slightly from the original QOLIE-31 with an addition of one item at the end of each subscale, asking the
participant to rate the degree of ‘distress’ caused by that particular topic. The measure was completed at
baseline and at 6- and 12-month follow-up (Table 4). The questionnaire provides a total QoL score and
contains seven individual subscales: (1) energy level (four items), (2) emotional wellbeing (five items),
(3) social functioning (five items), (4) cognitive function (six items), (5) medication effects (two items),
(6) seizure worry (five items) and (7) overall QoL (two items).80 The scale asks participants to reflect on how
they felt over the past 4 weeks. Scores range from 0 to 100, for which higher rank indicates better overall
QoL. Internal consistency reliability (Cronbach’s alpha) has previously been reported as α = 0.79–0.85.80
TABLE 4 Outcome measures and schedule of data collection
Outcome Measures Items
Time point
Baseline 6 months 12 months
Primary
outcome
QOLIE-31-P80 39 ✓ ✓ ✓
Secondary
outcomes
‘Seizure control’ (seizure frequency using two
scales35,99 and last seizure date)
2+ 1 ✓ ✓ ✓
‘Impact of epilepsy’100 9 ✓ ✓ ✓
‘Medication adherence’ (10-item subscale from
‘Epilepsy Self-management Scale’)89
10 ✓ ✓
‘Medication adverse effects’ (from QOLIE-31)80 2 ✓ ✓
Psychological distress (14-item HADS)101 14 ✓ ✓
‘Perceived stigma’ (from ‘Stigma of Epilepsy Scale’)102 3 ✓ ✓
‘Self-mastery’ over epilepsy (epilepsy-specific scale)103 6 ✓ ✓
‘Health Services Use’ and ‘Work Status’ in the past
12 months (modified ‘Client Service Receipt Inventory’)104
8 ✓ ✓
‘Health status’ (EQ-5D-5L)105 5 ✓ ✓
EQ-5D-5L, EuroQol-5 Dimensions, five-level version; HADS, Hospital Anxiety and Depression Scale.
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Secondary outcome measures
A number of measures were used to assess secondary outcomes (see Table 4).
Seizure control
Seizure control was assessed by three questions in total. Two questions were about frequency35,99 with a
recall period of 6 months at 6-month follow-up, and 12 months at 12-month follow-up. A third question
was on seizure recency: ‘Please tell us the date of your last seizure’ (day/month/year). All three questions
were asked at baseline and both 6- and 12-month follow-up assessments.
Impact of epilepsy scale
The Impact of Epilepsy scale100 contains 10 items that assess the perceived impact of epilepsy on social
relationships, occupation, personal health, standard of living and future aspirations. The scale was used at
baseline and at both the 6- and the 12-month follow-up. It was purposely adapted for use during the
SMILE (UK) trial (see Appendix 11), using the first 10 questions of the revised Impact of Epilepsy scale106
and the Likert-style response options from the original scale.100 Response options included ‘a lot’ scored as
1, ‘some’ scored as 2, ‘a little’ scored as 3, and ‘not at all’ scored as 4. Reverse scoring was used when
appropriate for negatively worded questions. A higher overall score on this measure indicates less
perceived impact of epilepsy. Research on the revised and original scale has reported α = 0.65–0.83.100,106
Medication adherence
Ten items about medication adherence were taken from the Epilepsy Self-Management Scale89 at baseline
and 12-month follow-up. This scale asks participants to evaluate how they took their medication in
the previous 6 months. The scale contains a series of statements about medication use, such as ‘I take
my seizure medication the way my doctor orders it’. Response options include (1) never, (2) rarely,
(3) sometimes, (4) most of the time and (5) always. After reverse scoring appropriate items, a higher
overall score indicates better adherence to treatment plans or, in other words, better medication-related
self-management behaviours. Internal consistency scores have been acceptable in past research,
with α = 0.81–0.86.107,108
Psychological distress
Psychological distress was measured at baseline and 12-month follow-up using the 14-item Hospital Anxiety
and Depression Scale (HADS).101 This is a commonly used measure that provides a score each for anxiety and
depression, and an overall total score. The questionnaire is widely used in outpatient and inpatient settings
with people affected by a range of health-care conditions.109 Anxiety and depression scores are grouped into
symptom categories: 0–7 normal, 8–10 borderline and 11–21 case.101 Internal consistency for these scales
has been reported as α = 0.82 (depression) and α = 0.83 (anxiety).109
Perceived stigma
Perceived stigma was assessed by the 3-item Stigma of Epilepsy Scale102 at baseline and 12-month follow-up.
The measure assesses felt stigma, and contains questions on the extent to which PWE believe that others
may treat them as inferior, avoid them, or are uncomfortable with them because of epilepsy.102 Response
options include a four-point Likert scale: (0) ‘not at all’, (1) ‘yes, maybe’, (2) ‘yes, probably’ and (3) ‘yes,
definitely’. Total scores range from 0 (does not feel stigmatised) to 1–6 (mildly to moderately stigmatised)
to 7–9 (highly stigmatised). In past research, internal consistency has been reported as α = 0.82.110
Self-mastery of epilepsy
Self-mastery over epilepsy was measured using a six-item epilepsy-specific scale.103 The scale contains
six statements such as ‘there is really no way I can solve some of the problems I have with my epilepsy’,
which can be answered as (1) ‘strongly agree’, (2) ‘agree’, (3) ‘disagree’ and (4) ‘strongly disagree’. Internal
consistency for this scale has previously been reported as α = 0.70.103 This measure was administered at
baseline and 12-month follow-up.
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Data collection for health economics
For health economics, data on employment, hospital service use, other health service use, home help and
medication were collected using the Client Service Receipt Inventory (CSRI)104 modified to include only data
related to epilepsy. This questionnaire documented service use over the previous 12 months. Data were
collected at baseline and 12-month follow-up.
The EuroQol-5 Dimensions, five-level version (EQ-5D-5L) was used to determine quality-adjusted life-years
(QALYs).105 This questionnaire asks one question on each of five topics: mobility, self-care, usual activity,
pain/discomfort and anxiety/depression. The participants were asked to answer based on how they felt
that day. The questionnaire also has a visual analogue scale (VAS) component, which asks the patient to
rate their QoL on a scale of 0–100. Data were collected at baseline and 12-month follow-up.
Data management
Data were collected at baseline (pre-randomisation) and at 6 and 12 months after randomisation. Full
assessments were performed at baseline and at 12 months during face-to-face meetings, when possible,
while an abbreviated questionnaire was sent by post at the 6-month follow-up (see Table 4). On receiving
the completed questionnaire, patients were contacted by telephone to obtain information about any AEs
over the past 6 months. At 12 months, data were collected about AEs over the previous year.
Demographic and clinical data collected at enrolment included the following: initials, date of birth, gender,
years since epilepsy had been diagnosed, other medical conditions, attained qualifications, living arrangements,
marital status and ethnicity. The first four digits of the person’s postcode were recorded to obtain the Index of
Multiple Deprivation (IMD).111 The IMD score measures the level of deprivation based on where a person
lives. The scores are distributed into quintiles where a normal distribution would have 20% in each group.
Data were collected on source document worksheets (i.e. manual questionnaire forms) and transferred to an
electronic case report form (eCRF) system (Infermed MACRO version 4.0; London, UK). Source document
worksheets were kept in the central research office with restricted access at KCL, in locked file cabinets.
Research workers entered data and the trial manager performed data entry checks; 80% of the primary
outcome data were checked and 50% of secondary outcomes were assessed, except for the CSRI for which
70% of questionnaires were checked. eCRFs to check were chosen at random using a random number
generator.
Participant contact information was kept on a secure central network server with access only granted to
study staff. Any electronic file with patient information was password protected. Only members of the
research team (trial manager, research workers and trial administrator) had passwords to the files.
Information about participants’ invitations and attendance to courses was kept in separate files with access
given only to the trial manager and administrator. All computers used were password protected and held
in an office with restricted access.
Participant interviews were recorded on digital recorders and transferred to computers on secured
networks. Recordings were sent to a transcription service and subsequently deleted. Interviews were
anonymised and kept on password-protected computers. A printed set of all interviews was kept in the
study office.
Compliance to intervention
For those in the intervention group, SMILE (UK) course attendance was logged on ‘treatment attendance
logs’ by the trial manager or administrator present during the course. Any missed sessions were recorded.
The occurrence of seizures during the course was recorded, including the length of seizure, whether the
participant could continue the course or had to leave, and whether this caused a significant disturbance to
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the course. Carers were permitted to attend the course if this was requested by the participant. This was
also noted in the treatment attendance logs. Data from logs were transferred into the eCRF by the trial
manager or administrator. The eCRF database was set up such that the course attendance information was
kept separate from follow-up assessments to facilitate blindness of the researchers and the trial statistician.
Non-attendance by participants at the course was recorded on course completion forms that noted the date
of missed course, the reason and whether or not the participant accepted a place on an alternative date.
Facilitators
Demographic data regarding course facilitators were collected and recorded in a separate electronic
database on MACRO. Data included initials, gender, current occupational role, years in current role,
highest level of education reached, specialist qualifications, size of current caseload, prior experience in
facilitating patient groups, and pay scale grade point. Each facilitator was given a randomised therapist
identification number to ensure anonymity and this number was recorded on treatment attendance logs
for each participant.
Power calculations and sample size
The analysis was planned as an intention-to-treat (ITT) analysis with two equal-sized treatment arms.
The primary outcome was the total QOLIE-31-P score at 12 months post randomisation. When the study
began, two drug trials at the time had used this questionnaire showing an effect size of d = 0.33112 and
0.59.113 A sample size of 320 participants, with a 1 : 1 randomisation scheme would detect an effect size
of d = 0.4 (a change of 6–7 points on the total score) with 91.3% power, using a two-sided analysis of
covariance with significance set at p ≤ 0.05. This sample size also took into consideration the variation in
intervention delivery by estimating that 160 participants would attend the course, with 10 present per
course and an intraclass correlation coefficient of 0.025 between QOLIE-31-P scores of different course
groups. A previous study on people with severe epilepsy estimated a follow-up loss of 25% after 1 year.12
Based on these data, we targeted a sample size of 428 (214 per treatment arm) to ensure 320 participant
data at the final follow-up.
Baseline data analysis
Baseline data were checked and baseline data were locked once recruitment and randomisation were
completed. Baseline data analysis included descriptive statistics of participant demographics and their
baseline values of outcome measures. These are presented when appropriate as means with standard
deviations (SDs), medians with 25–75% interquartile ranges (IQRs) and minimum to maximum ranges.
Additional analyses were performed, not initially as part of the statistical analysis plan, but as part of the
baseline data assessment.84 These were associations between different data collected (demographics and
outcome measures) evaluated using simple linear regressions. Results of the associations are represented by
Pearson’s correlation coefficients (r). When comparing categorical values, predicted means of QOLIE-31-P
were calculated within each factor to enable comparisons. One category within each factor was used as a
reference. For example, when looking at the association between gender and QOLIE-31-P, we used the
predicted means of males as the reference to which females were compared.
Trial outcome analysis
All statistical analyses were prespecified in a statistical analysis plan.4
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Primary outcome analysis
Outcome data are presented, when appropriate, as means with SD, medians with 25–75% IQR and
minimum to maximum ranges. All analyses of outcome measures followed the ITT principle as we aimed to
evaluate the effectiveness of the SMILE (UK) intervention. In other words, participants were analysed in the
groups to which they were allocated, irrespective of intervention receipt. The primary outcome was total
QOLIE-31-P score at 12 months post randomisation.
Prior to the statistician becoming unblinded, a binary variable was created to represent participants who
received full intervention [in the SMILE (UK) arm only] and a second variable represented whether primary
outcome data were present or missing. An independent statistician tested whether or not intervention
receipt was predictive of missing primary outcome data using a chi-squared test. In addition, the
relationship between baseline variables and missing primary outcome data was assessed using logistic
regressions, which looked at the predictive effects of each baseline variable separately. A number of
baseline variables were found to be predictive of missingness (see next paragraph) and treatment receipt
also predicted missingness in the intervention arm; therefore, multiple imputation was used to produce
inferences that are valid under such a missing at random data-generating process. The number
(proportion) of missing QOLIE-31-P data was 4 (1.0%) at baseline, 91 (22.5%) at the 6-month follow-up
and 73 (18.1%) at the 12-month follow-up.
Multiple imputation consists of two steps: an imputation step and an analysis step. As a guiding principle,
all variables included in the analysis model need to be included in the imputation step; further variables can
be included in the imputation step only. The first step was to impute missing values using multivariate
imputation by chained equations (MICE). All predictors of dropout (gender, education, comorbidities and
treatment receipt within active arm) were included to allow them to drive missingness. All variables that
formed part of the analysis model were included: trial arm [SMILE (UK) course or TAU], educational group
within SMILE (UK), the randomisation stratified by trial centre (the site from which participants were
recruited) and baseline QOLIE-31-P. The MICE model was used to impute QOLIE-31-P at baseline, 6 and
12 months simultaneously (i.e. QoL at different time points was allowed to predict QoL missingness and can
provide extra precision if predictive of QoL values). A total of 100 imputations were run. Once the multiple
imputation was complete, the Stata® (StataCorp LP, College Station, TX, USA) command ‘mi estimate’ was
used as a prefix so that the imputed data sets were used for the analysis (i.e. Rubin’s rules were used to
generate inferences based on multiple imputed data sets). The analysis model was a linear mixed-effects
model: total QOLIE-31-P score at 12 months post randomisation was the dependent variable. Baseline
QOLIE-31-P score, trial centre and treatment arm were included as fixed effects and educational group was
included as a random effect within the intervention arm only. The random effects were added to account for
potential clustering as a result of participants attending the same educational group in the SMILE (UK) arm.
Secondary outcome analyses
There were seven secondary outcomes that were measured as continuous variables: (1) HADS-anxiety
(HADS-A), (2) HADS-depression (HADS-D), (3) self-mastery and control, (4) impact of epilepsy, (5) medication
adherence, (6) medication AEs, and (7) stigma of epilepsy. All of these were analysed in the same way as
QOLIE-31-P (i.e. using MICE followed by linear mixed model for the respective secondary outcome variable).
The only terms that were amended between each analysis were the relevant outcome measures.
There were two secondary outcomes that were not continuous variables and they had to be analysed
slightly differently to reflect their distributions: (1) seizure recency and (2) seizure frequency.
Seizure recency was constructed from the date of last seizure and counts the ‘number of days since last
recalled seizure’. In addition to this variable allowing for positive values only, it has a maximum. As the
last recalled seizure can, by definition, involve recall bias (this was assumed at 6 months), and as the
eligibility criteria for the RCT stated that participants had to have at least two seizures in the last year,
seizure recency maximums were defined as follows: 548 days at baseline (1.5 years); 730 days at 6-month
follow-up (2 years); and 913 days at 12-month follow-up (2.5 years). Therefore, in order to analyse seizure
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recency, the variable was transformed onto a continuous scale using the logit transformation. This
transformation converted days into a proportion and then mapped the odds onto the continuous scale via
applying the logarithm. The logit-transformed recency variable was then analysed in the same way as the
other continuous variables.
Seizure frequency was collected on two different scales: Baker et al.99 and Thapar et al.35 The seizure
frequency variable as measured by the Baker scale was analysed as a binary outcome: less than one seizure
per month versus one or more seizure per month. A similar analysis approach was used as above, except
MICE imputed missing outcome values by assuming a logistic regression and a logistic mixed-effects model
was used as the analysis model. Similarly, seizure frequency as measured by the Thapar scale was analysed
as an ordered categorical outcome: 0–3 seizures, 4–6 seizures, 7–9 seizures or ≥ 10 seizures. In addition,
the MICE and mixed-effects models used ordinal logistic regression.
Intervention receipt
The primary analysis was modelled as an ITT analysis. Owing to non-receipt of the intervention [attending
all four SMILE (UK) sessions] being fairly high (38.5%), a complier average causal effect (CACE) analysis
was performed to assess the efficacy of the intervention in the presence of non-attendance. For this
purpose, binary intervention receipt of SMILE (UK) intervention was defined as attending all sessions
(i.e. receiving full treatment).
An instrumental-variables approach was used to estimate CACE for the primary outcome. Specifically, a
two-stage least squares estimate of an instrumental-variables regression was used (‘ivregress 2sls’ in Stata).
The estimator obtained by this approach is equivalent to that obtained by, first, regressing the treatment
received variable on the treatment allocated variable and baseline covariates and, second, controlling for
the saved residuals, regressing QOLIE-31-P on the treatment received variable and baseline covariates.
Statistical analysis was performed using Stata version 14.
Qualitative methods
Recruitment
Participants were approached to take part in the process evaluation. They were largely recruited from the
TAU arm but also included some from the intervention arm. Participants were purposefully chosen to
ensure a variety in age, gender, ethnicity and severity of epilepsy was represented.
Interview procedure
Semistructured interviews were held with topics selected after completing the external pilot study, and in
collaboration with research staff that held these interviews. All participants were interviewed face to face.
The interviews were undertaken by two researchers. Interview times were variable, ranging from 25 to
40 minutes each.
Analysis
All interviews were recorded and then transcribed verbatim by an external third party. Transcripts were
checked for accuracy by the researchers who conducted the interviews. Sample transcripts were checked
by two collaborators. Researchers then undertook a line-by-line coding approach with initial codes noted
in the margins of the transcripts and then grouped into broader themes. This process involved regular
discussion between the researchers and study supervisors.
Full methods are presented in Chapter 9.
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Summary
As requested by our NIHR funders, we used QoL measured 12 months after randomisation as our primary
outcome, with secondary variables such as seizure frequency, psychological distress and stigma. Data were
collected from participants at baseline and at 6 and 12 months after randomisation. Outcome analysis
followed an ITT protocol.
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Chapter 4 Recruitment and intervention delivery
Introduction
Participants were recruited from eight epilepsy clinics in their hospitals in London and south-east England.
The intervention was subsequently delivered to a total of 150 participants with 18 course offerings. The
interventions were attended partially or fully by 74% of participants randomised into the treatment group.
Participant flow through study
Recruitment
The process of generating patient lists and sending out study information occurred from September 2013
until May 2015. At the start of trial recruitment, lists were created with the names of patients seen at eight
different epilepsy clinics within the past year (≥ 4000 patients in total; Figure 2). Letters were sent to these
Medical notes screened
(n = 2854)
Sent a letter from their
consultant with
information about
the study
(n ≥ 4000)
Invited
(n = 2285)
To telephone
(n = 1986)
Contacted
(n = 1458)
Not eligible
(n = 370; 25.4%)
Declined
(n = 681; 46.7%)
Consented
(n = 407; 27.9%)
Randomised
(n = 404)
Opted out
(n = 243)
Return to sender
(n = 19)
Excluded
(n = 569; 19.9%)
Opted out
(n = 278; 2.1%)
Return to sender
(n = 21; 0.9%)
Not able to contact
(n = 528; 26.6%)
Not randomised
(n = 3) 
FIGURE 2 Recruitment pathway for SMILE (UK). Reproduced with permission from Ridsdale et al.114 2018. This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial
4.0 International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: https://creativecommons.org/licenses/by-nc/4.0/.
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patients explaining the study and giving them the chance of a first opt-out of further contact. During this
first stage of opt-outs, 262 people sent in opt-out slips or were unable to be reached by post.
Recruitment sites were opened progressively through the study and recruitment overlapped between sites.
For this reason, medical notes were screened by instalments for those not opting out, resulting in 2854 patient
notes screened. When medical notes had been screened by clinical staff, 569 patients were identified as not
eligible. A second letter was then sent to the remaining patients (n = 2285) with another option to opt out
of the study. During this second stage of opt-outs, 299 patients either returned their slips or could not be
reached by post.
In summary, the two opt-out stages resulted in 529 opt-out slips being received (reasons provided in
Table 5). Those who had not already opted out were contacted by telephone in order to assess their
eligibility and interest in the study.
Recruitment progressed in sequence at each of the centres involved with the study (Table 6). Owing to
overlapping 12-month follow-ups with continuous recruitment, we were able to adjust recruitment targets
in light of a higher than anticipated retention rate. Recruitment ultimately finished on 6 August 2015, with
an enrolment rate of 37% (n = 407; eligible patients, n = 1088).
Enrolment
Of those contacted by research workers (n = 1458), 46.7% declined to participate in the study, 27.9%
consented and 25.4% were ineligible. The process of enrolment (i.e. participant consent and baseline
assessment) began in December 2013 at KCH and concluded at the beginning of August 2015 at
St George’s Hospital.
TABLE 5 Reasons for not progressing through recruitment pathway
Reason Total
Opted out 349
Unable to make time commitment 64
Complaint, confidentiality issues 3
No reason given 150
Does not need or want information, meeting others 25
Does not wish to take part 40
Already taken part in the pilot/been invited 3
Does not want King’s team to look at notes 23
Does not want to talk about diagnosis 15
Lives too far away, cannot access site 24
Other 2
Ineligible: self-exclusion via opt-out method 180
Does not meet seizure requirement 78
Language 5
Does not have epilepsy 28
Unable to complete, learning disabilities or other comorbidity (self or carer reported) 69
Excluded: medical notes screening 569
Ineligible: via telephone contact 370
Uncontactable 528
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Sample size
The recruitment target was 426 participants with a 12-month retention rate of 75% (i.e. effective sample
size at 12 months of 320 participants). Owing to higher follow-up rates than expected (82% at the time),
we could stop recruitment after 407 participants were consented into the study and 404 randomised.
This decision was made with the approval of statisticians involved with the trial (SL, EJR) and agreed on by
study collaborators and the TSC.
Randomisation into trial arms was carried out by the King’s Clinical Trials Unit as explained in Chapter 3.
Early in the recruitment phase, the trial manager noticed an imbalance in the group allocation. This was
attributable to a software error and was rectified by the Clinical Trials Unit. For this reason, the number of
PWE was slightly unbalanced between the two groups (Figure 3).
Retention and follow-up
We enrolled 404 participants into the study and 331 (82%) completed follow-up assessments at 12 months
(see Figure 3). Withdrawal was defined as withdrawing from any further data collection. The most common
reason for withdrawal from the trial was being unable to contact the participant. Some participants chose
to withdraw as a result of time constraints, not feeling well enough to complete questionnaires or a change
in personal circumstances. One participant no longer had a diagnosis of epilepsy at the 12-month follow-up
and was withdrawn.
Follow-up retention rates were 77% for 6 months and 82% for 12 months. Final 6-month follow-ups
were completed in February 2016. A non-response at 6 months did not lead to an automatic withdrawal
from the study. Some participants who did not provide follow-up data at 6 months post randomisation
subsequently provided 12-month follow-up data. Final 12-month follow-ups were completed in July 2016.
Of note, the withdrawals at 6 months were initiated by participants only. If participants could not be
contacted at the 6-month follow-up, then they remained in the study and some could be reached at the
12-month follow-up. This explains why the completion rate at 12 months is higher than at 6 months.
Adverse events
The AEs were recorded at 6 months over the telephone after postal questionnaires were received and at
the 12-month follow-ups. A total of 41 participants reported AEs over the course of the study. Between
them, 63 AEs were reported (Table 7). Fourteen were considered mild, 21 were of moderate intensity,
26 were severe and two new psychological diagnoses were of unknown intensity. In the intervention group,
33 AEs were reported by 25 participants, while 16 participants in the control group reported 30 AEs.
Twenty-two AEs were considered SAEs, but no AE or SAE was considered to be related to the intervention.
TABLE 6 Recruitment by site
Site
Date of
Number recruited
(randomised)
First patient
randomised
Last patient
follow-up
KCH 5 December 2013 25 May 2016 99 (97)
Lewisham Hospital 17 March 2014 18 February 2016 14 (14)
NHNN 1 July 2014 16 May 2016 163 (163)
St George’s Hospital 3 July 2015 30 June 2016 36 (36)
Croydon University Hospital 4 June 2015 22 June 2016 17 (17)
Princess Royal University Hospital 18 February 2015 22 April 2016 27 (27)
Darent Valley Hospital 18 March 2015 28 April 2016 10 (10)
Guy’s and St Thomas’ Hospital 20 January 2015 7 July 2016 41 (40)
Total 5 December 2013 7 July 2016 407 (404)
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Contamination
Three participants in the control group attended the intervention early, rather than after the 12-month
follow-up. Two were invited in error and one came to the course without having been invited by the
research team. These participants were analysed in their original TAU group in order to adhere to the ITT
principle. They are not included in the course attendance numbers below.
Researcher unblinding
As participants knew their treatment group, there was a high risk of research workers becoming unblinded
during follow-up assessments. Following every 12-month follow-up or withdrawal, researchers completed
the ‘Research Worker Treatment Guess’ form. For the 331 participants completing the 12-month follow-up,
research workers reported being unblinded for 56 assessments (16.9%). When the blinding remained, most
guesses were that the participant was in the TAU group (73.7%) and this was mostly a random guess
(random guess 73.7% vs. educated guess 9.4%).
Randomised
(n = 404)
Withdrawn
(n = 19)
Withdrawn
(n = 16)
6-month outcome
measures collected
(n = 154)
Withdrawn
(n = 23)
Withdrawn
(n = 15)
Control
(n = 199)
Intervention
(n = 205)
6-month outcome
measures collected
(n = 160)
12-month outcome
measures collected
(n = 163)
12-month outcome
measures collected
(n = 168)
Reasons for withdrawal
(n = 42)
• Adverse event, n = 1
• Unable to contact participant, n = 32
• Participant not willing to complete
   assessments, n = 7
• No longer has a diagnosis of epilepsy, n = 1
• Unknown, n = 1
Reasons for withdrawal
(n = 31)
• Participant no longer willing to attend
   course, n = 1
• Unable to contact participant, n = 21
• Participant not willing to complete
   assessments, n = 9
Decision for withdrawal made by
• Participant, n = 8
• Research team, n = 33
• Trial manager, n = 1
Decision for withdrawal made by
• Participant, n = 6
• Research team, n = 24
• Carer/relative, n = 1
FIGURE 3 Retention through SMILE (UK) for intervention and control groups. Reproduced with permission from
Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 7 Adverse events reported during SMILE (UK) study
Body system
Number of AEs
(number of patients)
Related to
epilepsy Intensity
Hospital
admission
Related to
intervention SAE Outcome
Intervention
group, n (%)
Cardiovascular 6 (6) None Mild, n= 2 3 None 2 Resolved, n= 4 6 (100)
Moderate, n= 3 Ongoing, n= 2
Severe, n = 1
Gastrointestinal 3 (2) None Moderate, n= 1 3 None 1 Resolved, n= 3 1 (33.3)
Severe, n = 2
Genitourinary 8 (5) None Moderate, n= 2 7 None 5 Resolved, n= 8 2 (25)
Severe, n = 6
Haematological 4 (4) None Mild, n= 1 2 None 1 Resolved, n= 3 3 (75)
Moderate, n= 3 Ongoing, n= 1
Musculoskeletal 12 (10) 2 Mild, n= 4 6 None 2 Resolved, n= 7 7 (58.3)
Moderate, n= 3 Ongoing, n= 5
Severe, n = 5
Neoplasia 2 (2) None Moderate, n= 2 2 None 2 Resolved, n= 1 1 (50)
Ongoing, n= 1
Neurological 13 (11) 7 Mild, n= 3 8 None 4 Resolved, n= 7 8 (61.5)
Moderate, n= 3 With sequelae, n= 2
Severe, n = 7 Ongoing, n= 4
Psychological 6 (4) 3 Mild, n= 1 3 None 3 Resolved, n= 3 1 (16.7)
Severe, n = 3 With sequelae, n= 1
Unknown, n= 2 Ongoing, n= 2
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TABLE 7 Adverse events reported during SMILE (UK) study (continued )
Body system
Number of AEs
(number of patients)
Related to
epilepsy Intensity
Hospital
admission
Related to
intervention SAE Outcome
Intervention
group, n (%)
Dermatological 1 (1) 1 Severe, n = 1 1 None 0 Ongoing, n= 1 0 (0)
Ear, nose and throat 6 (4) None Mild, n= 3 3 None 2 Resolved, n= 3 3 (50)
Moderate, n= 3 With sequelae, n= 2
Ongoing, n= 1
Other 2 (2) None Moderate, n= 1 1 None 0 Resolved, n= 1 1 (50)
Severe, n = 1 With sequelae, n= 1
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial 4.0
International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
RECRU
ITM
EN
T
A
N
D
IN
TERVEN
TIO
N
D
ELIVERY
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
36
SMILE (UK) intervention delivery
Course attendance
Eighteen SMILE (UK) intervention courses were held between December 2013 and August 2015 (Table 8).
The majority were held at KCL (15 courses), which is a university-based research centre next to a teaching
hospital (KCH) in south London. The remainder were held at the NHNN (two courses) and the University
Hospital Lewisham (one course).
TABLE 8 The SMILE (UK) courses offered in 2013–15
Course
number Date Location Facilitators
Attendance
Day 1 Day 2
a.m. p.m. a.m. p.m.
1 December 2013 KCH,
WEC
Two EEG
technicians
6 6 6 6
2 January 2014 KCH,
IoPPN
ENS, EEG
technician
13 13 12 12
3 January 2014 KCH,
WEC
ENS, EEG
technician
6 7 8 8
4 February 2014 KCH,
WEC
ENS, EEG
technician
9 9 7 7
5 March 2014 LEW ENS, EEG
technician
5 5 5 5
6 July 2014 NHNN,
QS
ENS, EEG
technician
9 7 7 6
7 August 2014 NHNN,
QS
ENS, EEG
technician
12 11 12 11
8 September 2014 KCH,
WEC
ENS, EEG
technician
14 13 13 12
9 October 2014 KCH,
WEC
Chief
investigator,
EEG technician
9 9 9 9
10 November 2014 KCH,
WEC
ENS, EEG
technician
9 9 8 7
11 December 2014 KCH,
WEC
ENS, EEG
technician
6 6 6 6
12 January 2015 KCH,
WEC
ENS, EEG
technician
7 7 6 6
13 February 2015 KCH,
WEC
ENS, EEG
technician
8 8 8 7
14 March 2015 KCH,
WEC
ENS, EEG
technician
8 8 7 7
15 April 2015 KCH,
WEC
ENS, EEG
technician
9 8 9 8
16 June 2015 KCH,
WEC
ENS, EEG
technician
6 6 6 6
17 July 2015 KCH,
WEC
ENS, EEG
technician
10 8 9 9
18 August 2015 KCH,
WEC
ENS, EEG
technician
6 7 6 6
LEW, University Hospital Lewisham; QS, Queen Square; WEC, Weston Education Centre.
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Course attendance was recorded to determine receipt of intervention. To do this, we divided the course
into four sessions, and a session was defined as a half-day. Of the 205 participants who were randomised
to the intervention arm, 74% (n = 151) attended at least one session and the majority [62% (n = 126)]
completed all four sessions of the course (Table 9). Participants were invited up to three times to attend a
course. Overall, 80 reasons for missing sessions were given by 79 participants who did not attend all four
sessions. Reasons for non-attendance were typically as a result of feeling ill or prior work commitments
(Table 10). We hypothesised that often lengthy travel to the venue and course length may also have been
factors in course attendance rates. Seizures occurring during the course were recorded. There were six
observed seizures throughout the study period lasting between 2 and 20 minutes. Of these, three were
instances of non-epileptic seizures occurring in two participants, which were observed and documented by
the ENS facilitating the course. One participant had been aware of having these seizures in the past. It was
possible to document these instances of non-epileptic seizures as a result of the extensive experience of the
ENS facilitators (> 15 years each).
Effect of intervention receipt on retention
We assessed whether or not attending the SMILE (UK) course was associated with retention in the
intervention group (Table 11). Full receipt of the intervention was defined as having attended both days of
the SMILE (UK) course/four sessions (morning and afternoon of both days). Not having received the full
intervention was defined as having attended 0–3 sessions. Extent of receipt of the intervention was
TABLE 9 Intervention receipt of SMILE (UK)
Number of sessions completed Number of participants, n (%)
0 54 (26.3)
1 4 (2.0)
2 7 (3.4)
3 14 (6.8)
4 126 (61.5)
A session is defined as either a morning or an afternoon of the course. Compliance is defined as being present during all
four sessions.
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
TABLE 10 Reason for non-attendance to SMILE (UK) course
Reason Number of participants (n= 79)
Felt unwell 18
Work commitments 10
Family commitments 3
Could not travel unaccompanied 4
Other 22
Unknown 23
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
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associated with the likelihood of remaining in the study: 120 out of the 126 participants (95.2%) who
received the full intervention completed the 12-month assessment, compared with 43 of the 79
participants (54.4%) who did not receive the full intervention. This informed the need to use multiple
imputation in the inferential analysis of outcome measures.
Summary
Participant recruitment resulted in 404 participants being enrolled into the SMILE (UK) trial. For the
intervention group, 18 courses were delivered with 126 out of 205 participants attending all four sessions.
Reasons for not attending included not feeling well or having work/family commitments. AEs occurring
during the study period were not related to the intervention. A large proportion of participants could not
be contacted at the 12-month follow-up. Despite this, 82% completed the 12-month follow-ups, which
permitted adequately powered analyses.
TABLE 11 Extent of intervention receipt versus dropout from follow-up
Intervention receipt (N= 205) Withdrawal from the trial, n (%) Trial completed, n (%)
Full intervention received (4 sessions) 6 (4.8) 120 (95.2)
Received 0–3 intervention sessions 36 (45.6) 43 (54.4)
Total 42 (20.5) 163 (79.5)
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Chapter 5 Analysis of baseline data
Introduction
We undertook an analysis of baseline data collected at enrolment for 404 PWE enrolled in SMILE (UK).
Having data on such a large group of people with poorly controlled epilepsy offered a unique opportunity
to describe the characteristics of this group of patients. Because our measure of QoL, QOLIE-31-P, is still
not widely used, we looked at the subdomains of the scale and how they are interassociated. In addition,
we assessed which of our secondary outcome measures were associated with QOLIE-31-P.
Results
Study sample characteristics
Baseline demographics of the study group are presented in Table 12. Overall, the group had an average
age of 41.7 years, ranging from 16 to 85 years. There was a slightly higher proportion of females taking
part (54.2%) and the majority of participants were of white ethnicity (75.2%). The IMD score, measuring
TABLE 12 Participant demographic characteristics
Variable
Treatment group
Total (N= 404)Intervention (N= 205) Control (N= 199)
Age (years), mean (SD) [range] 42.5 (14.3) [16–85] 40.8 (14.0) [17–82] 41.7 (14.1) [16–85]
Age group (years), n (%)
16–25 31 (15.1) 26 (13.1) 57 (14.1)
26–35 40 (19.5) 58 (29.1) 98 (24.3)
36–45 50 (24.4) 45 (22.6) 95 (23.5)
46–55 45 (22.0) 42 (21.1) 87 (21.5)
56–65 27 (13.2) 19 (9.5) 46 (11.4)
> 65 12 (5.9) 9 (4.5) 21 (5.2)
Gender, n (%)
Female 115 (56.1) 104 (52.3) 219 (54.2)
Male 90 (43.9) 95 (47.7) 185 (45.8)
Ethnicity, n (%)
White 160 (78.0) 144 (72.4) 304 (75.2)
Mixed/multiple ethnic groups 19 (9.3) 21 (10.6) 40 (9.9)
Black/African/Caribbean/black British 16 (7.8) 17 (8.5) 33 (8.2)
Asian/Asian British 7 (3.4) 11 (5.5) 18 (4.5)
Other 3 (1.5) 6 (3.0) 9 (2.2)
IMD score, mean (SD) [range] 25.4 (12.8) [3–60] 26.3 (13.4) [1–59] 25.8 (13.1) [1–60]
IMD quintiles, n (%)
1 (least deprived) 20 (9.8) 19 (9.5) 39 (9.7)
2 27 (13.2) 29 (14.6) 56 (13.9)
continued
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TABLE 12 Participant demographic characteristics (continued )
Variable
Treatment group
Total (N= 404)Intervention (N= 205) Control (N= 199)
3 33 (16.1) 31 (15.6) 64 (15.8)
4 70 (34.1) 66 (33.2) 136 (33.7)
5 (most deprived) 55 (26.8) 54 (27.1) 109 (27.0)
Highest level of education, n (%)
No formal qualifications 31 (15.1) 30 (15.1) 61 (15.1)
Secondary level 69 (33.7) 62 (31.2) 131 (32.4)
Further education (post secondary) 44 (21.5) 41 (20.6) 85 (21.0)
Higher education (bachelor’s degree and
higher)
61 (29.8) 66 (33.2) 127 (31.4)
Living arrangements, n (%)
Household, living with others 159 (77.6) 146 (73.4) 305 (75.5)
Living alone 43 (21.0) 52 (26.1) 95 (23.5)
Other arrangements 3 (1.5) 1 (0.5) 4 (1.0)
Marital status, n (%)
Single 81 (39.7) 95 (48.0) 176 (43.8)
Steady relationship not cohabiting 23 (11.3) 21 (10.6) 44 (10.9)
Married/living with partner 83 (40.7) 70 (35.4) 153 (38.1)
Divorced/widowed 17 (8.3) 12 (6.1) 29 (7.2)
Employment, n (%)
Employed full time 42 (20.5) 46 (23.1) 88 (21.8)
Employed part time 22 (10.7) 31 (15.6) 53 (13.1)
Unemployed 94 (45.9) 83 (41.7) 177 (43.8)
Self-employed 15 (7.3) 13 (6.5) 28 (6.9)
Retired (because of age) 9 (4.4) 8 (4.0) 17 (4.2)
Retired (because of health) 5 (2.4) 3 (1.5) 8 (2.0)
Student 13 (6.3) 15 (7.5) 28 (6.9)
Housewife/husband 5 (2.4) 0 5 (1.2)
Employment for those aged < 65 years (binary), n (%)
Not employed 102 (53.1) 86 (45.3) 188 (49.2)
Employed or student 90 (46.9) 104 (54.7) 194 (50.8)
Clinical details
Years since epilepsy first diagnosed, median
(IQR) [range]
20 (8–32) [1–66] 18 (8–32) [1–64] 18 (8–32) [1–66]
Comorbidity, n (%)
None 101 (49.3) 118 (59.3) 219 (54.2)
Another medical condition 71 (34.6) 61 (30.7) 132 (32.7)
Psychiatric condition 10 (4.9) 10 (5.0) 20 (5.0)
Both medical and psychiatric 23 (11.2) 10 (5.0) 33 (8.2)
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
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levels of deprivation according to participants’ postcodes,111 indicated that the majority of our group
(60.7%) lived in areas of high deprivation. The group was highly educated, with approximately 50%
having post-secondary level qualifications [beyond General Certificate of Secondary Education (GCSE)
level]. Despite the high level of education, only 21.8% of the group were employed full time, 13.1% were
employed part time and 6.9% were self-employed. To better evaluate the proportion of participants not in
work, we grouped the employment category into a binary factor looking at participants aged < 65 years.
This showed that half of the group of working age were not employed. Roughly three-quarters of the
group lived with others and about 40% were with a partner.
Clinical details at baseline (see Table 12) showed a median 18 years since epilepsy diagnosis. Almost half
of the sample reported experiencing a comorbid health condition (45.9%), including 13.2% with a current
mental health diagnosis (e.g. depression, anxiety).
Associations with quality of life in people with poorly
controlled epilepsy
In order to better understand the primary outcome measure, QOLIE-31-P, we undertook an in-depth
analysis of the measure using values obtained at baseline. This was an additional post hoc analysis not
specified in the statistical analysis plan.84 We looked at the measure itself with its different domains, as
well as what secondary outcomes are associated with QOLIE-31-P scores.
Evaluation of Quality Of Life In Epilepsy 31-P and subdomains
We found strong pairwise correlations (using Pearson’s r) between QOLIE-31-P subscales and the total
score (0.63–0.71), suggesting that each subscale has a reasonable, but not overly strong, association with
the total score. Higher scores on the QOLIE-31-P reflect better QoL. Correlations between subdomains
were lower, indicating that each scale is measuring a sufficiently different topic in this sample (Table 13).
We then looked specifically at the relationship between QOLIE-31-P subscales and the HADS measure
(Table 14). As shown in Table 14, mood and seizure anxiety were most strongly negatively associated with
the anxiety subscale (HADS-A). Mood, energy and daily activity scores were most strongly negatively
associated with the depression subscale (HADS-D). This finding suggests that greater psychological distress
is associated with diminished QoL status.
TABLE 13 Pearson’s correlation coefficients (r) between all pairwise combinations of total and domain subscores of
QOLIE-31-P
Subscales Total
Subscale
Energy Mood Daily activity Cognition Medication effects Seizure worry
Energy 0.68
Mood 0.67 0.53
Daily activity 0.71 0.42 0.39
Cognition 0.68 0.44 0.44 0.43
Medication effects 0.68 0.33 0.27 0.47 0.38
Seizure worry 0.63 0.34 0.40 0.44 0.40 0.43
Overall QoL 0.67 0.55 0.65 0.43 0.44 0.25 0.38
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Associations between variables
As shown in Table 15, total QOLIE-31-P baseline scores were associated with a number of other variables.
Females scored lower on the QOLIE-31-P measure than males. Lower education level and unemployment
were also associated with reduced QOLIE-31-P scores.
A more recent epilepsy diagnosis (i.e. within past year prior to recruitment) and high seizure frequency
(≥ 10 seizures in the previous year) were strongly associated with lower QOLIE-31-P scores. Any
comorbidity, especially psychiatric or both psychiatric and medical, was also associated with low QOLIE-31-P
scores (see Table 15).
An association was found between reduced QoL and both HADS-A and HADS-D scores. Depression
‘caseness’ was more associated with lower QOLIE-31-P scores (predicted mean 47.2) than was anxiety
‘caseness’ (predicted mean 56.0). We found a strong association between total QOLIE-31-P and both
HADS scores (anxiety –0.63, depression –0.66; Figure 4).
TABLE 14 Pearson’s correlation coefficients (r) between total and domain subscores of QOLIE-31-P with HADS
QOLIE-31-P and subscales
HADS
HADS-A r HADS-D r
QOLIE-31-P scale (n= 400) –0.63 –0.66
Subscale
Energy (n= 402) –0.46 –0.57
Mood (n= 402) –0.67 –0.60
Daily activity (n = 400) –0.40 –0.51
Cognition (n= 402) –0.42 –0.46
Medication effects (n= 399) –0.35 –0.37
Seizure worry (n = 401) –0.51 –0.35
Overall QoL (n= 400) –0.45 –0.56
TABLE 15 Participant characteristics and associations with QOLIE-31-P
Baseline characteristics (categorical) Predicted mean (95% CI) Coefficient (95% CI) p-value
Gender (n= 400)
Male (reference) 68.2 (66.2 to 70.3) – 0.0043
Female 64.2 (62.3 to 66.1) –4.1 (–6.8 to –1.3)
Highest level of education (n= 400)
Higher education (reference) 68.3 (65.9 to 70.8) – 0.0096
Further education 67.8 (64.8 to 70.8) –0.5 (–4.4 to 3.4)
Secondary 64.6 (62.2 to 67.1) –3.7 (–7.1 to –0.2)
No formal qualifications 61.8 (58.2 to 65.3) –6.6 (–10.9 to –2.2)
Employment (≤ 64 years) (n= 379)
Employed or student (reference) 69.5 (67.5 to 71.4) – < 0.001
Not employed 62.0 (60.0 to 64.0) –7.5 (–10.3 to –4.7)
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TABLE 15 Participant characteristics and associations with QOLIE-31-P (continued )
Baseline characteristics (categorical) Predicted mean (95% CI) Coefficient (95% CI) p-value
Years with epilepsy diagnosis (n= 403)
32 years 67.1 (65.4 to 68.8) 0.1 (0.01 to 0.2) 0.037
18 years 65.7 (64.3 to 67.2)
8 years 64.8 (62.9 to 66.6)
1 year 64.1 (61.8 to 66.4)
Comorbid condition (n = 400)
None (reference) 68.5 (66.6 to 70.3) – < 0.001
Another medical condition 65.0 (62.7 to 67.4) –3.4 (–6.4 to –0.4)
Psychiatric condition 61.5 (55.4 to 67.6) –7.0 (–13.4 to –6.4)
Both medical and psychiatric conditions 56.8 (52.1 to 61.6) –11.6 (–16.7 to –6.6)
Seizure frequency in previous year (n = 400)
1–3 times (reference) 73.6 (69.7 to 77.5) – < 0.001
4–6 times 68.8 (64.9 to 72.6) –4.8 (–10.3 to 0.7)
7–9 times 69.3 (63.7 to 74.8) –4.3 (–11.1 to 2.5)
≥ 10 times 64.0 (62.3 to 65.6) –9.6 (–13.9 to –5.4)
HADS-D (n= 399)
Normal (reference) 70.8 (69.4 to 72.1) – < 0.001
Borderline 58.1 (55.4 to 60.8) –12.7 (–15.7 to –9.6)
Case 47.2 (43.6 to 50.7) –23.6 (–27.4 to –19.8)
HADS-A (n= 399)
Normal (reference) 74.4 (72.7 to 76.1) – < 0.001
Borderline 63.7 (61.1 to 66.3) –10.7 (–13.8 to –7.6)
Case 56.0 (54.1 to 58.0) –18.4 (–21.0 to –15.8)
Stigma of epilepsy (n= 397)
Not stigmatised (reference) 71.6 (69.4 to 73.8) – < 0.001
Mild to moderate 63.9 (62.1 to 65.8) –7.7 (–10.6 to –4.8)
Highly stigmatised 58.9 (55.1 to 62.6) –12.8 (–17.1 to –8.4)
Self-mastery of epilepsy scale (n= 396)
16 self-mastery score 70.0 (68.6 to 71.4) 2.1 (1.7 to 2.5) < 0.001
14 self-mastery score 65.9 (64.7 to 67.1)
12 self-mastery score 61.7 (60.3 to 63.1)
6 self-mastery score 49.2 (46.0 to 52.4)
Medication adherence scale (n= 399)
48 medication adherence score 66.8 (65.2 to 68.3) 0.3 (0.05 to 0.6) 0.023
46 medication adherence score 66.1 (64.7 to 67.5)
43 medication adherence score 65.1 (63.5 to 66.6)
16 medication adherence score 55.9 (47.3 to 64.6)
CI, confidence interval.
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As shown in Table 15 and Figure 4, low total QOLIE-31-P was associated with low self-mastery beliefs and
less medication adherence, reported using quartiles of the self-mastery and medication adherence scores.
Low QoL was also associated with high levels of felt stigma.
The variables that did not show any association with QOLIE-31-P scores in the analysis were age, ethnicity,
household living arrangements, marital status and IMD scores.
Summary
At baseline, our group with poorly controlled epilepsy had had active epilepsy (69% had ≥ 10 seizures in
the past year) for a long time (median 18 years). There was a high level of unemployment and more than
half of the participants lived in areas of high deprivation. The participants were highly educated, with
about 50% having had a post-secondary education.
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FIGURE 4 Correlational analysis with quality of life (QOLIE-31-P) and secondary outcome measures. (a) Anxiety
(HADS-A, r= 0.63, p < 0.001, n= 400); (b) depression (HADS-D, r= 0.66, p< 0.001, n= 400); and (c) self-management
(self-mastery subscale, r= 0.49, p< 0.001, n= 399). The green line displays the ‘line of best fit’ using a simple
regression analysis.84
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The various subdomains of the QOLIE-31-P scale contribute similarly to the total score. Subdomains
correlated with each other but did not have high correlation coefficients, suggesting that they measure
different factors of QoL.
Many of the collected participant characteristics were associated with lower QoL, for example being
female, having lower qualifications, not being in employment, having a more recent diagnosis of epilepsy
and having a comorbidity (especially a diagnosed psychiatric condition). Our secondary outcome measures
were also associated with QOLIE-31-P. These were, in order of most associated, HADS-D, HADS-A,
self-stigma, seizure frequency, self-mastery and medication adherence.
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Chapter 6 Outcomes of the randomised
controlled trial
Introduction
Participants completed assessments with primary and secondary outcome measures at the baseline, 6- and
12-month follow-ups. This chapter outlines results of the RCT.114
Trial outcomes
Primary outcome: quality of life
The primary outcome measure was QOLIE-31-P measured at 12 months after randomisation to the study.
This measure was also reported at 6 months post randomisation. The observed QoL outcomes are
summarised in Table 16. This table shows that the two domains with consistently the lowest scores across
all time points were energy and cognition. The highest scored domains were mood, daily activity and
medication effects. As many published studies115–117 use QOLIE-31 without the patient-specific weighting,
we calculated the total score according to the QOLIE-31 specifications for comparative purposes. These
scores are presented in Table 16. Similarly to QOLIE-31-P, the observed total scores were slightly higher
after 1 year in both groups. The total QOLIE-31 score improved in the intervention group by 2.7 and in the
control group by 2.5 at 12 months.
Importantly, the post-randomisation QoL scores in all domains were similar in the two trial arms (see
Table 16). We found no statistically significant differences between the trial arms at 6 months (p = 0.195)
or 12 months (p = 0.564) (Table 17).
In total, 129 (32%) participants enrolled in the study received full treatment by attending all four SMILE
(UK) course sessions. This consisted of 126 randomised participants who were allocated to SMILE (UK) and
three participants who were allocated to TAU alone. The CACE efficacy estimate was –1.28 (p = 0.528),
which was in the same direction as the ITT effectiveness estimate of –0.72 (p = 0.564). Neither result was
statistically significant.
Secondary outcomes
Seizure control
Overall, at baseline (Table 18) 69.3% of the group experienced ≥ 10 seizures in the previous 12 months
(Thapar scale) and 72.2% had one or more seizures per month (Baker scale). As intended, the study
group enrolled in the SMILE (UK) trial had highly active epilepsy despite being prescribed AEDs. The
percentage of participants experiencing such high levels of seizures according to the Thapar scale remained
fairly constant over the three study assessments. Thus, there were no statistically significant differences
between trial arms in the Thapar scale at either 6 or 12 months (p = 0.691) (see Table 17).
Seizure frequency measured by the Baker scale showed fewer participants having one or more seizures per
month at the follow-up times. However, overall post-randomisation Baker scores were similar between the
two trial arms and not statistically significant.
Finally, the number of days since last recalled seizure was lower at 6 and 12 months than was reported at
baseline. However, there was also no statistically significant difference in seizure recency at follow-ups
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TABLE 16 Descriptive summaries for outcome measure QOLIE-31-P
QOLIE-31 subdomain
Time point, mean (SD) [range]
Baseline 6 months 12 months
SMILE (UK)
(n= 203)
TAU
(n= 197)
Total
(n= 401)
SMILE (UK)
(n= 153)
TAU
(n= 160)
Total
(n= 313)
SMILE (UK)
(n= 163)
TAU
(n= 168)
Total
(n= 331)
Energy 52.1 (18.7)
[16.7–91.7]
54.7 (17.4)
[16.7–100.0]
53.4 (18.1)
[16.7–100.0]
54.8 (16.6)
[16.7–100.0]
55.5 (17.3)
[16.7–100.0]
55.1 (16.9)
[16.7–100.0]
53.3 (18.4)
[16.7–95.8]
55.8 (18.0)
[16.7–100.0]
54.6 (18.2)
[16.7–100.0]
Mood 65.7 (18.5)
[16.7–100.0]
68.8 (16.6)
[23.3–100.0]
67.2 (17.6)
[16.7–100.0]
66.9 (17.0)
[20.0–100.0]
66.6 (16.2)
[20.0–100.0]
66.7 (16.5)
[20.0–100.0]
67.0 (17.1)
[16.7–100.0]
69.6 (17.3)
[16.7–100.0]
68.3 (17.2)
[16.7–100.0]
Daily activity 64.3 (23.0)
[19.3–100.0]
66.0 (24.0)
[19.3–100.0]
65.2 (23.5)
[19.3–100.0]
67.8 (20.5)
[19.3–100.0]
66.5 (22.0)
[19.3–100.0]
67.1 (21.2)
[19.3–100.0]
69.9 (20.5)
[19.3–100.0]
71.1 (23.8)
[19.3–100.0]
70.5 (22.2)
[19.3–100.0]
Cognition 57.8 (24.1)
[18.6–100.0]
60.6 (23.0)
[18.6–100.0]
59.2 (23.6)
[18.6–100.0]
57.9 (22.0)
[18.6–100.0]
60.3 (19.9)
[18.6–100.0]
59.1 (20.9)
[18.6–100.0]
59.4 (23.7)
[18.6–100.0]
62.9 (22.7)
[18.6–100.0]
61.2 (23.2)
[18.6–100.0]
Medication effects 67.9 (23.4)
[21.7–100.0]
67.5 (24.3)
[21.7–100.0]
67.7 (23.8)
[21.7–100.0]
66.2 (21.7)
[21.7–100.0]
66.5 (23.3)
[21.7–100.0]
66.3 (22.5)
[21.7–100.0]
69.2 (21.5)
[21.7–100.0]
71.8 (21.5)
[21.7–100.0]
70.5 (21.5)
[21.7–100.0]
Seizure worry 60.7 (21.9)
[24.0–100.0]
63.0 (21.5)
[24.0–100.0]
61.8 (21.7)
[24.0–100.0]
60.6 (20.7)
[24.0–100.0]
61.3 (21.5)
[24.0–100.0]
61.0 (21.1)
[24.0–100.0]
67.2 (21.0)
[24.0–100.0]
69.2 (22.4)
[24.0–100.0]
68.2 (21.7)
[24.0–100.0]
Overall QoL 62.2 (18.0)
[10.0–100.0]
63.0 (18.4)
[10.0–100.0]
62.6 (18.2)
[10.0–100.0]
63.6 (16.7)
[15.0–100.0]
62.2 (17.3)
[10.0–95.0]
62.9 (17.0)
[10.0–100.0]
64.3 (18.0)
[15.0–100.0]
63.5 (18.5)
[10.0–100.0]
63.9 (18.3)
[10.0–100.0]
Total (non-P) 60.9 (15.6)
[24.5–93.7]
63.1 (15.7)
[24.7–97.6]
62.0 (15.6)
[24.5–97.6]
62.3 (13.8)
[33.3–95.8]
62.8 (14.6)
[26.3–94.8]
62.6 (14.2)
[26.3–95.8]
63.6 (15.2)
[28.0–95.8]
65.6 (16.1)
[26.4–95.2]
64.6 (15.7)
[26.4–95.8]
Total 65.2 (14.1)
[30.0–91.6]
66.9 (14.2)
[24.8–98.5]
66.0 (14.2)
[24.8–98.5]
66.3 (13.0)
[34.2–92.8]
65.5 (14.0)
[27.3–94.7]
65.9 (13.5)
[27.3–94.7]
67.4 (13.5)
[25.1–95.4]
69.5 (14.8)
[26.4–93.8]
68.5 (14.2)
[25.1–95.4]
The subdomains of the QOLIE-31 scale are calculated the same way for the QOLIE-31 and QOLIE-31-P versions. To calculate the total score for the QOLIE-31-P scale, each subdomain is
given a weight by the participant according to the impact it has on their lives (e.g. how are they distressed by medication effects).
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution-NonCommercial 4.0
International (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
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between the two trial arms (see Table 17). Seizure control is difficult to interpret as there is recall bias in this
patient population, who frequently have memory problems and can also be unaware of seizures occurring.
Impact of epilepsy
Scores from the Impact of Epilepsy scale were unchanged from baseline values at the 6- and 12-month
follow-ups (see Table 18). There were no differences between the treatment groups at either of the
follow-up time points (see Table 17).
Medication adherence
There was a 1-point improvement in the means of both treatment groups at the final follow-up. As the
baseline scores were high, we did not anticipate that much improvement on this scale could be possible.
In addition, 12 months after randomisation, there were no differences between the two treatment groups
(see Table 17).
Medication adverse effects
The impact of adverse effects from epilepsy medication was determined from two questions in the
QOLIE-31-P. The maximum score for the two questions is 10 and higher scores indicate less impact of
adverse effects. Scores were similar at all time points (see Table 18). There were no statistically significant
differences between the trial arms at the 6- or 12-month follow-ups (see Table 17).
TABLE 17 Final analysis inferential results
Outcome
Follow-up time point
6 months 12 months
Treatment
effect 95% CI p-value
Treatment
effect 95% CI p-value
QOLIE-31-P 1.70 –0.87 to 4.26 p= 0.195 –0.72 –3.19 to 1.74 p= 0.564a
Impact of epilepsy –0.35 –1.83 to 1.13 p= 0.640 –0.96 –2.30 to 0.38 p= 0.159
Medication adherence – – – –0.02 –0.74 to 0.71 p= 0.964
Medication AEs 0.03 –0.56 to 0.62 p= 0.923 –0.41 –0.97 to 0.15 p= 0.151
HADS-A – – – –0.04 –0.83 to 0.74 p= 0.917
HADS-D – – – –0.33 –1.14 to 0.49 p= 0.432
Stigma of epilepsy – – – 0.14 –0.39 to 0.66 p= 0.606
Self-mastery and control – – – –0.16 –0.94 to 0.62 p= 0.687
Seizure frequency
(Baker et al.99)
– – – –0.02b –0.63 to 0.58 p= 0.939
Seizure frequency
(Thapar et al.35)
– – – 0.11b –0.43 to 0.65 p= 0.691
Seizure recency
(days since last seizure)
–0.19c –0.60 to 0.22 p= 0.371 –0.31c –0.70 to 0.09 p= 0.129
CI, confidence interval.
a QOLIE-31-P at 12-month follow-up is the primary outcome.
b Treatment effect for seizure frequency is a trial arm difference on the log-scale.
c Treatment effect for seizure recency is a trial arm difference on the logit scale.
Reproduced with permission from Ridsdale et al.114 2018. This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: https://creativecommons.org/licenses/by-nc/4.0/.
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TABLE 18 Descriptive summaries for SMILE (UK)
Outcome measure
Time point
Baseline 6 months 12 months
SMILE (UK)
(N= 205) TAU (N= 199) Total (N= 404)
SMILE (UK)
(N= 154) TAU (N= 160) Total (N= 314)
SMILE (UK)
(N= 163) TAU (N= 168) Total (N= 331)
Seizure frequency in last
12 months (Thapar et al.35),
n (%)
n = 205 n= 199 n= 404 n= 161 n = 168 n= 329
None – – – 7 (4.3) 17 (10.1) 24 (7.3)
1–3 times 19 (9.3) 30 (15.1) 49 (12.1) 16 (9.9) 23 (13.7) 39 (11.9)
4–6 times 29 (14.1) 22 (11.1) 51 (12.6) 23 (14.3) 14 (8.3) 37 (11.2)
7–9 times 15 (7.3) 9 (4.5) 24 (5.9) 10 (6.2) 6 (3.6) 16 (4.9)
≥ 10 times 142 (69.3) 138 (69.3) 280 (69.3) 105 (65.2) 108 (64.3) 213 (64.7)
Seizure frequency in last
6 months (Thapar et al.35),
n (%)
n = 147 n= 157 n= 304
None 15 (10.2) 27 (17.2) 42 (13.8)
1–3 times 27 (18.4) 27 (17.2) 54 (17.8)
4–6 times 21 (14.3) 20 (12.7) 41 (13.5)
7–9 times 16 (10.9) 3 (1.9) 19 (6.3)
≥ 10 times 68 (46.3) 80 (51.0) 148 (48.7)
Seizure frequency in last
12 months (Baker et al.99),
n (%)
n = 199 n= 196 n= 395 n= 160 n = 168 n= 328
None – – – 7 (4.4) 17 (10.1) 24 (7.3)
< 1 per month 52 (26.1) 58 (29.6) 110 (27.8) 59 (36.9) 56 (33.3) 115 (35.1)
≥ 1 per month 147 (73.9) 138 (70.4) 285 (72.2) 94 (58.8) 95 (56.5) 189 (57.6)
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Outcome measure
Time point
Baseline 6 months 12 months
SMILE (UK)
(N= 205) TAU (N= 199) Total (N= 404)
SMILE (UK)
(N= 154) TAU (N= 160) Total (N= 314)
SMILE (UK)
(N= 163) TAU (N= 168) Total (N= 331)
Seizure frequency in last
6 months (Baker et al.99),
n (%)
n = 145 n= 155 n= 300
None 15 (10.3) 27 (17.4) 42 (14.0)
< 1 per month 40 (27.6) 34 (21.9) 74 (24.7)
≥ 1 per month 90 (62.1) 94 (60.6) 184 (61.3)
Seizure recency in last
12 months (days since
last recalled seizure),
median (IQR) [range]
n = 199; 33
(19–64)
[1–351]
n= 186; 34
(17–63)
[3–457]
n= 385; 34
(18–63) [1–457]
n= 161; 10
(2–66) [0–705]
n = 164; 14
(3–121) [0–815]
n= 325; 13
(2–95) [0–815]
Seizure recency in last
6 months (days since
last recalled seizure),
median (IQR) [range]
n = 143; 16
(6–55) [0–545]
n= 146; 19
(5–68) [0–611]
n= 280; 17
(5–62) [0–611]
Impact of epilepsy,
mean (SD) [range]
n = 203; 24.4
(8.0) [10–40]
n= 196; 24.4
(8.1) [10–40]
n= 399; 24.4
(8.0) [10–40]
n = 153; 25.1
(7.3) [10–40]
n= 155; 24.8
(8.2) [10–40]
n= 308; 25.0
(7.8) [10–40]
n= 162; 25.4
(7.9) [10–40]
n = 166; 26.0
(8.7) [10–40]
n= 328; 25.7
(8.3) [10–40]
Medication adherence,
median (IQR) [range]
n = 201; 46.7
(43.3–48.9)
[16.7–50.0]
n= 198; 46.7
(43.3–48.9)
[26.7–50.0]
n= 399; 46.7
(43.3–48.9)
[16.7–50.0]
n= 162; 47.8
(45.6–48.9)
[27.8–50.0]
n = 165; 47.8
(45.6–48.9)
[35.6–50.0]
n= 327; 47.8
(45.6–48.9)
[27.8–50.0]
Medication AEs, median
(IQR) [range]
n = 201; 7
(5–10) [2–10]
n= 198; 7
(4–10) [2–10]
n= 399; 7
(5–10) [2–10]
n = 151; 7
(5–10) [2–10]
n= 159; 7
(5–10) [2–10]
n= 310; 7
(5–10) [2–10]
n= 163; 7
(5–10) [2–10]
n = 168;
8 (6–10)
[2–10]
n= 331;
8 (5–10) [2–10]
Anxiety (HADS-A), mean
(SD) [range]
n = 204; 9.0
(5.0) [0–21]
n= 199; 7.8
(4.8) [0–21]
n= 204; 8.4
(4.9) [0–21]
n= 162; 8.1
(4.6) [0–20]
n = 167; 7.6
(4.3) [0–20]
n= 329; 7.9
(4.4) [0–20]
Depression (HADS-D),
mean (SD) [range]
n = 204; 5.5
(3.9) [0–18]
n= 199; 5.0
(3.9) [0–16]
n= 204; 5.3
(3.9) [0–18]
n= 162; 5.7
(4.1) [0–20]
n = 167; 5.7
(4.3) [0–18]
n= 329; 5.7
(4.2) [0–20]
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TABLE 18 Descriptive summaries for SMILE (UK) (continued )
Outcome measure
Time point
Baseline 6 months 12 months
SMILE (UK)
(N= 205) TAU (N= 199) Total (N= 404)
SMILE (UK)
(N= 154) TAU (N= 160) Total (N= 314)
SMILE (UK)
(N= 163) TAU (N= 168) Total (N= 331)
Anxiety categories
(HADS-A), n (%)
n = 204 n= 199 n= 204 n= 162 n = 167 n= 329
Normal (scores of 0–7) 83 (40.7) 104 (52.3) 187 (46.4) 78 (48.1) 93 (55.7) 171 (52.0)
Borderline (scores of
8–10)
44 (21.6) 35 (17.6) 79 (19.6) 28 (17.3) 27 (16.2) 55 (16.7)
Case (scores 11–21) 77 (37.7) 60 (30.2) 137 (34.0) 56 (34.6) 47 (28.1) 103 (31.3)
Depression categories
(HADS-D), n (%)
n = 204 n= 199 n= 204 n= 162 n = 167 n= 329
Normal (scores 0–7) 144 (70.6) 146 (73.4) 290 (72.0) 114 (70.4) 124 (74.3) 238 (72.3)
Borderline (scores 8–10) 37 (18.1) 34 (17.1) 71 (17.6) 29 (17.9) 15 (9.0) 44 (13.4)
Case (scores 11–21) 23 (11.3) 19 (9.5) 42 (10.4) 19 (11.7) 28 (16.8) 47 (14.3)
Stigma of epilepsy, median
(IQR) [range]
n = 203; 1
(0–4) [0–9]
n= 198; 2
(0–4) [0–9]
n= 401; 1 (0–4)
[0–9]
n= 161; 2
(0–4) [0–9]
n = 167; 1
(0–4) [0–9]
n= 328; 1 (0–4)
[0–9]
Stigma categories, n (%) n = 203 n= 198 n= 401 n= 161 n = 167 n= 328
Not stigmatised
(score of 0)
76 (37.4) 72 (36.4) 148 (36.9) 54 (33.5) 57 (34.1) 111 (33.8)
Mild to moderate
(scores of 1–6)
100 (49.3) 103 (52.0) 203 (50.6) 86 (53.4) 83 (49.7) 169 (51.5)
Highly stigmatised
(scores of 7–9)
27 (13.3) 23 (11.6) 50 (12.5) 21 (13.0) 27 (16.2) 48 (14.6)
Self-mastery, mean (SD)
[range]
n = 201; 13.9
(3.4) [6–23]
n= 198; 14.3
(3.3) [6–24]
n= 399; 14.1
(3.3) [6–24]
n= 162; 14.5
(3.4) [7–24]
n = 167; 14.6
(3.5) [6–24]
n= 329; 14.6
(3.4) [6–24]
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Psychological distress
Psychological distress, specifically anxiety and depression scores, was captured using HADS. The participants
were divided into categories based on scores for HADS-A and HADS-D. About one-third of the total group
had case scores for anxiety at baseline in both groups. About 10% of the group had case scores for
depression in both treatment groups at baseline (see Table 18).
At 12 months, there were no significant differences between the intervention and control groups (see
Table 17). There was a slightly higher proportion of participants with case anxiety scores in the intervention
group than in the control group, but this was not significant (see Table 18). In addition, there was a higher
proportion of participants with HADS-D case scores in the control group at the 12-month follow-up
(see Table 18).
Stigma of epilepsy
Felt stigma was measured using a scale with scores from 0 to 9 (see Chapter 4). The median scores were
similar at baseline and at 12 months (see Table 18). These scores were categorised into ‘not stigmatised’,
‘mild–moderate stigma’ and ‘highly stigmatised’. At baseline, approximately 60% of the sample felt some
level of stigma (majority in mild-to-moderate group) because of epilepsy. At the 1-year follow-up, this
level of felt stigma persisted in both treatment groups with no significant difference between the two
(see Tables 17 and 18).
Self-mastery
Self-mastery was assessed with a questionnaire with scores ranging from 0 to 24 (see Chapter 4). Both
treatment groups changed little at the 12-month follow-up with no statistically significant difference
between trial arms (see Tables 17 and 18).
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Chapter 7 Implementation fidelity
Introduction
Many complex interventions are delivered within group settings, such as self-management education
courses. When testing such interventions, it is important to monitor how well the intervention was
delivered. In a RCT setting, in which an intervention is delivered on many separate occasions to different
groups of participants by various facilitators, it is especially important to assess how the components of the
intervention were delivered in each setting. Intervention delivery can influence trial outcomes in complex
intervention RCTs. An ‘implementation fidelity’ study provides a structured method for assessing how an
intervention was delivered in a RCT setting. The main objective of this study was to evaluate whether or not
the SMILE (UK) intervention had been delivered as specified in the original protocol. To our knowledge, this
is the first study evaluating implementation fidelity of a group self-management course for epilepsy. For the
purposes of our implementation fidelity study, we evaluated facilitator adherence (to module content) and
facilitator competence during the intervention delivery.
Facilitator adherence can be defined as the degree to which facilitators followed the protocol in delivering
specific aspects of the course.118,119 Competence is defined as the quality of intervention delivery. This
includes aspects such as group interaction and pacing of delivery.119 A proxy for facilitator competence is
the evaluation of didactic teaching methods. This is when a facilitator spends a high proportion of time
speaking rather than having an interactive discussion with course participants. Educational courses that are
solely based on didactic teaching have limited impact on behaviour change.120 During the SMILE (UK)
intervention, we assessed implementation fidelity by developing an instrument that contained checklist
items on facilitator competence and adherence.
Method
For full details on SMILE (UK) intervention development, see Chapter 2. As described in Chapter 5 in more
detail, 18 courses were delivered by 12 SMILE (UK) course facilitators. All of these course offerings were
audio-recorded and, of those, approximately 25% were chosen for the fidelity evaluation.121 The trial
manager selected five courses in a purposeful manner to ensure the maximum number of facilitators could
be evaluated. As courses were given by teams of two, this resulted in 10 facilitators being evaluated.
To ensure courses were not selected based on content, a second researcher listened to the quality of the
recordings. The courses selected for fidelity evaluation were numbers 1, 8, 10, 13 and 15. During the
intervention arm of the trial, group sizes ranged from 6 to 13 participants. At the time of enrolment into
the RCT, participants gave their written consent to have the SMILE (UK) courses audio-recorded. Courses
were not recorded if a participant did not agree to this when giving written informed consent. This work
did not lead to any unblinding as the trial manager was unblinded throughout the study. Two raters
independent from the study listened to the full content of the recordings and were not involved in data
collection for the RCT.
Instrument development
The process of developing the implementation fidelity tool was based on past research.118,122 As MOSES
[and, thus, SMILE (UK)] was not developed according to a behaviour change model, we began by
determining which modules of the course were likely to influence behaviour change. Eight out of nine
modules were identified by study co-investigators; these were further reduced after reviewing suggestions
from participants in the external pilot study.82 Participants in the external pilot identified modules 3
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(basic knowledge), 4 (diagnosis) and 6 (self-control) as those from which they had learned the most.
Module 8 was also identified as helpful; however, this module is subject to participant input and, thus, is
highly variable between course sessions. For this reason, module 8 was excluded from the fidelity analysis.
The three modules ultimately selected for fidelity assessment were content heavy. Discussion points
included knowledge about epilepsy, the science behind clinical diagnosis, treatment options and seizure
auras or triggers.
Adherence
In order to assess facilitator adherence, we created a checklist based on facilitator workbook content. Each
checklist item could be awarded a score from 0 to 2 (0, content undelivered; 1, partial delivery; and 2, full
content delivery). In total, there were five checklist items for module 6 and six checklist items for modules
3 and 4 (maximum score of 2/2 per item).
Competence
We selected four criteria for evaluating facilitator competence: ‘group interaction’, ‘overall impression’,
‘didacticism’ and ‘trainer techniques’. Scores for ‘group interaction’ were allocated based on the number
of participants who interacted with the facilitator (0, one participant was speaking; 1, two or three
participants had spoken; or 2, four or more had participated in a discussion during the group session).
As with past research,118 ‘overall impression’ was assessed to understand how well the modules were
delivered. Scores ranged from 1 to 4 (1, poor performance – the session consisted of didactic teaching
strategies with few instances of interaction; 2, average performance – there was some interaction and
participant input, but not a great deal of cohesiveness 3, good performance with some didactic-style
teaching and considerable group participation and cohesiveness; and 4, indicates excellent performance –
minor instances of didactic teaching and major instances of group participation).
The total amount of speaking time was used as a proxy for ‘didacticism’ during recorded sessions. An
annotation programme called ELAN (Max Planck Institute for Psycholinguistics, The Language Archive,
Nijmegen, the Netherlands)123,124 was used to record instances of facilitator speech in number of seconds.
Filler words used by facilitators such as ‘yeah’ and ‘oh’ were not scored. Total speech time was divided by
the length of the module and was expressed as a percentage.
Finally, throughout each of the module recordings, raters also scored the number of the times that a
facilitator used teaching resources such as a flip chart or PowerPoint slide.
Instrument testing
We conducted a test of the fidelity instrument to ensure its feasibility, with two members of the research
team assessing a course delivered to the control group. For the fidelity assessment of the five courses,
two independent raters were recruited to reduce the possibility of bias. The raters were trained to use the
instrument by evaluating a control group offering of the course. A scoring guide was also developed in
order to minimise the possibility of scoring error or inconsistency. This included a list of specific topics
that the facilitator would need to cover during each module to receive a maximum score. For instance,
in module 3 a score of 2 out of 2 would be awarded for the section on ‘seizure types’ if the following
categories were described: generalised tonic–clonic, absence, complex partial, simple partial and myoclonic.
Statistical analysis
Several approaches were employed to measure inter-rater reliability. A weighted kappa statistic was used
with ordinal scores derived from checklist items. Intraclass coefficients were used with continuous scores
that were derived from didactic speech time measurements. The per cent agreement was calculated for
items on the instrument checklists in order to assess the frequency of raters giving the same scores. Simple
regression analysis was used to examine the associations between scores for different measures.
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Results
Fidelity measure evaluation
In total, 15 recorded sessions were analysed (i.e. five courses each with three modules) and 85 items were
scored. The results were charted in a table then assessed for inter-rater reliability. With a weighted kappa
score of 0.67, there was substantial agreement with allocated ratings.125 Percent agreement was also high,
at 81.2%.
A similar approach was taken in assessing the competence measure. There was also substantial agreement
between raters with a weighted kappa statistic of 0.65 and percentage of agreement at 60.0%. The
intraclass coefficient for didacticism was high at 0.97 (p < 0.0001), which indicates a high degree of
reproducibility. Most sessions received the maximum score of 2 for ‘group interaction’, and thus this item
was not assessed for inter-rater agreement.
SMILE (UK) course evaluation
Adherence
We averaged the scores for each module of the five evaluated sessions in order to determine a total
adherence score. The average adherence score ranged from 1.5 to 1.6 (Table 19). The median score was
2 out of 2 for modules 3 and 6, and 1.8 out of 2 for module 4.
TABLE 19 SMILE (UK) implementation fidelity: adherence scores
Module
Module score,
mean; median
(range) Checklist item
Total item score,
mean; median
(range)
Module 3:
basic knowledge
1.5; 2 (1.3–1.9) How do seizures develop? 2; 2 (2–2)
What are the different seizure types? 2; 2 (2–2)
What happens during a seizure? 1.1; 1 (0–2)
What are some examples of seizure types? 1.8; 2 (1.5–2)
Participants are facilitated to identify personal seizure type 1.7; 2 (1–2)
Participants facilitated to note seizure type in booklet 0.6; 0 (0–2)
Module 4:
diagnosis
1.5; 1.8 (1.2–2) Things that are noticed before, during and after a seizure 2; 2 (2–2)
The importance of detailing specifics of a seizure 1.6; 1.5 (1–2)
What a doctor may need to know about a seizure 1.6; 1.5 (1–2)
Participants prompted to record details of their last seizure
in handbook
0.9; 1 (0–2)
Importance of EEG 1.8; 2 (1–2)
Other diagnostic techniques 1.3; 1 (1–2)
Module 6:
self-control
1.6; 2 (1.3–2) Seizure triggers and how they vary 2; 2 (2–2)
Keeping a checklist of triggers 1.5; 1.5 (0.5–2)
Avoiding and eliminating triggers 1.6; 2 (1–2)
What is an aura and how might it be recognised? 1.4; 2 (0–2)
Countermeasures to achieve aura control 1.5; 1.5 (1–2)
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Out of all five courses that were evaluated, four checklist items were rated as fully delivered by facilitators:
‘how seizures develop’, ‘seizure types’, ‘events pre/during/post seizures’ and ‘seizure triggers’. Seven items
were scored at 0, indicating that the content was not delivered: five out of seven were for missing content
relating to the participant workbook, one out of seven was for missing content relating to seizures and the
other one out of seven was for missing content relating to seizure auras.
Competence
We evaluated group interaction by recording the amount of time that participants spoke during a session.
As shown in Table 20, almost every session was judged as having four or more people interacting in the
session; thus, the mean scores were close to the maximum of 2.
We also assessed ‘overall impression’ using a scoring scale ranging from 1 to 4. Out of the 15 sessions that
were evaluated, 12 were rated as ‘average to excellent’ and three sessions were given a score below two.
Modules 4 and 6 received a maximum score for overall impression for at least one session evaluated
(see Table 20).
There was considerable variation in the percentage of facilitator speech, especially for module 4
(i.e. 48–93%). The regression analysis showed no association between any of the competence measures.
Thus, the percentage of didacticism did not have an impact on adherence, group interaction or
overall impression.
Although we set out to evaluate facilitator teaching techniques, this was not possible because of the
nature of audio-recordings and ambiguity over the exact strategy in use. Raters were unable to assess this
component consistently across all recordings, so the measure was removed from the analysis.
Discussion
There is a fine balance between adherence and competence in delivering complex interventions.126,127
The SMILE (UK) course was designed to involve participant interaction with a certain allowance for
adapting the material to the group.78 This requires a high level of facilitator competence, which can have
an impact on adherence of the course. In the context of a RCT, it is important that the components of the
course be delivered consistently in order to evaluate their effectiveness; thus, a certain level of adherence
is required. It becomes important to achieve the optimum balance between adherence and competence.
How to negotiate between the two can be understood only after implementation fidelity assessments.
We developed our fidelity instrument based on published literature using audio-recordings and
checklists.118,122 We had two independent raters score the course delivery. Other studies have used
self-reporting by facilitators, which increases the risk of bias.128,129 We found that audio-recordings worked
well for assessing adherence and most competence measures. However, a visual approach is needed to
evaluate facilitator techniques used (e.g. flip chart or slides) as this was too difficult to assess with
audio only.
TABLE 20 SMILE (UK) implementation fidelity: competence scores
Module
Mean competence score (range)
Didacticism,
mean % (range)Group interaction Overall impression
Module 3: basic knowledge 1.9 (1.5–2.0) 2.6 (1.5–3.5) 71 (55–78)
Module 4: diagnosis 1.9 (1.5–2.0) 2.6 (1.0–4.0) 69 (48–93)
Module 6: self-control 2.0 (2.0–2.0) 3.0 (2.0–4.0) 58 (42–76)
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Our fidelity assessment showed that our instrument could be used with ease and the inter-rater reliability
was high. The addition of the novel didacticism measurement offered an objective result to the instrument
and was highly reproducible.
The results of our assessment demonstrated that SMILE (UK) was delivered with high adherence to
important topics while allowing for interactive sessions. Four topics received the maximum adherence score
across all the sessions evaluated. Every item received a maximum adherence score in at least one session.
Thus, all items listed in the facilitator’s manual could be fully delivered. We found that the majority of
omitted items were related to using the participant workbook during the course. It is unknown whether or
not using the workbook during the course is a factor in behaviour change. However, using the workbook
throughout the 2 days was an idea raised by volunteers during the pilot test of SMILE (UK). This way, the
book is a tool that participants were already familiar with, which could potentially lead to them using it
again at home.
Limitations of the fidelity assessment
Only three out of the nine SMILE (UK) modules were evaluated. The three selected modules involve more
teaching than the others and, thus, some level of didacticism is expected. However, despite this, the
facilitators still maintained a high level of group interaction. The modules not included in the fidelity
assessment were participant led and would not have been suitable for a structured evaluation. Yet, they
may be important in behaviour change by increasing self-confidence.130,131 Because some modules were
not assessed, it is possible that some overlapping content was touched on in other parts of the course.
Thus, an item could receive a score of 0 in our evaluation but have been delivered in another session.
Our group interaction score was based on a specific number of participants interacting, but this could also
have been represented by a percentage of the group, which would better account for varying group sizes.
Owing to constraints, we evaluated approximately 25% of the courses delivered. We were unable to
assess the same facilitator across multiple courses and thus we are unable to monitor how consistent they
were throughout the study.
Conclusion
The fidelity assessment demonstrated that SMILE (UK) was delivered with high levels of adherence and
competence. The implementation fidelity study offers, to our knowledge, the first such assessment of a
self-management course for epilepsy. The instrument that was developed offers a multicomponent
evaluation of a complex intervention.
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Chapter 8 Health economics
Introduction
This chapter contains the results of the economic evaluation. Few studies have looked at the cost of
epilepsy in the UK. We know of a recent Dutch study in which a cost evaluation of a self-management
course for epilepsy was undertaken132 and have collaborated with the trial team in assessing the
appropriateness of outcome measures for cost evaluations in epilepsy.133 Data on health service use and
QoL were collected with other secondary outcomes during the trial. The objectives were to assess the cost
of epilepsy health care and whether or not SMILE (UK) is cost-effective.
Analysis plan
Perspective
The primary perspective of the economic evaluation was the NHS/Personal Social Services perspective,
which, for decision purposes, is generally preferred by NICE. Other resources relevant to a wider societal
perspective, such as informal care and productivity loss (because of time off work) were included in the
secondary analyses (societal perspective).
Data collection: service use and costs
An adapted version of the CSRI104 was administered retrospectively to collect self-reported resource
utilisation for the 12 months preceding data collection at baseline and 12-month follow-up interviews.
This measure is used to collect the range of services and support accessed by study participants. The CSRI
has been successfully used in a variety of adult mental health populations since its design in 1985. Patients
in this study have different health needs and are likely to require varying health and social services, hence
the need to adapt the CSRI to ensure we capture services relevant to PWE. The CSRI was used to record
epilepsy-specific hospital services and community-based health and social care services, medication,
productivity losses as a result of illness, and help with usual activities provided by family and friends. Data
on the number and duration of SMILE (UK) and TAU sessions were centrally recorded as part of the RCT.
Costs are reported in Great British pounds at 2014–15 prices and, given the 1-year time horizon, discounting
was deemed unnecessary. Service use collected using the CSRI was combined with nationally applicable unit
costs to estimate total costs for each participant.134,135 Productivity losses as a result of epilepsy were derived
based on the human capital approach, which combines days off work with average UK wage rate. Family
and friends are not generally reimbursed for their support to patients but there is still an opportunity cost to
this time. The cost of this unpaid care was also estimated based on the average UK wage rate for adults.
Intervention costs were estimated based on staff time (facilitator) needed to deliver SMILE (UK) including
other non-staff costs, such as training and manuals. These were applied to group-session attendance data
to work out the cost per participant.
Data collection: quality of life
Health-related QoL was estimated using the EQ-5D-5L,136 a widely used standardised method for assessing
health-related quality. The EQ-5D-5L is a brief self-reported preference-based measure of health that
considers five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each
consisting of five levels of functioning (e.g. no pain, slight pain, moderate pain, severe pain and extreme
pain). This measure produces a possible 3125 distinct health states ranging from 11111 (full health) to
55555 (worst). Utility scores for each participant, between 0 (worse health) and 1 (full health)136,137 were
produced by combining UK population value sets with these health states. QALYs were derived from the
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transformed EQ-5D-5L utility scores using the area under the curve method,138 which is the preferred
measure for HRQoL in UK Health Technology Assessment research. The second part of the measure
[EuroQoL-5 Dimensions (EQ-5D) VAS] takes the form of a VAS, in which the participant is required to
rate their health from 0 (worst imaginable health state) to 100 (best imaginable state). It shows the
respondent’s self-perceived HRQoL on a scale with endpoints labelled ‘worst’ at 0 and ‘best’ at 100.
Cost-effectiveness analysis
Stata (version 14) was used to analyse data. Data were assessed two ways: complete cases (i.e. only
including participants with complete service use and QoL data) and on an ITT basis (i.e. according to the
group to which they were randomised regardless of intervention receipt). Missing costs and outcome data
were imputed using a single imputation method based on linear extrapolation, adjusted for baseline costs,
EQ-5D-5L utility scores and QOLIE-31-P score. Other epilepsy-related variables, such as seizure frequency,
were obtained by non-parametric bootstrap regressions to account for the non-normal distribution
commonly found in cost data.139
Costs and outcomes were compared between the two arms at baseline and 12-month follow-up and are
presented as mean values with SDs and 95% confidence intervals (CIs). Mean differences and 95% CIs
were obtained by non-parametric bootstrap regressions (1000 replications) to account for non-normal
distribution often found in cost data.139
Cost-effectiveness and cost-utility
Cost-effectiveness was assessed based on the health and social care (NHS) perspective, as well as the societal
perspective, by combining the costs with data on the primary outcome (QOLIE-31-P) measure at 12 months.
Cost–utility was explored by combining total costs with QALYs, derived from EQ-5D-5L data. Assuming the
intervention produced better outcomes and lower costs, it would be ‘dominant’. However, if it resulted in
better outcomes but higher costs, then incremental cost-effectiveness ratios (ICERs) would be estimated to
show the extra cost incurred for a 1-unit improvement on the QOLIE-31-P or one extra QALY (both at
12 months). There is no need to calculate ICERs for any combination in which one group has lower costs
and better outcomes as it is then considered to ‘dominate’ the other group.
To evaluate the uncertainty around point estimates, cost-effectiveness planes (CEPs) and cost-effectiveness
acceptability curves (CEACs) were created. These curves are an alternative to CIs around ICERs. Non-parametric
bootstrapping was used to create a joint distribution of incremental costs and outcomes to explore the
probability of SMILE (UK) or TAU being cost-effective, subject to varying willingness-to-pay (WTP) values
attached to a unit improvement in the QOLIE-31-P or one extra QALY gained. One thousand cost–outcome
combinations were plotted on a CEP, where the y-axis depicts the additional costs of the intervention
compared with TAU, and the x-axis represents a difference in the primary outcome between the intervention
and control groups.
Results were interpreted using CEACs140 to show the probability of the intervention being the cost-effective
option for a range of different values placed on an improvement in outcome. The range of values for
QALYs was £0 to £80,000; this includes the threshold recommended by the UK’s NIHR and NICE when
judging the cost-effectiveness of a health technology. The range for improvements on the QOLIE-31-P
was chosen such that values at which the intervention or TAU has a 50% and 70% and 90% likelihood
of being cost-effective were identified.
A series of net benefits [calculated using the formula net monetary benefit = (ΔE) × λ – (ΔC)] were
calculated for each individual for a variety of values (£0–80,000 for WTP for an additional QALY). Additional
gain in outcome (ΔE) was multiplied by the ceiling ratio (λ) defined by the decision-maker’s WTP for an
additional unit of health outcome, and the difference in costs (ΔC) subtracted. After calculating net benefits
for each participant for each value of WTP, coefficients of differences in net benefits between the trial arms
were obtained through a series of bootstrapped linear regressions (1000 repetitions), which included the
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same covariates used for comparisons of outcomes in the primary economic analyses. The resulting
coefficients were then examined to calculate the proportion of times that the intervention group had a
greater net benefit than the control group for each value of WTP. These proportions were then plotted to
generate CEACs for all cost–outcome combinations.
Results
Response rates
Resource use and QoL data were available for all participants at baseline and at the 12-month follow-up.
At the end of the trial, 18% of participants did not complete the final assessment (Table 21).
Service use
Participants from both groups reported contact with a variety of health professionals, including use of health
and social care services and the use of AEDs (Table 22). The service use between the two trial arms was
similar. As patients were recruited through their neurologist, this explains the high proportion of participants
in both groups who reported contact with a neurology consultant. At baseline, resource utilisation was
similar between the two trial arms with GPs being the most frequently reported contact, at an average of
three visits in the previous 12 months. Contact with ENS and mental-health services (counsellors and
psychologists) was also reported by several participants, with a mean contact (number of visits) of 1 and 2,
respectively, for both groups. Contact with community health professionals remained relatively similar at
follow-up, with notable variation in the ‘other’ category. Although a small proportion of patients (in both
groups) reported contact with home workers, activity centres with private nursing and other community
services, the number and duration of contacts reported was quite high.
The use of hospital services was also similar between the two groups at baseline, except for the use of
outpatient care, which was reported as higher in the SMILE (UK) group (but the number of contacts is
reported as almost identical between the two groups). At the 12-month follow-up, the proportion of
patients reporting use of hospital services had reduced for both groups. The percentage of participants
who reported informal care was low at baseline, but those who did received substantial help from family
and friends, especially for the ‘on call’ category. The number of hours spent on call per week by friends
and family had increased by a large amount at follow-up for both groups. Productivity loss was reported
by almost one-quarter of participants in both groups. Although remaining low at 12 months, the mean
number of days taken off work reported by the SMILE (UK) group was approximately five times higher
than in the control group (16.3 days vs. 3.19 days).
TABLE 21 Response rates
Assessment
Treatment group, n (%)
TotalSMILE (UK) TAU
Received at least one session of SMILE (UK) 151 (73.6) 3 (1.5) 154
QOLIE-31-P baseline 205 (50.7) 199 (49.3) 404
QOLIE-31-P 12 months 163 (49.2) 168 (50.8) 331
EQ-5D-5L baseline 205 (50.7) 199 (49.3) 404
EQ-5D-5L 12 months 163 (49.2) 168 (50.8) 331
CSRI baseline 205 (50.7) 199 (49.3) 404
CSRI 12 months 163 (49.4) 167 (50.6) 330
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TABLE 22 Self-reported use of services specifically for epilepsy at baseline and 12-month follow-up
Resource
Resource
unit of
measure
Time point
Baseline 12-month follow-up
Participants,a
n (%)
Resource use
of total SMILE
(UK)b (N= 205),
mean (SD)
Participants,a
n (%)
Resource use
of total TAUb
(N= 199),
mean (SD)
Participants,a
n (%)
Resource use
of total SMILE
(UK)b (N= 163),
mean (SD)
Participants,a
n (%)
Resource use
of total TAUb
(N= 167),
mean (SD)
Community care
GP Contacts 96 (46.8) 2.26 (4.5) 116 (58.3) 2.67 (5.0) 80 (49.1) 2.11 (3.8) 84 (50.0) 2.40 (5.5)
Practice nurse Contacts 15 (7.8) 0.12 (0.4) 17 (8.5) 0.16 (0.6) 7 (4.3) 0.07 (0.4) 6 (3.6) 0.07 (0.5)
Epilepsy nurse Contacts 64 (31.2) 0.65 (1.2) 82 (41.2) 0.93 (1.6) 65 (42.3) 0.86 (1.6) 56 (33.3) 0.88 (2.0)
Physiotherapist Contacts 9 (4.4) 0.36 (2.4) 12 (6.0) 0.36 (2.5) 5 (3.1) 0.23 (1.6) 11 (6.6) 0.49 (4.1)
Social worker Contacts 7 (3.4) 0.33 (2.7) 6 (3.0) 0.62 (7.1) 6 (3.7) 0.11 (0.6) 8 (4.8) 0.35 (2.3)
Counsellor
Psychologist
Contacts 24 (11.7) 1.54 (6.6) 26 (13.1) 2.47 (10.9) 19 (11.7) 2.27 (11.0) 29 (17.3) 1.93 (6.8)
Home help:
household tasks
Contacts 5 (2.4) 2.00 (15.0) 5 (2.5) 5.76 (44.4) 12 (7.4) 14.93 (91.1) 6 (3.6) 13.89 (101.9)
Home help: personal
care
Contacts 1 (0.5) 3.79 (54.3) 6 (3.0) 9.17 (57.1) 6 (3.7) 9.48 (81.5) 2 (1.2) 7.53 (74.8)
Other community
services
Contacts 5 (2.4) 0.42 (4.3) 7 (3.5) 2.16 (26.1) 13 (8.0) 3.29 (29.4) 6 (3.6) 8.13 (52.3)
AEDs Number of
AEDs
201 (98) 2.08 (1.0) 196 (98) 2.16 (1.1) 162 (99.4) 2.22 (1.0) 167 (99.4) 2.17 (1.1)
Hospital inpatient care Nights 36 (17.6) 0.60 (1.9) 36 (18.1) 1.48 (4.8) 23 (14.1) 0.80 (3.4) 22 (13.1) 1.01 (4.5)
Hospital outpatient
care
Attendances 83 (40.5) 0.24 (0.8) 58 (29.1) 0.10 (0.3) 13 (8.0) 0.3 (1.5) 11 (6.6) 0.3 (2.0)
ED Attendances 81 (39.5) 0.99 (2.2) 88 (44.2) 1.55 (3.6) 56 (34.6) 0.79 (1.6) 44 (26.2) 0.56 (1.4)
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Resource
Resource
unit of
measure
Time point
Baseline 12-month follow-up
Participants,a
n (%)
Resource use
of total SMILE
(UK)b (N= 205),
mean (SD)
Participants,a
n (%)
Resource use
of total TAUb
(N= 199),
mean (SD)
Participants,a
n (%)
Resource use
of total SMILE
(UK)b (N= 163),
mean (SD)
Participants,a
n (%)
Resource use
of total TAUb
(N= 167),
mean (SD)
Clinical decision unit Attendances 10 (4.5) 0.12 (0.7) 13 (6.5) 0.22 (1.3) 9 (5.6) 0.74 (0.3) 15 (8.9) 0.11 (0.4)
Hospital neurology
appointment
Attendances 191 (94.0) 2.20 (1.7) 187 (94.0) 2.20 (1.5) 152 (93.3) 2.27 (3.8) 145 (86.3) 1.79 (1.5)
Laboratory tests/
investigations
Attendances 72 (35.1) 0.53 (0.9) 47 (23.6) 0.40 (1.0) 36 (22.1) 0.37 (0.8) 45 (26.8) 0.37 (0.7)
Informal care
Personal care Hours/week 27 (13.2) 1.94 (12.6) 16 (8.0) 0.59 (2.9) 19 (11.7) 0.71 (2.5) 12 (7.4) 8.42 (7.5)
Help with medical
procedures
Hours/week 31 (15.1) 2.16 (12.9) 23(11.6) 0.46 (1.7) 25 (15.3) 0.39 (1.5) 27 (16.1) 0.51 (1.7)
Help in home Hours/week 61 (29.8) 4.59 (15.0) 46 (23.1) 2.38 (6.47) 49 (30.1) 3.56 (14.0) 39 (23.2) 3.20 (13.8)
Help outside home Hours/week 57 (27.8) 3.33 (13.4) 46 (23.1) 1.67 (5.0) 47 (28.8) 2.29 (13.4) 34 (20.2) 2.05 (13.3)
Time spent ‘on call’ Hours/week 21 (106) 5.73 (24.9) 33 (16.1) 6.24 (29.3) 37 (22.7) 28.80 (61.8) 33 (19.6) 29.52 (63.2)
Productivity loss
Days off work
because of illness
Days 49 (23.9) 9.61 (47.9) 48 (24.1) 9.21 (42.8) 37 (24.0) 16.3 (54.2) 29 (18.2) 3.19 (24.2)
Incapacity benefits 94 (46.9) 89 (44.7) 68 (38.7) 6 (38.1)
a Number of participants that reported using the resource in the treatment group.
b The mean of reported resource use (e.g. number of contacts with a GP) was calculated for the whole treatment group and not only for participants reporting resource use.
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Costs
Intervention costs
Intervention costs were estimated through microcosting using information on staff time involved in
delivering the intervention as well as other non-staff costs. Intervention costs are made up of teaching
manuals, training of facilitators and the actual SMILE (UK) intervention. The total cost of 20 teaching
manuals, each costing £15.70, was included in the costing. Training of facilitators was conducted by
two MOSES experts (one neurologist and one psychologist, both with expertise in epilepsy) for 2 days
(8 hours/day). For the intervention, the SMILE (UK) course was divided into four sessions (day 1 morning
and afternoon, day 2 morning and afternoon). Each session was delivered by two facilitators for a group
of eight patients for 3 hours.
The cost of training was estimated by applying the unit cost of two clinical psychologists at £140.00 each
per hour, to the duration (16 hours) of training. The total was added to the costs of teaching manuals and
divided by the number of participants who received the SMILE (UK) intervention.
The cost per SMILE (UK) session was estimated by combining the unit cost of two nurse specialists
(£44 per hour) with the duration of each session divided by the number of participants per group, and
added to the cost of training, producing £56.05 as the cost per session of SMILE (UK). A complete course
of SMILE (UK) with four sessions was estimated to be £224.00. Based on the number of sessions attended
by the intervention group, mean cost associated with SMILE (UK) was £175.00. Three patients in the
control group erroneously attended the course and mean costs were estimated to £3.00.
Service use costs
Table 23 reports costs associated with service use specifically for epilepsy. Health and social care costs
(NHS perspective) were higher at baseline for the TAU group (£3275 vs. £2227). For both groups, AEDs
contributed greatly to NHS health services costs. However, inpatient care contributed the highest proportion
of costs for the control group. Other high cost drivers included neurology appointments, mental health
services and ED attendance. At follow-up, the SMILE (UK) group still had lower costs than TAU, but the
difference was not statistically significant (–£1156, bootstrapped at 95% CI –£1755 to £1507). At this time
point, costs were still dominated by AEDs and inpatient care. Paid help at home and other community
services also produced large costs, particularly in the control group.
However, total costs were different from the societal perspective for complete cases, which includes costs
associated with productivity loss as a result of epilepsy and informal care. The intervention group had
higher costs both at baseline (£18,151 vs. £13,448) and at follow-up (£30,732 vs. £30,675). However, the
difference at 12 months was not statistically significant (–£1286, bootstrapped at 95% CI –£12,197 to
£11,560). Results based on the ITT analysis were different from the complete case. The SMILE (UK) group
had lower NHS costs at 12-month follow-up (£30,688 vs. £31,018 for the TAU group), but the difference
was not statistically significant (–£1864, bootstrapped at 95% CI–£11,949 to £7458).
Quality of life
The SMILE (UK) group had lower QoL (measured using the EQ-5D-5L utility scores) than TAU at baseline
(0.7997 vs. 0.8415) (Table 24). At follow-up, both groups reported reduced QoL, with SMILE (UK)
consistently having lower scores (0.7772 vs. 0.8302 in the TAU group), which subsequently translated to
lower QALYs for the intervention group in the complete case analysis. However, the difference was not
statistically significant (–0.0146, bootstrapped at 95% CI –0.0362 to 0.0071). Analysis using imputed data
showed similar results, producing statistically insignificant differences in QALYs (–0.0142, bootstrapped at
95% CI –0.0318 to 0.0034).
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Cost-effectiveness and cost–utility analysis results
The results from the cost-effectiveness analysis are presented in Table 25. Findings from the complete case
analysis show that SMILE (UK) is cost-saving, but produces fewer QALYs than TAU. The associated ICER
from a NHS and social care perspective is £5548 and this is how much extra it costs for TAU to produce
one extra QALY. This is below the NICE threshold of £20,000. The corresponding ICER from the societal
perspective is £88,082 per QALY. Imputed results produced a better ICER from the NHS perspective at
£1901 per QALY, but a higher one at £131,268 per QALY from the societal perspective.
TABLE 23 Costs at baseline and 12-month follow-up
Cost component
Time point, mean cost (£) (SD)
Baseline (n= 404) 12-month follow-up (n= 330)
SMILE (UK)
(n= 205) TAU (n= 199)
SMILE (UK)
(n= 163) TAU (n= 167)
Intervention 154 (98) 3 (27)
Health-care services
GP 88 (194) 102 (263) 79 (133) 87 (217)
Practice nurse 1 (5) 1 (5) 1 (4) 1(4)
Epilepsy nurse 16 (33) 23 (43) 38 (165) 18 (43)
Physiotherapist 14 (115) 15 (124) 10 (70) 22 (211)
Social worker 11 (85) 12 (98) 5 (27) 51 (390)
Mental health services
(counsellor/psychologist)
195 (898) 347 (1784) 376 (2415) 268 (886)
Home help: household tasks 93 (724) 194 (1593) 360 (1738) 925 (6952)
Home help: personal care 64 (596) 194 (1593) 140 (1065) 311 (3407)
Other community health services 70 (757) 90 (872) 323 (2703) 1075 (10,665)
AEDs 701 (1233) 719 (1039) 881 (1500) 756 (913)
Hospital inpatient care (including CDU) 381 (1188) 932 (3012) 499 (2092) 631 (2731)
Hospital outpatient care 20 (84) 7 (35) 28 (173) 31 (225)
ED 140 (313) 218 (510) 111 (226) 79 (203)
Neurology appointment 387 (296) 386 (273) 400 (666) 316 (260)
Laboratory tests/investigations 46 (109) 35 (108) 33 (78) 28 (58)
Health and social care costs 2227 (2768) 3275 (6536) 3453 (5970) 4608 (14,664)
Informal care (hours per week)
Personal care 1392 (9039) 364 (2048) 515 (1813) 434 (2084)
Help with medical procedures 1546 (9236) 328 (1207) 280 (1102) 348 (1186)
Help in-house 3292 (10,756) 1708 (4640) 2477 (9973) 2246 (9839)
Out-of-home help 2386 (9615) 1196 (3561) 1549 (9618) 1391 (9543)
Time spent ‘on call’ 4110 (17,839) 4475 (21,036) 20,655 (44,296) 21,293 (45,405)
Total informal care costs 12,726 (40,979) 8072 (24,243) 25,476 (53,952) 25,711 (55,759)
Productivity loss 1060 (5282) 1016 (4717) 1804 (5985) 354 (2679)
Total societal costs 18,151 (50,012) 13,448 (30,224) 30,732 (55,824) 30,675 (58,194)
CDU, Clinical Decision Unit.
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TABLE 25 Cost-effectiveness analysis
Scenario
Treatment group, mean (SD)
Observed
Difference
Adjusted
differences
(95% Cl)
ICER (using
adjusted figures)SMILE (UK) TAU
Complete case (n = 163) (n = 167)
QALYs 0.7903 (0.2163) 0.8385 (0.1757) –0.0482 –0.0146
(–0.0362 to 0.0071)
QOLIE-31-P 67.4 (13) 69.5 (15) –2.1 –0.62
(–2.86 to 1.79)
Health and social care
costs (£)
3453 (5970) 4609 (14,664) –1156 –81
(–1755 to 1507)
5548/QALY
135/QOLIE-31-P
Societal costs (£) 30,732 (55,824) 30,675 (58,194) 57 –1286
(–12,197 to 11,560)
88,082/QALY
2143/QOLIE-31-P
ITT (n = 205) (n = 199)
QALYs 0.7872 (0.2087) 0.8337 (0.1762) –0.0465 –0.0142
(–0.0318 to 0.0034)
QOLIE-31-P 67.3 (12.7) 69.0 (14.3) 1.7 –0.62
(–2.54 to 1.40)
Health and social care
costs (£)
3477 (5495) 4622 (13,537) –1145 –27
(–1545 to 1490)
1901/QALY
1847/QOLIE-31-P
Societal costs (£) 30,688 (50,239) 31,018 (53,759) –330 –1864
(–11,948 to 7458)
131,268/QALY
3006/QOLIE-31-P
TABLE 24 Quality of life comparison between treatment arms
Scale
Treatment group
Difference between groupsSMILE (UK) TAU
n (%)
Mean (SD)
[range] n (%)
Mean (SD)
[range]
Adjusted
coefficient 95% CI
Baseline EQ-5D-5L
score (N= 404)
205 (50.7) 0.7997 (0.2426)
[–0.157–1]
199 (49.3) 0.8415 (0.1967)
[–0.041–1]
–0.0418 –0.0016 to
0.0844
Baseline EQ-VAS
(N = 404)
205 (50.7) 65.2 (22.6)
[0–100]
199 (49.3) 70.0 (20.1)
[0–100]
–3.7687 –7.7942 to
0.5424
12-month EQ-5D-5L
score (N= 331)
163 (49.2) 0.7772 (0.2552)
[–0.181–1]
168 (50.8) 0.8302 (0.2084)
[–0.065–1]
–0.0291 –0.0143 to
0.0725
12-month EQ-VAS
(N = 331)
163 (49.2) 64.9 (20.3)
[0–100]
168 (50.8) 68.9 (21.6)
[5–100]
–1.7472 –5.6581 to
5.658
QALYs complete case
(N = 331)
163 (49.2) 0.7903 (0.2163)
[0.01–1]
168 (50.8) 0.8385 (0.1757)
[0.0015–1]
–0.0146 –0.0072 to
0.0369
QALYs ITT (N= 404) 205 (50.7) 0.7872 (0.2087)
[0.01–1]
199 (49.3) 0.8337 (0.1762)
[0.0015–1]
–0.0142 –0.0322 to
0.0037
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Findings based on the QOLIE-31-P are presented based on the ITT analysis, and the ICER from the NHS
perspective is £1847 for a 1-unit improvement on the QOLIE-31-P. Society, on the other hand, would have
to pay £3006 for one additional improvement on the QOLIE-31-P.
Cost-effectiveness planes (Figures 5 and 6) from the NHS and societal perspectives of complete cases show
the proportion of scatter points of simulated 1000 bootstrapped mean estimates of incremental cost and
outcome pairs (adjusted for baseline costs and EQ-5D-5L scores). Both figures show more scatter points
(51%) in the south-west quadrant, which indicates lower costs and fewer QALYs for SMILE (UK) than TAU.
Scatterplots produced from imputed data also produced similar results (Figures 7 and 8); thereby providing
further evidence that SMILE (UK) had lower costs and inferior QoL than TAU. The spread of scatter points
in the vertical plane indicates the existence of some uncertainty regarding the cost savings associated with
the intervention compared with TAU.
The probability of SMILE (UK) being cost-effective (compared with TAU) at the £20,000 WTP threshold
from the NHS perspective (Figures 9 and 10) is slightly above 40% (for both the complete-case and the ITT
analyses). However, this probability is somewhat higher (60%) from the societal perspective (complete
case, Figure 11; and ITT, Figure 12) at the same threshold.
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FIGURE 5 Cost-effectiveness plane of complete cases (NHS perspective) using QALYs. Scatterplot of bootstrapped
resampling of joint incremental costs and QALYs of SMILE (UK) vs. TAU, adjusted for baseline costs and
EQ-5D-5L scores.
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FIGURE 6 Cost-effectiveness plane of complete cases (societal perspective) using QALYs. Scatterplot of
bootstrapped resampling of joint incremental costs and QALYs of SMILE (UK) vs. TAU, adjusted for baseline costs
and EQ-5D-5L scores.
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joint incremental costs and QALYs of SMILE (UK) vs. TAU, adjusted for baseline costs and EQ-5D-5L.
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FIGURE 8 Cost-effectiveness plane of ITT (societal perspective) using QALYs. Scatterplot of bootstrapped resampling
of joint incremental costs and QALYs of SMILE (UK) vs. TAU, adjusted for baseline costs and EQ-5D-5L.
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FIGURE 9 Cost-effectiveness acceptability curve of complete cases (NHS perspective) using QALYs. CEAC showing
the probability of SMILE (UK) being cost-effective compared with TAU for WTP ranges in QALYs.
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FIGURE 10 Cost-effectiveness acceptability curve of ITT (NHS perspective) using QALYs. CEAC showing the
probability of SMILE (UK) being cost-effective compared with TAU for a range of WTP.
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FIGURE 11 Cost-effectiveness acceptability curve of complete cases (societal perspective) using QALYs. CEAC
showing the probability of SMILE (UK) being cost-effective compared with TAU.
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FIGURE 12 Cost-effectiveness acceptability curve of ITT (societal perspective) using QALYs. CEAC showing the
probability of SMILE (UK) being cost-effective compared with TAU for WTP ranges in QALYs.
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Quality Of Life In Epilepsy 31-P
Cost-effectiveness results based on the QOLIE-31-P are similar to those emanating from QALYs. Results
from the complete-case analysis show the majority (36%) of scatter points in the north-west quadrant,
indicating that the SMILE (UK) group costs more and has lower QoL than the TAU group (Figure 13). For
the ITT analysis, findings are slightly different from the complete-case analysis, with most scatter points
located in the south-west quadrant (i.e. lower costs and lower QoL) (Figure 14).
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FIGURE 13 Cost-effectiveness plane of complete cases (societal perspective) using QOLIE-31-P. Scatterplot of
bootstrapped resampling of joint incremental costs and QOLIE-31-P score comparing SMILE (UK) with TAU,
adjusted for baseline costs and QOLIE-31-P.
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FIGURE 14 Cost-effectiveness plane of ITT (NHS perspective) using QOLIE-31-P. Scatterplot of bootstrapped
resampling of joint incremental costs and QOLIE-31-P score comparing SMILE (UK) with TAU, adjusted for baseline
costs and QOLIE-31-P.
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Discussion
Offering SMILE (UK) to PWE is cost-saving but does not result in more QALYs than TAU. If we compare the
intervention with TAU then we see that the ICER falls into the south-west quadrant of the cost-effectiveness
plane. The positive ICERs here need careful interpretation. They indicate fewer QALYs but cost savings.
The question here is whether or not the cost savings are sufficient to justify the QALY loss. From an NHS/
social care perspective, the ICER is below the NICE threshold of £20,000. As such, we can conclude that the
intervention SMILE (UK) does not save sufficient costs to justify the QALY loss and TAU is the preferred
option. This is further indicated by the CEAC, which shows the probability that the intervention is
cost-effective at £20,000 is below 50%. From a societal perspective, the intervention saves in excess
of £80,000 per QALY lost.
From the NHS perspective, the main cost contributors were AEDs, inpatient care and outpatient
neurological care. Costs associated with contacts with psychologists and counsellors were also high,
indicating the burden of mental health in epilepsy. There was a notable reduction in the cost of hospital
emergency visits at 12-month follow-up. A large proportion of epilepsy costs are associated with caregiving
by family and friends and these are persistently high.
The QoL based on the EQ-5D-5L was generally high in both groups. The high mean utility scores do not
seem to be uncommon in epilepsy,141 which leads us to question whether or not QoL is the appropriate
outcome. Few PWE in our study reported being on the lowest levels of the five dimensions of the EQ-5D-5L,
which may be consistent with the population group. Some dimensions of the EQ-5D-5L (e.g. pain) may not
be relevant to PWE, whose symptoms are not necessarily chronic but recurring. This brings into question the
ability of the measure to detect changes and to evaluate the impact of recurring seizures. This was also
confirmed in a larger trial,142 which had large proportions reporting ‘no problems’ in the five dimensions.
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Chapter 9 Process evaluation of the SMILE (UK)
intervention
Introduction
Two qualitative studies were completed during the course of this research. The first study was an external
evaluation of the pilot SMILE (UK) course to test the adaptation of the course with content modified for the
UK population.82 The results regarding the course content and its organisation are presented in Chapter 2.
Findings regarding patients’ experiences and responses to the intervention are considered in this chapter
together with the main qualitative process evaluation of the SMILE (UK) intervention.83 Both qualitative
studies have already been published82,83 and this chapter provides a summary of themes emerging from
these studies.
Qualitative study: process evaluation
The process evaluation took place 2 years after the initial pilot and within 6 months of receiving the SMILE
(UK) intervention. The aims of the process evaluation were to complement the quantitative evaluation of
SMILE (UK) by providing more detailed descriptions of participants’ views and experiences.
Methods
Recruitment
Of the 404 participants recruited into the SMILE (UK) trial, 24 were initially approached to take part in
the process evaluation. They were largely recruited from the TAU arm, but also included some from the
intervention arm (before the protocol was amended; see Chapter 3). The list of participants was selected
based on the register of attendance from the January, May and June 2015 courses. People were chosen to
ensure that a variety in age, gender, ethnicity and severity of epilepsy was represented. Two participants
were unable to remember taking part in the SMILE (UK) course and two participants were not available to
complete the research interview. Overall, 20 participants agreed to take part in the qualitative interviews.
Interview procedure
Semistructured interviews were held with topics selected after completing the external pilot study, and
in collaboration with research staff that held these interviews. Although the pilot study topics focused
on experiences of participating in the course, the main study topics were more tailored to the patient’s
experience of epilepsy, as well as their views on the SMILE (UK) course. An abbreviated topic guide can be
found in Box 2 (see Appendix 7 for full guide). Topics included (1) participants’ experience of living with
epilepsy, (2) negative and positive aspects of the course, (3) social contact after the course and (4) if or how
they used what they had learned in the course. Interviewers probed and clarified responses as required. All
participants were interviewed face to face. The interviews were undertaken by two researchers and interview
times were variable, ranging from 25 to 40 minutes each.
Analysis
All interviews were recorded and then transcribed verbatim by an external third party. Transcripts were
checked for accuracy by the researchers who conducted the interviews, and sample scripts were then
checked by two collaborators (MM, LR). Researchers then undertook a line-by-line coding approach with
initial codes noted in the margins of the transcripts and then grouped into broader themes. This process
involved regular discussion between the researchers and study supervisors (MM, LR).
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External pilot evaluation
The external pilot evaluation identified reasons for participating in the trial, views of the SMILE (UK) course
and suggestions for changes (reported in Chapter 2). In addition, it provided data on their views of the
intervention which complement the formal process evaluation. These findings from the two studies are
briefly summarised in this chapter.
Methods
The methods of the external pilot are described in Chapter 2 and differed from the process evaluation in
three main ways.
l Data were based on 10 participants.
l Participants were volunteers recruited through Epilepsy Action.
l Data gathered by semistructured interviews (seven participants) and a focus group (three participants).
Despite these differences, the findings regarding patients’ experiences and responses to the SMILE (UK)
intervention identified similar themes that provide support for their validity and conceptual generalisation.
BOX 2 Brief topic guide for interviews during the process evaluation. Full topic guide can be found in Appendix 7
Patient’s epilepsy
Can you tell me a bit about your epilepsy? How did you feel when you were first diagnosed? How do you feel
about it now?
Help-seeking behaviour
In the past, have you tried to find out more about your epilepsy? How?
SMILE (UK) course
When you first heard about SMILE (UK), how did you feel about coming on the course? How did you feel
about being part of a group? How did you feel about hearing other people’s stories? Did you find out any
things that were helpful?
Life after the course
Do you think the SMILE (UK) course has helped you in managing your epilepsy? Although the workbook is not
an essential part of the course, have you found it useful?
Social network
Have you stayed in touch with anyone from the course?
Course improvements
Would you recommend other PWE to go on the SMILE (UK) course? Is there anything about the course that
you would like to change?
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Characteristics of participants
Both studies were successful in including a range of participants (i.e. age, gender, education and years since
diagnosis) (Table 26). Between the pilot study and process evaluation, the main difference in participants
was the higher level of education in the external pilot study with 5 out of 10 having a degree, compared
with 4 out of 20 in the process evaluation. This is likely to reflect the differing sources of recruitment with
the external pilot study being recruited through Epilepsy Action, while the main evaluation was based on
participants recruited from usual NHS clinic settings. Similarities between the two groups were the
proportion of participants with epilepsy for over 10 years (7/10 of external pilot and 15/20 of process
evaluation) and the number employed (3/10 external pilot and 6/20 main evaluation).
Findings
Main themes
Four themes were strongly represented in both studies (Figure 15), namely the importance of the
intervention for reducing isolation, the opportunity to learn from each other, finding reassurance in the
experiences of others and changing behaviours and practices after learning from others.
Reducing isolation
Peer support and a sense of feeling ‘less alone’ were common themes and outcomes of the intervention.
Many participants had not discussed their epilepsy with anyone before other than family or health-care
staff, and described how they appreciated being able to meet others with the same condition:
Nobody without epilepsy can really understand what it’s like to have a seizure . . . To see how they
[other course members] deal with it makes it more easy to live with your illness because you think
‘I am not alone’.
M, 39, process evaluation
At the conclusion of the course, many attendees had shared contact information and reported that they
would keep in touch with group members in the future.
Therefore, the group setting of the SMILE (UK) course provided a positive sense of being connected
through the shared experience of having epilepsy:
Normally, I’d be a bit self-conscious about these groups but once I got used to it, knowing that
everyone’s like, the same, as me and there’s like a big understanding amongst the group and become
friends and stuff, it was actually pretty good.
M, 21, pilot study
A chance to talk and learn from each other
Epilepsy-related knowledge was imparted not only by facilitators (as with traditional teaching), but also by
other group members. Participants were asked to share their experiences of coping and, by doing so,
taught others about how they had overcome epilepsy-related challenges. This observation was noted by
participants in both studies:
I was very keen to meet other people with epilepsy and learn new information . . . it was really
interesting to see a variety of perspectives based on personal experiences . . .
F, 21, pilot study
Group members who had been living with epilepsy for a long time were able to speak with others still
coming to terms with their own diagnosis. In this way, the person sharing was seen as the ‘expert’ of their
own experience, with knowledge to be shared on how they had coped with past challenges.
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TABLE 26 Characteristics of participants in both qualitative evaluations
Participant number
Characteristic
Age Gender Years since diagnosis Education level Employed
External pilot
1 33 F 13 PG No
2 21 M 21 SS No
3 48 M 47 SS No
4 60 F 44 UG No
5 53 M 52 SS Yes
6 40 F 34 UG No
7 32 F 9 SS Yes
8 32 M 8 UG No
9 21 F 15 SS No
10 29 F 8 UG Yes
Process evaluation
1 32 F 10 SS No
2 81 F 24 SS No
3 46 M 19 SS No
4 50 M 20 None No
5 41 M 29 UG No
6 38 M 4 UG Yes
7 36 F 35 Other No
8 59 M 3 None No
9 52 F 49 None No
10 65 F 46 UG No
11 55 M 2 None No
12 54 F 33 SS No
13 27 F 16 SS Yes
14 51 F 40 SS No
15 39 M 13 UG Yes
16 22 F 6 SS No
17 38 M 10 Other Yes
18 54 F 43 UG No
19 38 M 6 SS Yes
20 58 M 36 UG Yes
F, female; M, male; other, post-secondary level qualification; PG, postgraduate; SS, secondary school; UG, undergraduate.
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As highlighted by the following quote, the experience of being able to share their feelings with others had
the benefit of being cathartic for some:
I felt that I wanted to discuss my story . . . When I said it out loud it was a way of admitting to myself
just how bad I have been over the years.
F, 54, process evaluation
Finding reassurance in the experiences of others
The benefit of social interaction during the course was multifaceted. By speaking with people who were at
different stages of coping with epilepsy, those who were managing well seemed to realise how far they
had come in their own process.
Many were quick to point out they were not glad that others had suffered, but grateful that their
circumstances were not as bad as they could be. Therefore, the process of social comparison and
interaction contributed to a change in attitude about their own epilepsy. One participant also spoke of
how his perspective had shifted since participating in the interactive group sessions:
I felt like I was the only one dealing with it really and it was getting me down . . . and I met the other
people who have got it, I kind of changed my mind . . . I look at it in a different way.
M, 47, process evaluation
Changes noticed after the course
Participants described a number of changes after attending the SMILE (UK) course. In the process
evaluation, 12 out of 20 participants spoke of changing their self-management practices after the course.
Behaviour changes after the course included reducing alcohol intake, record keeping of seizures and
improved medication adherence:
The programme has helped me to understand more about epilepsy and medication. I take my
treatment more seriously now.
M, 39, process evaluation
Reducing isolation:
seeing how others live
with the same
condition
Learning from the
experiences of others:
gaining perspective on
the situation
Applying practices
used by others in
their own
self-management
Peer learning:
a chance to talk
and learn from
each other
FIGURE 15 Common themes reported by participants in the external pilot and process evaluation.
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Some spoke of sharing their newfound knowledge with others. Half of the participants in the process
evaluation felt they were now talking more with others about their condition.
Fourteen participants across both studies (4/10 in the pilot study and approximately 10/20 in the process
evaluation) described improved self-confidence after the course. This empowered many to have an open
dialogue with their neurologist, GP or ENS either to suggest or to resist changes in medication. As one
participant explained:
Last time I saw my neurologist he wanted to increase the medication. After having the course, I had
the confidence to say that it isn’t worthwhile increasing the medication. I know that I’d only had these
seizures because I hadn’t taken the medication.
F, 22, process evaluation
Similarly, participants described feeling more informed when discussing treatment options with their
clinician, empowering them to take an active role in their health care:
It’s empowering you when you got to see the doctor to be more two-way about the discussion.
F, 60, pilot study
The participant handbook was also described as a new and useful tool in improving knowledge about
epilepsy. Nine out of 20 participants from the process evaluation read the workbook during or after the
course. Four participants had lent it to family members or friends. The workbook was used to access what
they had learned during the course and to teach others about epilepsy. As one participant remarked:
I can’t stop carrying it around. Before I used to carry around my iPad all the time and bring that out all
the time. But this is what I have to read all the time.
F, 32, pilot study
Limitations of SMILE (UK)
A group course offers participants the opportunity to share their own experiences and to learn from
others. In cases when language or learning abilities vary, some participants may not understand the
exercises or what is being discussed. PWE who had severe learning disabilities or were not able to
understand English were excluded from the RCT. However, we recruited PWE from a diverse metropolitan
population with varying levels of English mastery and learning skills. For three participants in the process
evaluation, this was an issue. Four participants reported memory issues, which are frequent in PWE. This
later had an impact on what they retained from the course and whether or not they could remember to
do things in ‘real life’. And as mentioned above, two did not remember the course at all and thus were
not interviewed. Together, nine PWE had language, learning or memory problems that affected what they
retained from SMILE (UK).
Summary
Similar themes arose from the pilot study and process evaluation. Participants found the course informative
and particularly appreciated the opportunity to meet other PWE. Sharing their own experience with others
led to some participants feeling more empowered. With the reflective exercises in SMILE (UK) (see Figure 1)
using stickers on a scale, participants could compare themselves with others and, for some, this meant
thinking about epilepsy in a more positive way.
Participants reported behaviour changes as well. Thirteen participants felt increased self-confidence, and
this included half of those interviewed in the process evaluation. Over half of those interviewed as part of
the process evaluation applied self-management practices learned during the course, such as keeping a
seizure diary or reducing alcohol intake.
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Memory, language and learning difficulties play a significant role in how group courses can impact PWE.
A large proportion of the group interviewed as part of the process evaluation felt the impact of such issues
and, thus, a 2-day course may have a limited impact at 1-year follow-ups.
To our knowledge, there is only one other study that evaluated patients’ views of a group intervention for
PWE.115 However, it was not a qualitative study but was carried out via open-response sections on a
written questionnaire. PWE in both studies appreciated meeting others like them, some for the first time.
This reinforces the benefit of group self-education courses for PWE.
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Chapter 10 Discussion
Summary of principal findings
External pilot
An external pilot, undertaken immediately after two pre-trial SMILE (UK) courses, demonstrated the
feasibility and acceptability of providing group courses among volunteers with epilepsy in the UK.82 Having
two facilitators and locating the courses near a hospital centre can be an advantage when PWE report
frequent seizures.
Main outcomes
We described the characteristics of 404 participants at baseline and the relationship between clinical,
psychological and social factors and an epilepsy-specific QoL measure (QOLIE-31-P).84 Participants’ mean
age was 42 years, 54% were female and 75% were white. Median time since diagnosis was long at
18 years and a large proportion (69%) had experienced ≥ 10 seizures in the prior year. Nearly half (46%)
reported additional medical or psychiatric conditions, 64% reported current anxiety and 28% current
depression symptoms at borderline or case level, with 63% reporting felt stigma.
Baseline QoL was measured by the mean QOLIE-31-P (range 0–100). The mean score was 66, with a wide
range (25–99). Psychosocial impairment at baseline appeared to be most closely linked to impaired QoL.
In order of descending magnitude of association: current depression, anxiety, a history of medical and
psychiatric comorbidity, felt stigma, greater seizure frequency, low self-mastery and low self-reported
medication adherence were associated with lower QoL scores.
There were no significant differences in the primary outcome measure (QOLIE-31-P at 12 months) between
the treatment groups [intervention mean 67.4 (SD 13.5) vs. control mean 69.5 (SD 14.8). Nor was there a
significant difference at 12 months in any of the secondary outcome measures, including seizure control,
impact of epilepsy, medication adherence, medication adverse effects, psychological distress, epilepsy
stigma and self-mastery.114
A process evaluation undertaken within 6 months of the intervention found that participants valued the
opportunity to meet ‘people like them’. The structured learning methods encouraged them to share and
compare feelings and experiences. Specific benefits included overcoming the sense of ‘being alone’ and
improving self-acceptance through meeting people with similar experience. Over half reported that this
and the group-learning exercises, eliciting comparison of attitudes and experience, helped them to
improve their confidence to talk openly, as well as to make changes in their health behaviours.
However, almost half of those participants approached for interviews reported they experienced language
or memory problems, which limited their ability to understand and/or learn on a group course, and
sometimes their ability to manage their activities or behaviour changes in practice. Memory problems are
well described by many PWE, particularly those with recurrent seizures.143 Mood disturbance (like anxiety
and depression) is also associated with self-reported memory impairment in epilepsy. This makes it possible,
even likely, that without psychological interventions and reinforcement of a 2-day course for people with
persistent seizures, it will be difficult to demonstrate sustained improvements after a 1-year period. Even
those with average memory may struggle to recall the content of a 2-day course 1 year later. For this
reason, Taylor et al.59 emphasised the importance of integrating and reinforcing self-management
education during routine care.
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Recruitment
Recruiting volunteers via advertisements or through user groups requires an active response from patients.
Those responding are often already more engaged in their health care and can result in a group less
representative of the patient group as a whole.144 Our study recruited from routine NHS epilepsy clinics.
We used an opt-out process in creating patient lists from clinic lists, reducing to an extent how engaged
patients needed to be in order to remain in the recruitment process. In a patient population who frequently
report memory problems, such as those with epilepsy, people may forget to respond to invitations. It is also
known that men are less likely to participate in research, including self-management trials.145 Nevertheless
our recruitment process resulted in a group fairly balanced between males and females.
Owing to the UK data protection regulations, which do not allow researchers to screen notes without
consent, a large number of letters were sent out to patients attending neurology clinics prior to screening
for eligibility for the study. This makes it difficult to assess the rate of enrolment as the first stage of
recruitment included people without a confirmed diagnosis of epilepsy, people who had moved away and
some with no recent seizures. Thus, we report the rate of enrolment from the final patient list, which
contained patients who had not opted out of the recruitment process and who were deemed to meet the
eligibility criteria. This list contained 1986 people, of whom 1458 could be contacted and 1088 were found
to be eligible. Therefore, our recruitment rate was 37%. PWE may be reluctant to commit to a 2-day course
because of the unpredictable nature of epilepsy, especially if additionally experiencing anxiety, depression
and/or perceived stigma. Despite this, our recruitment rate was equal to or higher than that we have
achieved in a prior individual self-management intervention for PWE recruited from EDs (27%).12
Retention
At 82%, our retention rate in the study was high. There was no difference in follow-up rates between the
two intervention arms, although those in the intervention arm who attended the course were more likely
to complete the study (see Table 11). From the total group, 73 participants did not complete the study.
Most (53 out of 73) could not be reached for the 12-month follow-up and, therefore, were withdrawn
from the study. This can be an issue in large cities and in some of our catchment areas, where there is a
17% resident turnover per year.146 Factors associated with loss to follow-up were being female, fewer
years in education and more comorbidity.
Generalisability
We have already commented on recruitment and retention, which affect generalisability.
Our complex intervention trial made considerable demands on adults with poorly controlled epilepsy in
terms of completing long questionnaires, attending a 2-day course and, for some, in-depth interviews.
Recruitment might have been greater if the trial had been undertaken with participants who included
volunteers, who were predominantly white and who were of higher socioeconomic and educational status,
if the workload required of them had been less and, in our past experience, if they were recruited by GPs
in primary care.115,145,147
The pattern of predictors of high/low recruitment to complex interventions is consistent across research
and also predicts uptake of educational interventions in routine NHS practice. For example, the offer by the
NHS of a course on diabetes mellitus in south London met with a 30% uptake.146 The diabetes mellitus
group found that characteristics that reduced uptake of the offer of a course included lower socioeconomic
status and black and ethnic minority status.146
We offered an epilepsy course untested in the UK, which also required the completion of a questionnaire
three times over 1 year and achieved a similar response rate as the offer of a fully evaluated and
commissioned course for people with diabetes mellitus in practice.146 Our recruitment rate was similar and
the response rate at 1 year compared well with a more recent study of a UK cohort of PWE in primary
care.145 That research group found that, among all LTCs they studied, PWE had the lowest response rate.
We therefore believe that our findings are as representative as it is possible to be of people with long-term
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poorly controlled epilepsy living in cities. We believe that they are generalisable to people internationally
who are in receipt of specialist care in the context of a universal health-care system.
Meaning of the study
Quantitative findings
Baseline
Among this group of people recruited from epilepsy clinics, a large proportion (69%) had experienced
≥ 10 seizures in the prior year. Moran et al.11 found that, among a UK sample of PWE recruited through
general practice, 52% had no seizures in the prior year. Among those with two or more seizures in the
prior 12 months, 57% had ≥ 10 seizures in the prior year.11 Comparing this with our sample, who were
recruited from epilepsy clinics, shows that more participants in our group (69%) had frequent seizures.
This may partially reflect a tendency for GPs to refer to specialists those PWE whose seizures are more
difficult to control.11
Little is known about population-level QoL among PWE in the UK.116,145 In this context, and prior to
carrying out an evaluation of the effect of a self-management course on QOLIE-31-P, we aimed to answer
the questions (1) What are the clinical and psychosocial characteristics of UK adults with frequent/poorly
controlled seizures? and (2) To what extent are clinical and psychosocial characteristics, which underlie
constructs of QoL, associated with QOLIE-31-P?
For the purpose of comparisons to other studies, we were able to derive the more commonly reported
QOLIE-31, without patient-weighting (‘P’). The mean total QOLIE-31 score of our group was similar to
studies reported of PWE from other countries for people with all types of epilepsy. Our group’s mean total
QOLIE-31 was 62.0 (SD 15.6), which is similar to the global mean score of 59.8 (SD 8.0).116 Considering
that PWE in our SMILE (UK) study had persistent and frequent seizures, which are generally associated with
lower QoL, their QoL was better than might be expected internationally.116,148
Comparing our results with other national studies, a recent cohort study by Peters et al.145 of PWE in UK
primary care found higher QOLIE-31 total scores than our group (baseline QOLIE-31 mean 69.9, 1-year
QOLIE-31 mean 70.13). Their study included all PWE regardless of seizure frequency. Their group would be
expected to have higher QoL because half to two-thirds of PWE in the population registered in primary
care report no seizures in the prior year (Mark Ashworth, KCL, 2017, personal communication). The
findings of Peters et al.145 suggest that in the UK the mean QoL in all PWE is about 8 points higher than it
is among PWE identified in specialist clinics with frequent seizures.
Evidence from our UK group is consistent with evidence internationally that PWE and particularly those
with persistent, frequent seizures have significant psychosocial disadvantage and impaired QoL.26,116,148–151
Luoni et al.148 suggest that when epilepsy is accompanied by persistent seizures there is ‘a diagnostic gap’
when it comes to depression. Screening for depression has been recommended,26 but is still not routine. In
PWE who have persistent seizures, anxiety symptoms are even more common than depression. This is not
surprising as PWE know seizures can lead to injury, hospitalisation and even death.7,35,152,153 Anxiety is a
second diagnostic gap.154
In the NHS, primary care groups were rewarded for annual epilepsy monitoring for 10 years but, in 2014, this
scheme was withdrawn.155 Primary care groups were also remunerated for identifying psychological comorbidity
in LTCs, such as heart disease and diabetes mellitus. During this time, identification of psychological comorbidity
increased.156 Compared with other LTCs, psychological comorbidity is equally or more common in PWE.157
This is important in PWE, particularly as depression is also a predictor of poor epilepsy control and premature
death.35,158 In the UK after diagnosis, specialists follow up/monitor less than half of PWE69 and do not generally
have multidisciplinary team support to address mental health issues, even if they identify them.
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Post-intervention outcomes
In our trial, a 2-day educational course for people with epilepsy and persistent seizures did not change
participants’ QoL after 1 year, nor were secondary outcomes changed, including psychosocial
characteristics. This is consistent with evidence from two other trials of self-management educational
interventions,1,2 which were cited in the NIHR funding call (see Appendix 1). These two trials followed
participants up for a shorter period, that is, at 4 and 6 months.1,2 A more recent trial, which recruited a
small, highly educated group of participants (an unspecified number of whom were volunteers) in a
fee-for-service health-care context, has found aspects of QoL were improved immediately after the course,
but not subsequently at the 6-month follow-up.115 This evidence supports a hypothesis that a discrete
course in isolation is not likely to affect QoL for PWE.
A Colombian trial that included an educational epilepsy course together with four cointerventions,
including monthly ongoing advice from a pharmacist, demonstrated an improvement in QoL at the
6-month follow-up.117 However, QoL at baseline was about 10 points lower than is usual in resource-rich
countries, most of which have universal health care. Baseline QoL was, however, not significantly different
from that pertaining in other South American countries. It is likely that improvement in QoL from a low
level is more easily achievable in this context. In addition, medication adherence for LTCs is a known
challenge.159 Attendance at the course itself was poor. It may be that the regular one-to-one pharmacist
intervention was key to improvement in QoL. There was no process evaluation to assess the ‘how’ and the
‘why’ of this. Nonetheless, it supports a hypothesis that when mean QoL is low at baseline, it can be
sensitive to a large quantity of additional condition-specific services.
Our own, and others’, findings are that psychological factors are closely associated with QoL.3,4,26,73,116,160–163
Therefore, it is not surprising that different sorts of interventions, which focus on treating psychological
distress with cognitive behavioural therapy or with acceptance and commitment therapy, show more
promise in improving in QoL for PWE.164–166
Comparison with MOSES
The RCT methods of evaluating MOSES and SMILE (UK), and the participant groups, differed in
many ways.1
1. The participants recruited in MOSES from epilepsy centres were informed about the trial via
advertisements. Participants needed to actively engage prior to enrolment.
2. There was no minimum seizure requirement to participate in the MOSES study; 42% of the group did
not have a seizure in the previous 6 months.
3. A total of 35% had comorbid conditions in the MOSES evaluation compared with approximately 50%
in SMILE (UK).
4. The MOSES evaluation control group had a statistically significant longer median duration of epilepsy
(18.2 years) than the intervention group (13.5 years). Thus, the duration of epilepsy in the MOSES
control group was similar to the SMILE (UK) group, whereas the group receiving the MOSES
intervention had a more recent diagnosis.
5. Seizure frequency was measured over a period of 6 months (6 months prior to intervention and
6 months post MOSES intervention). SMILE (UK) reported seizure frequency at 6 months and
12 months post intervention. SMILE (UK) also evaluated self-reported seizure frequency over the
previous 12 months with a top category of ≥ 10 seizures.
6. The analysis of MOSES outcomes was based on a per-protocol assessment, which took into account
participants having completed questionnaires at both follow-ups only. From 383 recruited participants,
242 remained in the analysis (63%).
7. The MOSES study included a ‘knowledge-of-epilepsy’ questionnaire, designed specifically for the study.
8. In the MOSES study, the longest follow-up duration was 6 months after the course.
The MOSES study resulted in an improved score with regard to knowledge measured by the questionnaire
designed for the study, and also with regard to coping with epilepsy scores and in seizure frequency.
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No improvement was found on their generic measure of QoL. Statistical analysis using a per-protocol
design was used to evaluate the efficacy of an intervention, or the effect of treatment receipt. The SMILE
(UK) RCT was designed to evaluate the effectiveness of SMILE (UK) or, in other words, the effect of an
offer of the intervention on the group. Efficacy results tend to be greater as they only include participants
who have received the intervention. Participants not completing the assessments or the course are thus
excluded. This can lead to bias in interpretation of the results as randomisation is no longer in effect. In
our secondary analysis, we included a CACE study for the primary outcome to account for participants not
receiving the intervention. We found no difference in QOLIE-31-P total scores at the 12-month follow-up
between the participants in the SMILE (UK) group who had received the full intervention and the control group.
The only measure in common with SMILE (UK) that showed an improvement with the MOSES intervention
was seizure frequency (although it was assessed differently). A greater proportion of participants in the
MOSES group improved in terms of seizure frequency (i.e. they improved by two seizure frequency
categories). As the actual numbers of participants in each category were not published, comparisons with
SMILE (UK) are not possible. As the last follow-up was short, it is unknown whether or not the changes
observed at 6 months would have persisted at 1-year follow-up.
Measuring knowledge and behaviour change
Evidence from prior trials supports the hypothesis that education can affect knowledge of epilepsy scores
in people with well controlled and uncontrolled epilepsy.1,2,95 However, the follow-up periods in these trials
were 4–6 months, much shorter than the 12-month follow-up used here. This may be important in light of
the memory problems described particularly by people with poorly controlled epilepsy.
In an earlier trial for people whose epilepsy was long term, we found a non-significant trend towards
higher knowledge of epilepsy scores following a nurse intervention.167 In a subsequent trial of nurse advice
for people with new epilepsy, we found that for those groups of participants in lower quartiles of
knowledge-of-epilepsy scores at baseline, there was improved knowledge-of-epilepsy scores after the
nurse intervention.95 These trials had a short follow-up period of 6 months.
In view of the above, we did consider adding a knowledge-of-epilepsy questionnaire in this trial, but
decided not to do so. The reason for this was that the number of questionnaires needed to provide the
information specified by our funding agency already demanded much time and energy from participants.
More questionnaires might have reduced their participation and response rate at follow-up. These were
also important concerns for our funders, ourselves and our ethics committees which reviewed the
research proposal.
Studies of other LTCs with large numbers of participants have examined associations between knowledge
increase and adoption of taught behaviours, and between adoption of taught behaviours and health
outcomes;58 however, the associations were weak. A sequential concept of the health education triggering
change in health outcomes is probably too simple. Lorig et al.168 point out that patient education can bring
about changes in behaviour and in health status, but the mechanisms involved are still not clear.168
Research in many LTCs confirms that linking education to behaviour change and other outcomes is a
continuing challenge.59,169 Given the high prevalence of LTCs and the impact that they have on the
individuals and service cost, there is a need for further research on this.
We believe that such research, especially in conditions such as epilepsy, for which few complex interventions
have been evaluated, should be exploratory at first. The conclusions from this study suggest researchers
need to be given flexibility in determining potential outcomes, undertake cohort studies to identify predictors
of change and continue to use mixed-methods research, with process evaluations to describe ‘how’ and
‘why’ complex interventions work, or fail to do so.
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Process evaluation: key themes
Social isolation and stigma
In the quantitative part of the study, we found that 63% of participants felt stigmatised at baseline. In
prior work we had found that stigma is more common when seizures have occurred more recently.170
Those with newly diagnosed epilepsy have also been found to be at particular risk of perceived stigma.171
Nevertheless, using the same stigma scale, Taylor et al.149 measured felt-stigma among UK adults with
newly diagnosed epilepsy and found a lower percentage of patients (53%) reported stigma than our
group with epilepsy and persistent seizures. One inference may be that the recency and frequency of
seizures is more powerful in its influence on an individual’s sense of self-stigma than the diagnosis of
epilepsy itself.
The process evaluation helped us to understand this finding. It highlighted that, despite having epilepsy
for a median of 18 years and being in receipt of specialist epilepsy care, PWE and people with persistent
seizures still felt isolated from other people like them. In stigmatised conditions, people may tend to
conceal their condition and withdraw socially.42 We infer that either participants’ lack of sharing with peers
early on after diagnosis and/or their continuing seizures may have had a continuing detrimental effect over
time, reinforcing a sense of isolation and loss of self-esteem, and potentially reducing their ability to learn
and apply epilepsy self-management skills.
In 1986, Scambler and Hopkins42 described felt-stigma in patients recruited from UK primary care. In the
30-year period since then, attitudes may or may not have changed to reduce this.18 There are now also
different populations living in big cities. According to the census from 2011, London’s population was
just under 60% white, 19% Asian/Asian British and 13% black/African/Caribbean/black British.172 In the
context of a prior study,173 we described that felt-stigma was associated with higher usage of EDs for
seizures in PWE. Non-white individuals were less likely to participate in a study of nurse-specialist
education aimed at increasing self-management among those attending an ED.174 At follow-up 1 year
later, people of non-white ethnicities were more likely to use an ED for their epilepsy, generating more
health-related cost.12 In a follow-on qualitative study, we found that felt-stigma appeared greater among
people from sub-Saharan Africa than it was among Caribbean people.175 Epilepsy stigma is greater in
resource-poor countries18 and these attitudes are likely to persist and may have clinical importance when
epilepsy is diagnosed, and at follow-up, in Western cities with multiethnic and multiracial populations.
In this study, most participants had waited in clinics with people with similar experiences of epilepsy on
each occasion they visited the hospital. But presumably they had not been aware of this or talked to others
about it. In the UK, people with diabetes mellitus visit departments that are clearly labelled the Diabetes
Clinic. This is not generally the case for PWE. Respect for confidentiality in a stigmatised condition may
reinforce the impression that epilepsy cannot be acknowledged publicly and, in this context, PWE may be
less likely to share information about their condition with others in the clinic space or elsewhere.
Learning by sharing and comparing experiences in a group
The process evaluation found that the sense of ‘feeling alone’ can be ameliorated by group learning
with others with similar experiences. This may improve self-confidence and self-management. In a classical
text on diffusion of innovations, Rogers176 described that for change in behaviour to be adopted, not only
knowledge but also attitudes need to change. Through qualitative studies, researchers are just beginning
to understand the importance of group work in stigmatised conditions.169,177 As described earlier, the
relationship between these characteristics is not clear in other conditions or in epilepsy. There is evidence
from some studies of PWE, with and without seizure control, that learning more about epilepsy can enhance
self-mastery/efficacy.1,89 This relationship could not be confirmed in the quantitative aspect of our study with
people with poorly controlled epilepsy at 12-month follow-up. It is possible that having recurrent seizures
over time compounds people’s sense of loss of control and self-mastery. After a median of 18 years with
epilepsy and persistent seizures, it is perhaps not surprising that a 2-day course has no measurable effect
1 year later. It is likely to have been too little, too late.
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Memory in poorly controlled epilepsy and its implications for learning and practice
The process evaluation highlighted that language or memory problems made it more difficult for adults
with recurrent seizures, many of whom also had mood disturbance, to remember new information and to
remember to do things in practice. This is not rare for people with persistent seizures, as it affected about
25% of the small group of participants approached for the process evaluation. Memory impairment is well
documented in epilepsy and particularly affects those with frequent seizures or mood disturbance.143,178
Social scientists believe that beyond 2 weeks, memory for routine events declines in all people and with it
the accuracy of reporting. If this is particularly so in poorly controlled epilepsy and mood disorders, it may
be more appropriate to describe outcomes soon after an intervention. In addition, Taylor et al.59 have
reported that to be optimally effective in changing outcomes, interventions for all LTCs will ideally be
supported and augmented by integrated hospital and community care services. For those with persistent
seizures and memory issues, such liaison may be particularly important. However, in practice, it rarely
occurs in a systematic way and would be more costly to provide in trials as well as in routine practice.
Cost of epilepsy and service use
Our group of 404 PWE with recurring seizures were recruited from specialist clinics and thus almost all
(94%) reported seeing a neurologist twice in the previous 12 months at baseline assessment. Only about
one-third had seen an ENS. Half of the group saw a GP for epilepsy in the past year and on average they
had two visits. Although for the majority of PWE their epilepsy is managed in primary care, the participants
in our study also have care provided in secondary or tertiary services. It may be that some may not feel the
need to see their GPs for epilepsy.
About 40% of our group with persistent seizures had been to an ED once in the previous year. This is
twice the proportion of PWE who attend an ED in community studies, which reflects the fact that half of
PWE in the community have their seizures controlled by medications.11,152 The total cost of service use
reported at baseline for the whole group was an average of £2751 for the previous year. This increased at
the 12-month follow-up to £4030. The difference is due mostly to costs for paid home help. The majority
of the cost was associated with AEDs in our group. This is consistent with a study of costs in epilepsy
where AEDs and frequency of seizures were reported to drive the cost of epilepsy.20 In general, there are
few studies on the cost of epilepsy.12,173 In comparison, type I and type II diabetes mellitus cost about
£9.8B a year in direct costs for the NHS for 3.8 million patients,179 which extrapolates to approximately
£2500 per year per patient.
Cost-effectiveness of SMILE (UK)
The cost-effectiveness analysis of SMILE (UK) showed that, for the NHS perspective, the course is cost-saving
but does not correspond to more QALYs than TAU. Further analysis concluded that the cost savings do not
justify the loss of QALY. However, looking at societal costs, SMILE (UK) could be cost-effective.
The assessment of QALYs is based on the QoL of the patient group. This was measured in two ways for
our study. The standard for health economic evaluations is the EQ-5D-5L. Our group displayed a high QoL
using this measure compared with other studies.142 We questioned whether or not this was the most
appropriate scale to use for epilepsy as symptoms can be intermittent, unlike other LTCs. The EQ-5D-5L
was found to be weakly correlated with QOLIE-31-P in a recent substudy.142 Our group had a high total
QOLIE-31-P score at enrolment and it may be hard to improve on, especially in a group having epilepsy
long term. This in turn has an impact on the cost-effectiveness analysis.
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Limitations
1. We used self-report data to measure outcomes. This is common and accords well with concepts such as
QoL, which emphasise the experience of the individual. Reliance on patient reports of seizure frequency
introduces the possibility of bias. However, there is limited consensus on how else to measure seizures
over a sustained period in community studies, when many patients are not aware of, or are amnesic
for, a proportion of seizures.180
2. We also relied on patients to self-report their ED use, as PWE have been found to be reasonably
accurate in recalling use of other health-care services, particularly hospital-based services, over the
previous year.181,182
3. A 2-day course may have been inconvenient for people with work and family commitments. Lengthy
travel to the course during peak rush hour times may have been difficult for many PWE, especially as
publicly funded, free-to-user transport passes do not cover rush hour times in England.
Strengths
1. A large sample size and good recruitment and retention in this complex intervention trial mean that
we have confidence in our findings that a 2-day course does not influence QoL at 1 year.114
2. The population from which we recruited is likely to represent people with epilepsy and persistent
seizures, particularly those attending specialist clinics in cities. Our study also includes a representative
proportion of males.
3. Our results may be influenced by one-third of the intervention group not attending the full course.
Some trials analysed their results per protocol.1 SMILE (UK) results were analysed according to ITT with
a secondary CACE analysis on the primary outcome.4
4. To our knowledge, our report on the fidelity of the intervention was the first time this had been
reported for educational intervention trials in epilepsy.85
5. The sample size used in the process evaluations was small, but purposefully selected, and the results
helped both to explain how patients benefit from group interventions and why PWE and people with
persistent seizures would require more than a 2-day course if long-term benefits are to be demonstrated.83
6. The process evaluation highlighted that PWE felt isolated from people like themselves, despite having
epilepsy for a median of 18 years and being in receipt of specialist epilepsy care.
7. The process evaluation found that patients believed group learning with others with similar
experiences was helpful in reducing their sense of ‘feeling alone’. For many, the sharing of experiences
improved their self-confidence and self-management.
8. The process evaluation identified that memory problems make it more difficult for some adults with
recurrent seizures or mood disturbance to remember new information and to remember to do things
in practice.
9. This is the second economic analysis of a complex intervention for epilepsy, and the first in the UK.132
10. The economic analysis highlighted the health cost for poorly controlled epilepsy and the capacity
burden placed by use of EDs, which is twice as much as for all PWE.
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Chapter 11 Conclusions
Main conclusion
People with chronic epilepsy for a median 18 years and those with frequent seizures did not show
improvement in their QoL 1 year after being offered a 2-day self-management education course. Two-thirds
of the participant group reported current anxiety symptoms at borderline or case level and felt-stigma, and
one-quarter reported current depression symptoms at borderline or case level. Their QoL was associated
closely with these psychosocial characteristics.
We conclude that discrete educational courses are unlikely on their own to enhance QoL, particularly
1 year later. The evidence does suggest that only courses that were supported by additional cointerventions,
such as ongoing monitoring by a nurse specialist or pharmacist, may have influenced QoL.117,183 This may be
because memory and/or mood disturbance is a problem for PWE, or that QoL is not much affected by an
education intervention on its own. A combination of interventions may be more likely to improve outcomes
in all LTCs, particularly in epilepsy with poor control.59
As QoL is most associated with psychological and social factors, psychosocial interventions are more likely
to influence QoL.164,165 By contrast, educational interventions are more likely to show benefit by improving
knowledge of epilepsy, and there is evidence that knowledge-of-epilepsy scores can be changed by
educational courses.1 However, it is more difficult to demonstrate that education changes people’s
attitudes and behaviour. Ideally, future interventions will integrate education and advice given in primary
and secondary care, and include a process evaluation to emphasise the ‘how’ and the ‘why’.59 There will
ideally be a system of monitoring of PWE in primary care as there is for those with diabetes mellitus,
possibly with screening for anxiety and depression, and clear communication between the two sectors.59
A process evaluation was helpful in explaining our quantitative results. Despite receiving specialist epilepsy
care in addition to primary care, and having a median of 18 years’ experience of managing their epilepsy,
participants reported ‘feeling alone’. Overcoming this and improving self-acceptance through meeting
people with similar experience was seen to be helpful. Over half reported that this, and comparison of
attitudes and experience with others, helped them improve their confidence to talk openly and make
changes in health behaviours. Memory problems may be reported by at least one-quarter of those with
poorly controlled epilepsy. Clinicians should encourage PWE to join groups of peers as a priority, as well
as finding ways to reinforce learning about how to self-manage their epilepsy early on when QoL is
more impaired.
Recommendations for research
1. A group intervention is valued for helping people overcome their sense of isolation, loss of self-esteem
and self-efficacy. After a median of 18 years with seizures, some people may find a 2-day course to be
too little, too late. We found that QoL was lower in people with more recent onset of epilepsy. Based
on these findings, we propose that group courses be evaluated for people with newly diagnosed
epilepsy earlier on. This might include testing of simple reminders to join local self-help groups.
2. We have found QoL to be closely associated with psychological distress. This finding confirms evidence
from other countries.20,148,150,151,163 If the main aim is to improve QoL, and/or mitigate anxiety and
depression symptoms, then psychological interventions such as cognitive behavioural therapy or
acceptance and commitment therapy are likely to hold promise for this group of PWE and require
more trials in the UK.165
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3. Epilepsy is associated with stigma, as are human immunodeficiency virus (HIV) and mental ill health
conditions.42,169,177 The results from this research suggest that there needs to be a similar approach for
epilepsy as in these other conditions to developing and testing interventions to reduce stigma early on
after diagnosis.169,177 This may be particularly important for groups that mat be likely to experience more
self-stigma, like PWE from ethnic minority cultures and those with persistent seizures.175
4. If the aim is particularly to help people with long-term epilepsy and frequent seizures, a range of
interlinked interventions are more likely to have a positive effect, as observed in other studies.59,117,183
They might include (1) peer-group work to reduce stigma and loss of self-esteem and self-mastery,
(2) education on self-management and (3) for those with psychological distress, an intervention to
reduce this.
5. When memory issues are a challenge, intermittent visits to a nurse or other professional allied to
medicine should be evaluated, with additional memory prompts to assess how reinforcement of
self-management learning can help recall.
6. Appropriate outcome measures need to be selected in each case, with latitude in choice provided by
funders to the researchers.184 Outcome measures should also include those deemed important by the
target population. Assuming patients know what it means, QoL (‘The treatment’s effect on your
quality of life’) has been ranked by users as the third most important outcome measure for trials.184
7. The connection between knowledge, attitudes and behaviour is complex in all LTCs and requires more
research for PWE. This has important implications as national and international policy is to prevent
unnecessary ED use and hospital admissions.185 A UK audit found most ED visits for seizures by PWE
are clinically unnecessary; nonetheless, about half of those who come are admitted to hospital with no
health gain.16 The cost of this, and of not testing prevention strategies, is high.12
8. Although there has been much health services research and many complex intervention trials in
similar LTCs such as diabetes mellitus in the UK, there has been little in epilepsy. As so little is known,
research describing PWE, developing complex interventions for them and methods of evaluation
should be regarded as exploratory.
9. A cohort study, with modelling of clinical, psychological and social predictors, would help to
understand determinants of QoL among UK PWE.
10. If research is to build on the shoulders of prior research for UK PWE, the development and evaluation
of complex interventions should follow MRC guidelines, with process evaluation at each stage to
understand ‘why’ and ‘how’ interventions work or fail to do so.186
Implications for health care
After diagnosis has been confirmed, many people with epilepsy and persistent seizures in the UK are
managed mainly in primary care. Our research focused on a large group of people with epilepsy and
persistent seizures, who also attended a specialist clinic. They had chronic epilepsy, with the majority
having seizures at least once a month. Our findings suggest that when clinicians encounter PWE with
this seizure severity, they can expect that more often than not the PWE will feel isolated from people like
themselves, feel stigmatised and suffer anxiety symptoms. Some of these social experiences and attitudes,
if identified, may be ameliorated by joining groups. Clinicians might take a more active role in identifying
these issues, recommending local and national user groups, and providing reminders subsequently.
Clinicians, policy-makers and user groups should canvass for more research on this.
We found that anxiety and, even more so, depression symptoms are strongly associated with impaired
QoL. Clinicians in primary care and NHS patients have direct access via self-referral to psychological
therapists.187 If clinicians identify PWE who have persistent seizures, they will find anxiety and depression
symptoms are common and likely to be associated with a poorer QoL. Inferring from our own and others’
evidence, active identification and management of this may improve outcomes, possibly including
self-management of epilepsy.35,153 In LTCs affecting mental health, clinicians and policy-makers may
grade the severity to enable a step-care approach, with the intensity of interventions varying depending
on severity.188 More research is required on this for epilepsy.
CONCLUSIONS
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Appendix 1 National Institute for Health
Research call for research
This information can be found at www.journalslibrary.nihr.ac.uk/programmes/hta/0916501/#/.
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Appendix 2 The process of adopting
self-management behaviours
Five core self-management skills
1. Problem-solving
2. Decision-making
3. Using resources
4. Forming of a patient/health-care provider relationship
5. Taking action
Medical management
behaviours (e.g.
adherence to AEDs)
Emotional management
behaviours (e.g.
managing anxiety)
Role management
behaviours (e.g. having a
manageable workload)
Self-mastery
leads to
enactment of
the five skills
FIGURE 16 The process of adopting self-management behaviours. Dotted lines represent the effects of behaviours,
positive or negative, that can modify skill utilisation and a feeling of mastery. The figure is adapted from Taylor
et al.57–59 Contains information licensed under the Non-Commercial Government Licence v2.0.
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Appendix 3 SMILE (UK) intervention
development timeline
To begin, SMILE
investigators chose the
MOSES intervention to be
adapted for use in the UK
MOSES workbook
material was then
translated from German
into English
The SMILE participant 
workbook also
contained two new
sections specific to UK
audiences
Group facilitators were
then selected and trained
by MOSES trainers to
deliver SMILE content
An external pilot study
took place with epilepsy
charity volunteers to
ensure acceptability of
the course in the UK
Some course logistics
were amended based on
external pilot study
feedback
A final course offering
was agreed on and
offered to participants
FIGURE 17 A timeline of events during the SMILE (UK) intervention adaptation.
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Appendix 4 SMILE (UK) course schedule
TABLE 28 SMILE (UK) course schedule: day 2
Day 2
Topic
Duration
(minutes) Session objective
Welcome, ice breaker 15
Treatment (module 5) 90 Provide information on various treatment options, including most
commonly used AEDs. Discussion on taking active role in treatment
Break (coffee/tea provided) 15
Diagnosis (module 4) 75 Inform participants about diagnostic investigations and methods
of documenting seizures
Prognosis (module 7) 45 Describe different courses of epilepsy and instances where
seizure freedom is achieved
Lunch (provided) 45
Personal and social life part 1
(module 8)
75 Discuss impact of epilepsy on QoL and ways of cultivating
self-worth and social support
Break (coffee/tea provided) 15
Personal and social life part 2
(module 8)
90 As above
Summary of course and close 10
TABLE 27 SMILE (UK) course schedule: day 1
Day 1
Topic
Duration
(minutes) Session objective
Introductions 15
Living with epilepsy part 1 (module 1) 90 To encourage PWE to open up about their experiences of living
with their condition
Break (coffee/tea provided) 15
Living with epilepsy part 2 (module 1) 90 As above
Lunch (provided) 45
PWE (module 2) 30 Discuss frequencies and distribution of different epilepsy
subtypes. Specific examples of PWE are discussed
Basic knowledge (module 3) 60 Describes how epileptic seizures start, develop and stop; how
seizures are different; and causes of different seizures
Break (coffee/tea provided) 15
Self-control (module 6) 90 Discuss seizure triggers and explain how seizures can be affected
by behaviour
Network (module 9) 15 Provide information on support networks and means of developing
a personal network that can be helpful in managing epilepsy
Summary of the day and close 15
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Appendix 5 List of SMILE (UK) facilitators
TABLE 29 List of SMILE (UK) facilitators
Role
Facilitator characteristics
Years in profession Qualifications
Taught
groups
before
Number of
treatment
courses
taught
Number
of control
courses
taught
Total
courses
taught
ENS 32 years as RN UG Yes 6 0 6
16 years as ENS PQ
EEG technician 25 UG No 1 0 1
ENS 25 years in profession UG Yes 3 1 4
17 years as ENS PG
EEG technician 26 PG Yes 5 1 6
EEG technician 5 UG No 3 1 4
EEG technician 23 UG No 2 0 2
PG
EEG technician > 15 PG Yes 1 1 2
ENS 19 UG Yes 3 2 5
PG
PQ
EEG technician 7 UG No 0 0 0
ENS 26 UG Yes 1 1 2
PG
PQ
EEG technician 2 UG No 4 1 5
PG, postgraduate degree; PQ, professional qualification; RN, registered nurse; UG, undergraduate degree.
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Appendix 6 SMILE (UK) ‘train the trainers’
course schedule
TABLE 30 SMILE (UK) training course schedule: day 1
Time Duration (minutes) Content
09.00–09.45 45 Welcome
Introduction of participants – professional background, epilepsy experience,
why interested in MOSES
Expectation: best and worst expectations about course
09.45–10.10 25 Presentation of work schedule
10.10–10.30 20 Input: Presentation of material
(Nine modules, trainer’s manual, exercise book, number of participants, trainer)
10.30–10.45 15 Break
10.45–12.15 90 Living with epilepsy (module 1)
Aims, going through the chapter and commenting it
Demonstrating mind map and scale/thesis
12.15–13.00 45 Lunch
13.00 – 13.45 45 PWE (module 2)
Aims, going through and commenting on it
13.45–14.30 45 Basic Knowledge (module 3)
Aims, going through and commenting on it
14.30–14.45 15 Break
14.45–15.30 45 Diagnosis (module 4)
Aims, going through and commenting on it
15.30–16.15 45 Input: MOSES: idea, development, aims, actual situation
16.15–16.30 15 Break
16.30–17.45 75 Therapy (module 5)
Aims, going through and commenting on it
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TABLE 31 SMILE (UK) training course schedule: day 2
Time Duration (minutes) Content
09.00–09.15 15 Welcome and morning round
09.15–09.45 30 Input: educational tools
09.45–10.30 45 Self-control (module 6)
Aims, going through and commenting on it
10.30–10.45 15 Break
10.45–11.15 30 Input: MODES evaluation – domains with/without effects
11.15–12.15 60 Prognosis (module 7)
Aims, going through and commenting on it
12.15–13.00 45 Lunch
13.00–14.15 75 Social Life (module 8)
Aims, going through and commenting on it
14.15–14.30 15 Network (module 9)
Aims, going through and commenting on it
14.30–14.45 15 Break
14.45–15.00 10 Input: qualification of MOSES trainers
15.00–15.20 20 Input: my first time with MOSES
15.20–16.00 40 Closing round: expectations and feedback
Certification of attendance
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Appendix 7 Topic guide during qualitative
interviews
Pilot study
Following a brief introduction, reappraisal of consent and questions about participants’ circumstances
(age, living arrangements, educational achievement), they were asked about their views and experience of
taking part in the pilot SMILE (UK) programme. The main prompts (in italics) are given below:
Why did you decide to take part in the SMILE pilot?
Have you been involved in anything like this before?
Was it because it was something you had been looking for already, or was it the idea of being part of
something new in epilepsy treatment, for example?
What did you think of the content of material that was delivered during the two days?
Topics covered? Were there any that were particularly useful? Any that you found you didn’t
particularly like?
How did you find the way in which information was delivered? Was it easy to understand or a bit difficult?
How did you find learning with others in a group?
Were there any advantages to this for you? Were there any disadvantages for you?
Did you find it easy to participate and contribute or was this difficult?
What did you think of the different teaching methods used? (statements, mind maps, brain
storming and information slides)
Did you like the different teaching methods used during the course or did you find them confusing?
How useful do you consider the course to be for the future?
Do you think you’ll be able to use anything you experienced on SMILE again? Useful to use with others in
your life?
Process evaluation
‘Thanks for agreeing to take the time out and talk with me today, before we begin I just want to let you
know that although I will be asking you about your experiences with SMILE, I am not actually working on
SMILE and I am doing this as part of my degree at King’s. Everything you say today will be completely
confidential; unless you explicitly ask for something to be passed on no one will know which responses
came from you. With this in mind, I would like to encourage you to feel comfortable to express your
honest opinions – which will be really useful in the further development of the course. Do you have any
questions before we start?’
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Patient’s epilepsy
Can you tell me a bit about your epilepsy?
When did you find out you had epilepsy?
How did you feel when you were first diagnosed? How do you feel about it now?
How do you feel you cope with your epilepsy day-to-day?
Prompts: employment, relationships, anxiety
Help-seeking behaviour
In the past, have you tried to find out more about your epilepsy?
How have you done this?
Prompts: Nurses? Clinicians? Support groups? Internet? Alternative therapies?
SMILE course
When you first heard about SMILE, how did you feel about coming on the course?
Prompt: some people may feel worried or anxious before coming on a course like this, is this something
that you experienced?
Prompts: any worries about going on the course? Looking forward to it?
So thinking about the SMILE course, what was the most interesting part of the course for you?
How did you feel about being part of a group?
How did you feel about hearing other people’s stories?
How did you feel about discussing your emotions in the group?
During the course you were asked to place stickers on a line to describe how you felt about certain topics,
how did you feel about doing this?
I believe there was some discussion about medication for epilepsy, was this useful?
Did you find out any things that were helpful?
Did you learn anything new about your epilepsy?
Prompts: types of seizures, triggers diagnostic techniques, other people’s experiences
Since completing the course, do you think differently about your own epilepsy?
Prompts: triggers, medication management
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Life after the course
Do you think the SMILE course has helped you in managing your epilepsy?
Prompts: Medication? Triggers? Warning signs? involvement in treatment?
Have you used any of the techniques you learned on the course?
Although the workbook is not an essential part of the course, have you found it useful?
Social network
Have you stayed in touch with anyone from the course?
Prompts: How many people? Have you found this useful?
Course improvements
Would you recommend other PWE to go on the SMILE course?
Is there anything about the course that you would like to change?
Is there anything else you would like to say about the SMILE course that you have not said so far?
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Appendix 8 Ethics approval letter
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Appendix 9 Participant information sheet example
PARTICIPANT INFORMATION SHEET  
Study title: Research offering people with epilepsy a course to help them get the 
information they want and improve their quality of life: a randomised trial
(REC reference no: 12/LO/1962)
Invitation paragraph
You are being asked to take part in a research study. Here is some information to help 
you decide if you want to. Please take time to read it carefully. If you wish to you can 
talk about it with friends, relatives and your GP. Ask us if there is anything you do not 
understand or if you want more information. You can take time to decide whether you 
want to take part.
1. What is the purpose of the study?
People with epilepsy need to do things to lower their chances of having seizures and 
to reduce the effect epilepsy has on their lives. They may need to take medicines 
every day and learn to stay away from triggers for seizures. They need to learn first 
aid for epilepsy and tell others what to do if a seizure happens. 
To feel confident in doing these things, some people with epilepsy say they want 
more information about epilepsy. Therefore, we are bringing an information course to 
England for people with epilepsy. The course is already given to people with epilepsy 
in other countries and has been found to help them. After taking the course, people 
there know more about epilepsy, feel more confident in dealing with epilepsy and 
have fewer seizures.  
The course is called MOSES. This stands for Modular Service Package EpilepSy. It 
was designed with the help of people who have epilepsy themselves. The course takes 
two days to do and patients take it together with other people with epilepsy. If they 
want, patients can take a family member or friend to the course with them. Two health 
professionals run each course. 
Our study is going to test the MOSES course in England. We want to see if it can help 
people with epilepsy here get the information they want and improve their quality of 
life. 
3. What type of study is it that you are doing?
The type of study we are doing is called a randomised trial. In this sort of study, 
people taking part are put into one of two groups at random by a computer. The first 
group is called Group A and the second Group B. 
People who get put in Group A get the MOSES course straightaway and people in 
Group B continue to receive their normal medical care. The health of the people in the 
two groups is then compared to see if MOSES was helpful or not. After the two 
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groups’ health has been compared, people in Group B then get to go on a MOSES 
course if they want it.
At the moment we do not know if the MOSES course is any more helpful than the 
normal medical care people already receive from the NHS. This means a randomised 
trial is the most exact and fair way to test how helpful MOSES is. Each year 
thousands of people take part in randomised trials.
4. Why am I being invited to take part?
We are looking for people with epilepsy to take part in our study. To take part in our 
study, people need to be aged 16 or over. They must have been diagnosed with 
epilepsy and have had two or more epileptic seizures in the last 12 months. The 
seizures can be of any type. The course is given in English. This means people can 
also only take part if they can speak, read and understand English well. You are being 
invited to take part because we believe you fit this description. 
5. Do I have to take part?
No. It is up to you. Even if you decide to take part, you are still free to change your 
mind at any time. You would not need to give a reason. 
A decision to not take part will not affect your medical care. No new information 
would be collected on you. However, any information that has already been collected 
would be kept. 
6. What will happen to me if I take part?
If you want to take part, a researcher will arrange to see you at a time and place that is  
convenient for you. They could meet you at your home or our university offices. At 
the appointment, the researcher will explain the study to you some more and answer 
any questions you have. You will be given this information sheet to keep and be 
asked to sign a consent form. You will then be asked to fill in a questionnaire about 
your epilepsy. It will ask you about your seizures and what affect they have on your 
life. The researcher will be on hand to help you with the questionnaire if needed. The 
appointment will last about one hour. 
After the appointment, the researcher will use a computer programme to put you into 
either Group A or Group B. The group you are put in will decide when you get to go 
on the MOSES course. You will not be able to choose which group you are put in and 
we will not make the decision ourselves. We will let you know which group you have 
been put in. 
7. What will happen to me if I am put into Group A?
If you are put into Group A you will be asked to go to on a MOSES course about a 
month after you signed the consent form. 
After going on the MOSES course you will be asked to fill in the questionnaire about 
your epilepsy two more times. You will be asked to complete it by post six months 
after you first filled it in.  Then again during a face-to-face appointment with a 
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researcher one year after you first completed it. This appointment will last about one 
hour and take place at a time and place that is convenient for you. 
After filling in the questionnaire for the last time you may be asked by the research 
team if you want to take part in an extra face-to-face interview. We are doing these 
interviews with a small number of participants from Group A so we can hear their 
views of the course. If you are invited to be interviewed, it is up to you if you take 
part. If you do, it will last about one hour and take place at a time and place 
convenient for you. With your permission, the interview will be audio-recorded to 
provide an accurate record of the conversation. The recording will be destroyed once 
the research team have listened to it and typed it up.
8. What will happen to me if I am put into Group B?
If you are put into Group B you will continue to receive your normal medical care for 
the next 12 months, and be asked to fill in the questionnaire on your epilepsy two 
more times. You will be asked to complete it by post six months after you first filled 
it in. Then again during a face-to-face appointment with a researcher about one year 
after you first completed it. This last appointment with the researcher will last about 
one hour and take place at a time and location that is convenient for you.  
You will be able to go on a MOSES course after everyone in the study has completed 
their final questionnaire. This should mean your MOSES course will typically take 
place about six months after you fill in your final questionnaire. 
9. Where and how will the MOSES courses be run?
The courses will be run at a hospital near to your home. For the course you will need 
to go to the hospital two days in a row. The course will run from 9 o’clock in the 
morning until half past five in the evening on both days, with breaks included. Some 
courses will run at weekdays and some at weekends. The research team will speak 
with you to find a course that is convenient for you to attend.
You will take the course with about 10 other people with epilepsy. If you want them 
to, there will be some space for a family member or friend of yours to take the course 
with you.
The course will be led by two health professionals, such as epilepsy nurse specialists. 
At least one of the people running the course will have a medical or nursing 
background in case a seizure happens. 
During the course, the health professionals will give lots of information about 
epilepsy. They will talk about things people with epilepsy have said they want to 
know more about. This includes giving information on: 
• how common epilepsy is 
• its causes 
• the different types of epilepsy
• the emotional side of having epilepsy
• the tests doctors use to diagnose it
• how epilepsy is treated and ways to remember to take medicines
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• how to spot triggers for seizures 
• the chances of becoming seizure-free
• the rights of people with epilepsy
• how to improve your confidence and tell others what to do to if you have a 
seizure.
At the course, you can ask questions.  If you want to, you can also share your own 
experiences with the other people taking the course. 
Everyone taking the course is given an information book to keep. This book has been 
designed with the help of people with epilepsy. It includes all the things talked about 
on the course. It also gives the details of support organisations. 
If you agree, we will audio-record the MOSES course sessions. We want to do this to 
provide a record of how well the course was run by the health professionals. 
If illness means you can only go to one day of the course, we can arrange for you to 
finish the course on another day somewhere else.
10. How long would I be involved in the study?
If you are put into Group A you will be in the study for about one year, or slightly 
longer if you take part in an interview about the course. If you are in Group B you 
will be in the study for about 18 months.
11. Expenses 
We do not expect you will have any expenses from taking part in our study. If needed, 
we can pay for a taxi to take you to and from the course. We will also provide lunch 
and drinks for you. If you decide to take time off work to go on the course, we will 
not be able to pay you or your employer. All participants will receive a £20 shopping 
voucher on return of their final questionnaire to thank them for their time and effort.
12. What are the possible benefits of taking part?
We hope you will get helpful information on epilepsy and learn some things that may 
help you with your epilepsy. However, this cannot be guaranteed. The information we  
get from the study may help us support people with epilepsy better in the future.
13. Are there any restrictions on what I can do?
No. There will be no restrictions in terms of your lifestyle when taking part in this 
study. Your medicines will not be altered in anyway. You will still see your usual 
doctors and/or nurses as normal.
14. What are the possible disadvantages and risks of taking part?
There are no known disadvantages or risks of taking part. The course is routinely 
given to people with epilepsy in other countries. However, the course and some of the 
questionnaires involve thinking about your epilepsy and feelings. For some people, 
this can be upsetting. You can stop taking part in the course or doing the 
questionnaire at any time. This would not affect your medical care. 
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If taking part in the course or answering the questionnaires makes you worried about 
your feelings, you can talk to your GP. You can also ask the health professionals 
giving your MOSES course for advice. However, they would not be able to refer you 
to any NHS service themselves. 
15. Will my taking part in this study be kept confidential?
All the information we collect on you during the study will be kept confidential. This 
includes the audio recordings. Only the research team will be able to see the 
information. Anything that we publish or pass on will have your name and address 
and any personal information removed so that you cannot be identified. All 
information will be stored on password protected computers at King’s College 
London. Your participation will not affect your medical care. 
With your permission, we would want to tell your GP about your taking part and see 
your medical file. We would also need to tell your GP if one of the health 
professionals giving your MOSES course or our researchers becomes worried about 
your well-being. However, we would discuss this with you first. 
The MOSES course is given to groups of about 10 people at a time. Because of this, 
we cannot promise that other participants will not share information about one 
another outside of the group. To lower the chance of this happening, we will get all 
participants to sign a form. This will say that they agree that anything they hear about 
other participants should not be discussed outside of the group. The health 
professionals giving the course will remind participants of this at the start of the 
course.
16. What happens when the study stops?
You continue to receive your normal medical care.
17. What if something goes wrong?
King’s College London provides insurance cover just in case you experience a 
problem from taking part in the study. If you are worried about anything to do with 
the study, you should contact the research study manager. Their details are at the end 
of this sheet. 
18. What will happen to the results of the study?
The results from this study will be published in scientific journals. You will not be 
identified in any publication. If you want a copy of the published results, you can ask 
for one by contacting the study team. 
19. Who is funding and organising the study?
The study is funded by the National Institute for Health Research.  The study is being 
done by the Clinical Neuroscience Department, PO 57, King's College London, 
Denmark Hill Campus, London, SE5 8AF. The lead researchers are Professor Leone 
Ridsdale and Professor Laura Goldstein.
20. Who has reviewed the study?
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This study has been reviewed and approved by NRES London – Fulham Research 
Ethics Committee. 
21. Contact for further information:
Should you need further information about the study you can contact the study 
manager at any time (contact details removed for this report)
You will be given a copy of this information sheet and a signed copy of your consent 
form to keep.
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Appendix 10 Participant consent form
 
Date:....................................... 
 
CONSENT FORM
       Please initial boxes
(1 copy for participant, 1 copy for researcher) 
Participant number      
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Appendix 11 Modified ‘Impact of Epilepsy’ scale
Next, we would like to know how much you feel your epilepsy and its treatment 
affect your everyday life.  For each item listed, please ring the number which shows 
best how you feel.
Does your epilepsy and its treatment affect:
a) Your relationship with your spouse/partner?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
Does not apply - no spouse/partner ....................... 5
b) Your relationship with other close members of your family?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
c) Your social life and social activities?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
d) Whether or not you are able to work in paid employment?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
e) The kind of paid work you can do?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
Does not apply - not in employment ....................... 5
f) Your health overall?
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A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
g) Your relationship with friends?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
h) The way you feel about yourself?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
i) Your plans and ambitions for the future?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
j) Your standard of living?
A lot ....................... 1
Some ....................... 2
A little ....................... 3
Not at all ....................... 4
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Appendix 12 Capacity development
SMILE (UK) research team training
Trial Manager: NHS – Good Clinical Practice; KCL – chairing meetings, Managing research data, unconscious
bias workshop, introduction to project management, management essentials (for professional services and
academic managers), psychometrics; UK trial Managers network – clinical trials project management.
Research Associate: NHS – Good Clinical Practice; NIHR – Journals Library webinar; KCL – search techniques
for systematic reviews, assertiveness skills for researchers, mental health first aid, managing research
projects, essentials of copyright, fundamentals of good writing, ‘publish or perish’ and journal metrics.
Research Assistant: KCL – CVs and applications for academic jobs, Microsoft Excel® intermediate, Learning
to use NVivo, Desktop EndNote for PC, writing for publication in the sciences, qualitative data analysis,
long document work and tutorial for video making.
Clinical Trials Administrator: NHS – Good Clinical Practice; KCL – minute-taking, assertiveness skills for
researchers, CV and interview skills, search techniques for systematic reviews, pure training for
administrators, and literature review workshop for health and clinical sciences.
SMILE (UK) research team activities
In November 2016, the research team arranged and attended an Advanced SMILE (UK) Facilitator Training
course. The session was chaired by MOSES experts and involved SMILE (UK) facilitators’ meeting to discuss
their experiences of teaching SMILE (UK). The chief investigator also presented the SMILE (UK) trial
outcomes during the event.
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